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ABSTRACT
Cefuroxime axetil (CA) is a widely prescribed anti-infectious drug. It exists in an 
amorphous (CAA) and a number of crystalline (CAC) forms. In this study the 
physico-chemical properties and dissolution behaviour of the various forms of CA 
were studied using a combination of analytical techniques and in-vitro dissolution 
testing.
Thermal analysis indicated that CAA exhibited a glass transition temperature (Tg) 
at 74°C, while commercially available CAC is processed as two polymorphic forms 
each with a melting transition at 130°C and 180 °C, respectively. The amorphous 
form was found to have higher dissolution and intestinal absorption rates than 
CAC. The former was also found to have adequate chemical and physical stability 
upon exposure to high relative humidity conditions. Plasticization effects relating to 
the uptake of moisture was limited to only small shifts in the Tg to lower 
temperatures, with no evidence of a rubbery transition and re-crystallisation. This 
was shown to be associated with the limited moisture uptake of CAA (maximum 
2% at 90%RH, 25 °C), indicating a distinguished stability of this amorphous form of 
the drug.
In this study, stability of CAA was also determined under different formulation 
process conditions, specifically upon compression and coating. It was found that 
CAA underwent partial crystallisation upon direct compression. This transition was 
only observed, however, with the DSC technique indicating its potential for 
detecting the presence of small crystalline content in predominantly amorphous 
material. The induction of crystallisation by compression was inhibited by 
introduction of the excipients: Ac-Di-Sol, Starch 1500, and Aerosil 200, either each 
individually or together.
Such stabilisation is thought to be brought to CAA by the high molecular weight 
polymers (Ac-Di-Sol and Starch 1500). Thus, the relatively small drug may link its 
molecular motions to those of the polymers, leading to reduction in its molecular
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mobility, and subsequently inhibiting crystallisation. Also, the high Tg value of 
Aerosil 200 is also thought to deplasticize CAA upon compression. Thus, the 
excipients chosen prevented crystallisation of CAA under formulation process 
conditions.
Wax coating (needed to mask the very bitter taste of CA) was also found to 
significantly alter the stability of CAA, and led to complete transformation of CAA to 
CAC.
In vitro gut absorption testing and a pilot bioavailability study conducted on wax 
coated CAA, in different formulations, indicted a dramatic loss of absorption rate 
and extent, related to crystallisation of CAA upon coating. Introduction of the 
studied excipients to the coated granules, maintained 70% of the original 
absorption rate of CAA.
Thus, stabilisation of CAA under different formulation conditions was possible to 
achieve by the inclusion of some excipients. This maintained the favourable 





Many pharmaceutical solids can exist in a number of different physical forms, 
which differ in their physicochemical properties. These type of forms include 
solvates, hydrates, enantiomorphs and pseudopolymorphs of a crystalline material 
and an amorphous form. Polymorphism is often characterised as the ability of a 
drug substance to exist in two or more crystalline phases that have different 
arrangements and/or conformations of the molecules in the crystal lattice (Grant et 
al, 1999).
Amorphous solids consist of the disordered arrangement of molecules which do 
not possess a distinguishable crystal lattice. Solvates are crystalline solid adducts 
containing solvent molecules incorporated within the crystal structure. If the 
incorporated solvent is water, the solvates are also commonly known as hydrates.
Polymorphism occurs when there exists one or more way to satisfy the energy 
constraints imposed on molecules as they arrange into a crystalline lattice. The 
lattice properties of various polymorphs reveal differences in symmetry elements, 
and intermolecular binding (Elliott et al, 1990). Because intermolecular forces 
contribute to the properties of a solid, each polymorph is a distinct thermodynamic 
entity.
Polymorphs exhibit a variety of chemical, physical, mechanical, electrical, and 
thermodynamic properties. These differences are often observed in their 
corresponding properties: solubility, melting point, dissolution rate, chemical 
stability, physical stability, powder flowability, compaction, and particle morphology, 
(Hancock et al, 1997). These properties can have a direct impact on the 
processing of the drug substances and the quality/performance of drug products, 
such as stability, dissolution, and bioavailability.
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Conducting early screening studies may eliminate or minimize the effect of 
discovering an unforeseen polymorph during a later stage of drug development 
(O’Neil et al, 2003).
1.1.1 Screening of polymorphs
Screening is the first stage in the polymorph life cycle. The goal of polymorph 
screening is to discover the various polymorphic forms of a molecule. Polymorph 
screening methods generally rely on dissolving the crystalline phase and permitting 
the molecules or ions to reassemble under a controlled array of conditions. The 
rate of nucleation is influenced by the various conditions applied during 
crystallisation, which can lead to the isolation of the polymorphic forms, (Yu-L et al, 
2001).
The solids resulting from each screening experiment are analyzed to determine 
whether new or different crystalline forms exist. Many analytical tools are required 
to fully characterise the polymorphic behavior of drug systems. Single crystal X-ray 
diffraction (XRD) is one of the most routinely used techniques for polymorphic 
screening (Jenkins et al, 1996).
The most common approach for polymorph screening is based on solvent 
recrystallisation (Barnett, 2002). However, alternative approaches include 
recrystallisation from the melt, antisolvent addition, vapour diffusion, solution slurry, 
and annealing. These approaches are summarised below.
1.1.1.1 Solvent re-crystallisation
Saturated solutions are prepared by agitating excessive amounts of solids with 
various solvent systems at a saturation temperature. The mother liquor is 
separated from the residual solids by filtration and is then heated above the 
saturation temperature to dissolve any remaining solids. This step is necessary to 
ensure all solids of the original polymorphic form have been eliminated. The 
temperature of the solutions is adjusted to the desired growth temperature, and 
solids are produced by a controlled solvent evaporation and/or by a temperature 
reduction profile (Mullin et al, 1998).
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1.1.1.2 Re-crystallisation from the melt
Re-crystallisation from the melt is often an attractive screening approach because 
it requires only few milligrams of material and does not require a solvent. The 
analytical techniques most useful for re-crystallisation from the melt are differential 
scanning calorimetry (DSC), and hot stage microscopy (HSM). This approach is 
only applicable to materials that are thermally stable. By manipulating the thermal 
profile after melting, polymorphic systems can often be frozen in various crystalline 
forms (Hino et al, 2001).
1.1.1.3 Antisolvent addition
In this approach, saturated (or undersaturated) solutions of a material are prepared 
in different solvent systems. Rather than using cooling or solvent evaporation to 
reduce solubility (i.e., generate supersaturation), a set of miscible antisolvents are 
selected. The direct introduction of a miscible antisolvent to the solutions causes 
rapid precipitation of the material, due to the large decrease of the solute solubility 
upon its addition. The possibility exists that the precipitated solid may be in a less 
stable form than the most stable polymorph as a result of the rapid conversion of 
the material to solid form. Such crystalline phases are referred to as metastable.
In general, at a given temperature and pressure, the polymorph with the lowest 
free energy is the most stable form and all other polymorphs are metastable. 
Metastable polymorphs tend to spontaneously convert into a more stable form 
(Craig et al, 1999). If the material has sufficiently poor crystallisation kinetics, this 
approach may even result in an amorphous solid (Blaisdell et al, 2001).
1.1.1.4 Vapour diffusion
Diffusion methods are specialized cases of solvent re-crystallisation. This 
technique can be useful for materials that exhibit poor crystallisation kinetics and/or 
are difficult to crystallise. Saturated solutions are exposed to a volatile antisolvent 
vapour in a closed system, or a second solvent is allowed to slowly diffuse into a 
saturated solution. As the antisolvent (or second solvent) diffuses into the 
saturated solution, it reduces the solubility of the drug. Because the system is 
generally not agitated, the reduction in solubility is slow, causing continually small 
decreases in the degree of relative supersaturation.
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This provides sufficient mobility for the controlled nucleation of single crystals and 
the growth of existing nuclei and crystals in favour of the formation of nucleation 
and growth. A relatively small number of significantly sized crystals are typically 
formed. The slow nature of this approach makes the diffusion method one of the 
better techniques for isolating single crystals of adequate quality for structure de­
termination using single-crystal XRD, and is the preferred route for high throughput 
screening techniques in the pharmaceutical industry (Blaisdell et al, 2001).
1.1.1.5 Solution slurry
Polymorphic forms generally exhibit variations in their solubilities, and the relative 
solubility of each form (at a given temperature) is dependent on the free energy of 
the solid and independent of the solvent identity. Slurries are prepared by stirring 
an excess amount of solid in a variety of solvent systems (Yul et al, 2001). Upon 
reaching equilibrium, the solution is saturated with respect to the polymorphic form 
that was dissolved, and supersaturated with respect to any polymorph that is less 
soluble than the form that was initially dissolved. Under these conditions, a less 
soluble form can nucleate and precipitate from solution.
1.1.1.6 Annealing
Polymorphic systems are capable of undergoing direct solid-solid phase 
transitions. These transitions are often kinetically impaired, making them difficult to 
detect under the time constraints of screening. One way to overcome this limitation 
is to first produce the material in the amorphous state. Molecules in the amorphous 
state have greater mobility than their crystalline counterparts, which results in the 
amorphous form being less stable than any crystalline forms of the material 
(Debendetti et al, 1996). Annealing the amorphous form of a drug candidate can 
result in crystallisation, especially above the glass transition temperature. XRD and 
DSC are then used to evaluate the resulting crystalline forms.
1.1.2 Characterisation of polymorphism
The initial step in polymorph characterisation is to confirm that the material 
generated by the screening experiments is in fact the intended drug candidate and 
that the screening process itself has not altered the material through 
decomposition, isomerization, or other inadvertent reaction.
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A number of methods have been employed for characterising polymorphs in 
pharmaceutical solids (Brittain et al, 1999-b). Polarizing optical microscopy and 
thermomicroscopy have proven to be useful tools. Thermal analysis procedures, 
such as differential scanning calorimetry (DSC) and thermogravimetric analysis 
(TGA), can be used to obtain additional information, including phase changes.
These thermal methodologies are employed to distinguish between enantiotropic 
and monotropic systems. For an enantiotropic system, the relative stability of a pair 
of solid forms inverts at some transition temperature beneath the melting point 
while a single form is always more stable beneath the melting point in a monotropic 
system (Brittain et al, 1999-b).
Each polymorph is generally evaluated by DSC to determine melting point and 
enthalpy of fusion. This analysis will often indicate other important thermal events 
such as phase changes or thermal decomposition of the material. If solvents were 
used in the screening process that generated the polymorphs, thermogravimetric 
analysis (TGA) of the polymorphs may be used to determine whether the materials 
are solvated or whether they contain significant residual solvents (Giron et al, 
1998).
The utility of solid-state spectroscopy for characterisation of polymorphic systems 
is becoming exceedingly important. Nuclear magnetic resonance (NMR) (Hogan et 
al, 2000), infrared absorption and Raman spectroscopy (Sepaniak et al, 2003) are 
used to study crystal structures. These methods require that either the nuclei of the 
pair of substances being examined exist in magnetically inequivalent environments 
or the vibrational modes are sufficiently different between the structural forms to 
permit differentiation.
The definitive criterion for the existence of polymorphism is via demonstration of a 
nonequivalent crystal structure, usually by comparison of the x-ray diffraction 
patterns. Microscopy, thermal analysis methodology and solid state NMR are 
generally considered as sources of supporting information.
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1.1.3 Phase transitions
Most compounds do not exhibit solid-solid phase transitions. For these materials, 
an accurate determination of the melting enthalpies can be used to determine the 
stability relationship between the polymorphs.
If phase transitions do occur, they are usually slow in the solid state, but they may 
be accelerated in the presence of moisture, solvents, or energy input, if the drug 
candidate exhibits a solid-state phase transition, calorimetry may be used to 
determine whether the transition is endothermic or exothermic (Burger et ai, 1979).
Solubility experiments can also be used to evaluate the energy relationships 
among polymorphs. For a given solvent, the most stable polymorph has a low 
solubility at a given temperature. Competitive slurry experiment is another quick 
method to determine the energy relationship among polymorphs without having to 
determine their specific solubilities (Mullin et al, 1993). Competitive slurry 
experiments are performed by placing excess solids of two (or more) forms in 
contact with a solvent and mixing. Because each form has a different solubility, 
particles of the form with the low solubility grow at the expense of the more soluble 
form, which occurs because the more soluble form is slightly undersaturated, and 
the less soluble form is supersaturated.
Sometimes a competitive slurry experiment results in a polymorphic form that is 
more stable than either of those initially placed in contact with the slurry solvent. 
This result can occur when a polymorphic form that has a lower solubility than 
either of the initial polymorphic forms precipitates from solution. In this case, the 
two forms initially present are converted into the form that has precipitated (Mullin 
et al, 1998). Examining thermal data in conjunction with the slurry data can give a 
general thermodynamic hierarchy for most polymorph systems.
1.1.4 Controlling the crystallisation of a polymorphic form
Developing a robust crystallisation process is the third and final stage in the life 
cycle for materials that exhibit polymorphism. The final process should be 
economical, deliver the correct polymorphic form, and provide the desired chemical 
purity.
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Polymorph screening results provide information about the effect of various 
solvents and crystal growth conditions that lead to the different solid-state forms. 
These parameters may be used as a starting point to conduct small-scale 
crystallisation experiments. Crystallisation studies focus on the systematic 
manipulation of relevant crystal growth parameters (process variables) that are 
known to influence and control polymorphic forms. Parameters such as 
temperature, supersaturation, and interfacial tension between the saturated 
solution and the forming crystallites influence the rates of nucleation of each 
polymorphic form (Brittain et al, 1999-b).
The process variables that are important in controlling solid-state forms are 
thermodynamics, hydrodynamics, solvent composition, seeding, impurity profile, 
time, cooling profile, supersaturation, and reactor geometry (Brittain et al,1999-b).
To evaluate the scalability of the crystal growth conditions that are established at a 
small scale, additional large batches are recrystallised at intermediate scales 
(laboratory to pilot plant) to mimic plant-scale conditions. These experiments 
provide an insight into the scalability and transferability of the crystallisation 
process to other facilities. In some cases, crystallisation conditions must be fine- 
tuned or re-examined if the crystallisation process produces different results when 
performed at a large scale. Differences can occur as a result of varying impurity 
profiles of large batches, changes in residual solvent content of reaction mixtures 
and differences in the reactor heat flow, geometry, and hydrodynamics (Brittain et 
al, 1999-b).
The ruggedness of a crystallisation process can be evaluated and improved by 
intentionally altering the crystal growth process variables and determining the 
amount of variance required to affect the resulting crystalline form. This evaluation 
can identify the significant process variables that exert a considerable influence on 
the polymorphic form along with the sensitivity of processing parameters (Wilson et 
al, 2000).
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Thus, during the final stage of developing a synthetic procedure for a new drug 
entity, a great deal of emphasis is usually placed on obtaining material of high 
purity and reproducibility in terms of its physical, chemical, and biological 
properties, and emphasis are placed on what multi polymorphic or solvated crystal 
forms of the compound can be obtained (Byrn et al, 1982).
1.1.5 Amorphous materials
Most of solid drugs are introduced in pharmaceutical dosage forms in their 
crystalline form. This is because the physical structures of crystalline materials are 
generally thermodynamically stable, and are relatively simple to study using 
techniques such as differential scanning calorimetry and X-ray diffraction (Craig et 
al, 1999-a).
However in pharmaceuticals, amorphous phases had been intentionally produced 
to improve the dissolution and bioavailability of poorly soluble compounds (Byrn et 
al, 1982), to stabilise the tertiary structure of proteins (Carpenter et al, 1994) and to 
improve the mechanical properties of excipients. The three dimensional long-range 
order that normally exists in a crystalline material does not exist in the amorphous 
state, and the position of molecules relative to one another is more random, as in 
the liquid state. Typically, amorphous solids exhibit short range order over a few 
molecular dimensions and have physical properties quite different from those of 
their corresponding crystalline states.
As a result of its higher internal energy e.g. -  25 kJ.mol for cephalosporins (Pikal 
et al, 1978), the amorphous state should have enhanced thermodynamic 
properties relative to the crystalline state (e.g. solubility, vapour pressure) and 
greater molecular motion (Zhou et al, 2002). From a pharmaceutical perspective, 
the high internal energy and specific volume of the amorphous state relative to the 
crystalline state can lead to enhanced dissolution and bioavailability.
A major phenomenon that a solid amorphous phase exhibits is the glass transition 
temperature, where there is an abrupt change in its kinetic (molecular mobility) and 
thermodynamic properties (e.g., heat capacity or thermal expansivity) at the critical 
temperature.
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As pharmaceutical solids rarely exist as 100% crystalline or 100% amorphous 
phases, it is necessary to consider how partially crystalline or amorphous systems 
are likely to behave. The coexistence of two thermodynamically different states of 
a material will probably result in significant and measurable structural 
heterogeneities and batch to batch variations in physical properties. The presence 
of one phase in another can act as a focal point for spontaneous phase transitions 
such as crystallisation (Gerhardt et al, 1994). In addition, as each phase is 
intimately dispersed in the other, there may not be complete independence in their 
behavior. For example, the dispersion of crystalline drug in an amorphous carrier 
has been reported to alter the observed glass transition temperature of the 
amorphous phase (Broman et a l , 2001).
The most common means by which amorphous solids and characteristics are 
formed are: condensation from the vapour state, super cooling of the melt (quench 
cooling of a material), mechanical activation of a crystalline mass (e.g. during 
milling), and rapid precipitation from solution (e,g. during freeze-drying or spray 
drying) (Hancock et al, 1997).
The general procedure for preparing amorphous solids has been described by 
(Turnbull et al, 1961, 1986) as a sequence of three steps. First, the material is 
energized, for example, by melting, grinding, etc. Second, the material is 
deenergized by means such as quenching. The third step involves kinetically 
trapping the amorphous form, and is often continuous with the second step. Melt 
quenching is a technique for preparing an amorphous solid by rapidly cooling the 
molten form of a material, typically by pouring it into liquid nitrogen. The 
amorphous form is trapped due to the continuously increasing viscosity 
(continuous hardening) of the rapidly cooling melt. In contrast, crystallisation of the 
melt occurs with an abrupt change in viscosity (discontinuous hardening), during 
which the crystallites grow in the body of the melt. A requisite for glass formation 
from the melt is that cooling must take place quickly enough to prohibit nucleation 
and growth of crystals.
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Despite the fact that amorphous systems may be desirable, their use is associated 
with some difficulties. Of these, amorphous materials are thermodynamically 
unstable and will tend to revert to the crystalline form on storage (devitrification); 
such behavior had been reported for a number of drugs (Fukuoka et al. 1989; 
Yoshioka et al. 1994; Hancock et al. 1995). The devitrification process may be so 
slow so as to be effectively irrelevant within the storage time of a product (Craig et 
al, 1999-a).
On the other hand, the physical structure of glassy materials is more difficult to 
characterise and control than that of crystalline systems. The scientific 
understanding concerning the relationship between Tg and pharmaceutical product 
performance has not been fully developed. Furthermore, considerable care must 
be taken with regards to the use of conventional accelerated stability studies in 
predicting chemical or physical stability, as the behavior above and below Tg is not 
directly comparable (Duddu et al, 1997).
1.1.5.1 Thermal history effects
Although various techniques can be used to produce an amorphous phase, the 
increase in free energy of the amorphous phase relative to the crystalline phase of 
the same compound depends on the technique used.
The dependence of free energy on preparation conditions is referred to as thermal 
history. The effects of thermal history have been shown to affect relaxation time, 
stability, and location of the glass transition temperature (Garcia et al, 1997). It has 
been found that slower cooling rates, when preparing the amorphous material, 
results in a lower Tg. The actual value of Tg may vary by as much as 5%-10% for 
widely differing cooling rates, although the variation is typically quite small in 
pharmaceutical systems. Thus, one may not expect glasses of the same material 
prepared and stored under different conditions to have a single glass transition 
temperature (Elliott, 1990).
1.1.5.2 Glass transition temperature of the amorphous state
The nature of the glass transition has been widely described (Elliott, 1990; Angell, 
1995; Hancock et al, 1997). Craig et al. (1999-a) illustrated the essential
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differences between the formation of amorphous and crystalline systems in terms 
of their thermodynamic behaviour. These differences are schematically 











Figure 1.1: Schematic depiction of the variation of enthalpy (or volume) with 
temperature (Elliott et al. 1983; Zografi et al. 1996; Craig et al. 
1999a).
For crystalline systems, when the temperature is reduced from the liquid state to 
the melting point (Tm) a transition to the crystalline form occurs (if no super-cooling 
is initiated). The crystalline state below Tm is thermodynamically stable compared 
to non-crystalline forms. The exothermic crystallisation process leads to a sudden 
contraction of the system due to a decrease in free volume. Consequently, both 
the enthalpy (H) and specific volume (V) decrease at Tm.
As the temperature is lowered, as a result of heat capacity and thermal contraction 
effects, a less marked decrease in enthalpy and volume can be observed. For 
glass-forming materials, the crystallisation process is not favored either due to the 
molecular size and shape (e.g. proteins) or due to the quench cooling, where the 
degree of supersaturation is too high for controlled crystallisation to occur. For 
these materials, no discontinuity in enthalpy or volume is seen on cooling the 
material below Tm, and the system forms a super-cooled liquid. Upon further 
cooling a point is reached (Tg) at which the material becomes ‘frozen’ into a glassy 
state.
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At the Tg, the bonding between molecules remains essentially the same as that of 
the liquid but the translational and rotational motions of those molecules are 
dramatically reduced (Craig et al, 1999-a). The glass transition can then be 
characterised via a step change in heat capacity Cp and the transition is dependent 
on molecular mobility with no associated heat transfer in the process.
At slower cooling rates lower values for Tgare obtained, as indicated in Figure 1.1. 
The material is considered to be in the liquid or ‘rubbery’ above Tg and in the 
glassy states below Tg. Changes in mechanical properties arising as a result of the 
decrease in molecular motions as the system is cooled through the Tg will lead to 
strong or fragile amorphous solids.
To explain the glass transition, it is helpful to consider the entropy of the system 
(Craig et al, 1999-a), which at equilibrium is related to the heat capacity via Cp = T 
(AS/AT)P. The heat capacities of the glass < Tg, and crystalline states for a given 
material are essentially the same. While at temperatures > Tg the higher values of 
Cp observed are caused by the material possessing additional configurational 
degrees of freedom when in the rubbery state. Consequently, the Tg may be 
considered to occur at a given value of excess entropy (Elliott, 1990).
The glass transition may also be explained by the relaxation processes that occur 
as the liquid is cooled (Craig et al, 1999-a). These relaxation times will be 
temperature dependent and governed largely by reorganization of hydrogen bonds 
in the hydrogen bonded fluids. At temperatures above Tg, the relaxation time of the 
material (tr) will be short with respect to the time of observation (to), in this case, 
the material will appear liquid-like. Consequently, above Tg the sample is in 
equilibrium with the cooling program as it will be able to respond to change in 
temperature with cooling.
Below Tg , the relaxation process is slow with respect to the timescale of the 
cooling program, thus t0 will be < tr, and the material will assume solid-like 
characteristics due of reduced molecular mobility. The glass transition may 
therefore be considered to occur when tr -  to.
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Another approach to interpret the glass transition is to consider the free volume of 
the system. Cohen and Turnbull originally proposed the free volume theory in1959 
(Kasapis et al, 2001 ).
The model was developed for fluids assumed to be composed of thermally 
oscillating hard spheres. The total volume of the liquid is divided into two parts, the 
part occupied by the spheres or molecules in the absence of thermal motion, i.e., 
at 0 K (V0k) and the part in which the molecules are free to move, the free volume 
(Vf). The free volume can be further divided into the thermal volume (Vthermai), 
which represents the additional volume occupied by a molecule during thermal 
motion, and the excluded volume (V eXci). which represents any volume that is never 
occupied. The model assumes that diffusive motion only occurs when Vf is above a 
critical value (Debenedetti et al, 1996).
The free volume can be divided into voids of varying sizes and locations 
determined by the random motion of the molecules. Redistribution of the free 
volume occurs without a change in the local free energy. When the liquid is heated, 
Vthermai increases, corresponding to a decrease in density, while as the liquid is 
cooled, Vthermai decreases resulting in a liquid with higher density. At temperatures 
lower than Tg, the decreased V f (higher density) creates an energetic barrier to 
non-uniform distribution of Vf (i.e results in a more uniform distribution of Vf).
Under these conditions, the thermal expansion coefficient of the glassy phase (ag) 
is similar to that of the crystalline phase (ac) of the same compound. Below Tg, a 
slightly increasing temperature results in increased vibrational molecular motion 
about effectively fixed positions causing expansion. In this case, the free volume 
remains uniformly distributed, and the increase in entropy with temperature is small 
because translational molecular motion does not accompany a change in volume. 
At T>Tg, there is enough thermal energy to overcome the energetic barrier, 
allowing non-uniform distribution of Vf and translational molecular motion. The 
thermal expansion coefficient is then liquid-like, and there is a significant increase 
in entropy with temperature. In this formalism, vitrification occurs when Vf becomes 
zero.
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Free volume theory is commonly used to describe polymeric systems, where 
segments of the polymer chain are treated as rigid bodies and Vf consists of the 
“holes” present between the segments. At the glass transition temperature, the 
free volume is insufficient for rearrangement of the polymer backbone to occur. As 
a result, Vf is considered a constant at or below Tg for polymers (Debenedetti et al, 
1996).
For a glassy system, the free volume reaches a lower limit at Tg and is thereafter 
temperature independent, hence in essence the glass transition occurs when Vf 
falls below a critical value (Her et al, 1994).
Ediger et al. (1996) reported that the glass transition can be considered to be a 
thermodynamic requirement for a super-cooled liquid, since without such a 
transition the amorphous material would attain a lower enthalpy than the crystalline 
state at some critical temperature and this critical temperature is known as the 
Kauzmann temperature Tk, and is thought to mark the lower limit of the 
experimental glass transition Tg, and to be the point at which the configurational 
entropy of the system reaches zero. The case in which the metastable glass would 
obtain configurational entropy lower than that of the crystal has been named the 
Kauzmann paradox (Kauzmann et al, 1948).
Experimental studies of the glass transition are complicated by the existence of 
many different modes of molecular motion in most systems (e.g. rotational or 
translational), changes in the scale and type of motions with temperature, and 
cooperativity or coupling of molecular motions.
At Tg the mean molecular relaxation time t associated with the predominant 
molecular motions is about 100s, and Tg can be expected to vary with 
experimental heating and cooling rates. A fast cooling rate produces a higher value 
for Tg than does the use of slower rates (Ramos et al, 2004), this can be related to 
the relaxation behavior of the system. The time scale for the relaxation processes 
is higher at lower temperatures, i.e. the relaxation will be slower (Moynihan et al, 
1996). Consequently, at slower rates the temperature at which the relaxation
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process becomes comparable with the time scale of the experiment will be lower, 
hence the measured Tg will be lower.
Tg is also affected by the sample molecular mass (Mckenna et al, 1989), sample 
history, sample geometry, and sample purity (Ford et al, 1999). The experimental 
glass transition temperature is also influenced by the choice of technique used to 
measure it because of the varying sensitivities of available techniques to different 
types and speeds of molecular motions.
Depending upon the magnitude and temperature dependence of the apparent 
activation energy for molecular motions near and above Tg in super-cooled liquids, 
it is possible to classify them as either "strong" or "fragile" amorphous systems 
(Angell et al, 1988). A strong liquid typically exhibits little changes in its molecular 
mobility with temperature and a relatively small change in heat capacity at Tg. 
Proteins are good examples of strong glass formers, with their changes in heat 
capacity at Tg often being so small that they cannot be detected using standard 
calorimetry techniques (Angell, 1995). A fragile super-cooled liquid has much 
stronger temperature dependence of molecular mobility near Tg and a relatively 
large change in heat capacity at Tg and will typically consist of nondirectionally, 
noncovalently bonded molecules (e.g. ethanol).
The behavior of amorphous systems is dependent upon the assumption of 
constant pressure and composition (Mishima et al, 1991). Pressure effects upon 
amorphous materials are likely to be significant with effects on molecular packing 
potentially modifying the glass transition temperature, the thermal expansion 
behavior, and the strength/fragility of a super-cooled liquid.
Simple mixing rules have been used by many authors to describe the variation of 
the glass transition temperature with blend composition, however the effects of 
non-idealities (e.g. immiscibility, molecular size differences, specific interactions, 
etc) are often significant. The simplest and most reliable approach for use with 
amorphous pharmaceutical materials appears to be a modified Gordon-Taylor-
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equation (Eq.1.1) established by Gordon. M, and Taylor. J in 1952, which is based 
on free volume theories, for simple two-component mixtures.
T,„, = (W’T-' + KW‘T*) .................................................. Eq.1.1
(wi + Kw 2)
Where:
Tg : Is the glass transition temperature
wi and W2 : Are the weight fractions of components 1 and 2,
K : Can be calculated from the densities p and glass transition temperature Tg of 
the components is in Eq.1.2:
k  _  E q 1 2
(T»* P2)
Similar equations can be readily derived for mixtures of more than two 
components. A perfectly miscible system will display a single sharp glass transition 
event. Immiscibility, incompatibility, or nonideality is often indicated by a poor fit to 
the theoretical equation and the appearance of more than one Tg or broadening of 
the glass transition event.
Simple solution theories also can be used to provide a qualitative understanding of 
the important factors regulating the glass transition in pharmaceutical systems. 
This is very important since the presence of very low levels of low molecular weight 
contaminants or additives (including water vapour) is predicted and observed to 
have significant plasticizing effects on pharmaceutical glasses. Whereas the 
addition of low levels of high molecular mass additives often has antiplasticizing 
effect (Gerhardt et al, 1994).
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1.1.5.3 Relaxation phenomena
Relaxation in the glassy state is often referred to as structural relaxation, physical 
aging, or annealing. The term “structural relaxation” refers to changes in 
atomic/molecular arrangements that occur during relaxation. The spontaneous 
conversion from the amorphous to crystalline state is quantified in terms of 
enthalpy or volume changes with time and temperature. As a glass is aged 
isothermally below the glass transition temperature, enthalpy, and entropy 
decrease spontaneously with time towards a temperature-dependent equilibrium 
value (Super cooled Liquid curve). The process by which the glass contracts 
toward the lowest free energy state is known as physical aging (McCram et al, 
1998). The term was introduced by Struik to distinguish relaxation effects from 
those produced by chemical reactions, degradation, or changes in crystallinity 
(Struik et al, 1978). The temperature range in which aging occurs is not restricted 
to a narrow range just below Tg. Since the time for molecular relaxation is 
approximately 100s at Tg, and of the order of hours to days at temperatures well 
below Tg (Hancock et al, 1997) these motions have to be measured using 
extended experimental techniques, sensitive to motion on the same time-scale.
The Williams-Watts equation has been applied to enthalpy relaxation data to find 
the temperature where molecular mobility is decreased to a level where it becomes 
negligible with respect to the expected life time of a drug (William et al, 1970). It 
has been reported that shelf lives estimated by the Williams-Watts mean molecular 
relaxation time constant are similar to those determined experimentally (Hancock 
et al. 1995; Van de Mootor et al. 1999).
1.1.5.4 Plasticization of amorphous materials
A highly important consideration with regard to the glass transition of amorphous 
materials is the effect of the presence of additional materials, particularly water, on 
the value of Tg. The study of mixed systems has been of particular importance in 
the polymer science field, whereby materials may be multi-component, with the 
degree of mixing being estimated by observing the glass transitions of the product 
in relation to those of the individual components. Mixing of amorphous
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pharmaceuticals is an approach that may be used to raise the glass transition of a 
product in order to improve stability (Fukuoka et al, 1989).
Water has a profound effect on the glass transition of amorphous pharmaceuticals, 
acting as a plasticizer by increasing the free volume of the material, hence leading 
to a decrease in Tg. Exactly the same principle applies to the inclusion of 
plasticizers in polymeric film coats.
In the amorphous state considerably more water may be taken up relative to the 
crystalline form (Hancock et al, 1997), effectively due to absorption of water into 
the solid, hence in contrast to crystalline systems the uptake process tends to be 
dependent on sample mass rather than surface area. As the concentration of water 
in the solid increases, the Tg is seen to decrease. Ahlneck et al. (1990) have 
emphasised that at higher storage temperatures, a lower amount of water is 
required to lower the Tg to that particular temperature.
In considering the importance of the amorphous state in determining the solid state 
properties of pharmaceuticals, four areas are most important: dissolution, 
crystallisation, chemical degradation, and mechanical responses to stress, (e.g. 
powder compression in tabletting).
1.1.5.5 Amorphous drugs and dissolution
The solid state characteristics of drugs are known to potentially exert a significant 
influence on the solubility parameter. Polymorphs of a drug substance can have 
different apparent aqueous solubilities and dissolution rates. When such 
differences are sufficiently large, bioavailability is altered and it is often difficult to 
formulate a bioequivalent drug product using a different polymorph.
Solubility at a defined temperature and pressure is the saturation concentration of 
the dissolved drug in equilibrium with the solid drug.Aqueous solubility of drugs is 
traditionally determined using the equilibrium solubility method that involves 
suspending an excess amount of a solid drug in a selected aqueous medium. The 
equilibrium solubility method may not be suitable to determine the solubility of a
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metastable form, since the metastable form may convert to the stable form during 
the experiment.
When the solubility of metastable forms of a drug substance can not be determined 
by the equilibrium method, the intrinsic dissolution method may be useful to 
deduce the relative solubilities of metastable forms (Amidon et al, 1995). The use 
of the intrinsic dissolution method assumes that the intrinsic dissolution rate is 
proportional to the solubility - the proportionality constant being the transport rate 
constant, which is constant under the same hydrodynamic conditions in a 
transport-controlled dissolution process.
Polymorphic differences and transformations that result in different apparent 
solubilities and dissolution rates are generally detected by dissolution testing. This 
test provides a suitable means to identify and control the quality of a product both 
from bioavailability and (physical) stability perspectives (Amidon et al, 1995).
It is well recognised that for many drugs, improvement in the dissolution rate may 
enhance the bioavailability of that drug. One approach for such an improvement is 
to prepare the drug in an amorphous form. The higher molecular mobility of this 
form compared to the equivalent crystalline material may lead to enhanced 
dissolution rate and bioavailability.
A number of examples of enhanced dissolution for amorphous drugs are available 
in the literature. These include the 9,3”-diacetylmidecamycin (MOM), a 16- 
membered macrolide antibiotic, was prepared in the crystalline and amorphous 
forms, and the dissolution behaviour of both at a range of temperatures was 
compared (Sato et al, 1981). The amorphous form showed higher dissolution 
rates, although at longer dissolution times the concentration in water decreases 
due to the formation of crystalline MOM from the supersaturated solution. Similarly, 
the dissolution rate of amorphous indomethacin has been reported to be greater 
than for the crystalline material (Fukuoka et al, 1989). Cefuroxime axetil in the 
amorphous form was found to have a higher dissolution and bioavailability than the 
crystalline form (Crisp et al, 1985).
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Drying or grinding may deliberately or accidentally induce amorphous 
characteristics. A ground mixture of griseofulvin and microcrystalline cellulose 
significantly improved both the dissolution rate and bioavailability of the drug 
compared to a micronised griseofulvin powder preparation (Yamamoto et al, 1974). 
This was ascribed to an increase in amorphous content of the drug as a result of 
the grinding process. Grinding of phenytoin with microcrystalline cellulose was also 
found to enhance drug dissolution rate, this again being attributed to the formation 
of an amorphous form of the drug (Yamamoto et al, 1976).
Various particle engineering processes such as spray drying may be used to 
prepare amorphous systems. A review of the physical structure of spray dried 
products, with special reference to thermal analysis, has been undertaken by 
Corrigan et al. (2004). The formation of amorphous pharmaceuticals via this 
process has been demonstrated for a number of drugs such as salbutamol.
1.1.5.6 Crystallisation of an amorphous material
Since molecules in the amorphous state are thermodynamically metastable relative 
to the crystalline state, the potential for crystallisation during handling and storage 
is omni present. Evidence exists to show that such crystallisation can be 
responsible for phenomena such as postcompression hardening of tables (Elamin 
et al, 1994), lyophilized cake collapse and particle aggregation in dry powder 
inhalers (Ward et al, 1995). It would appear important to be able to anticipate 
conditions that give rise to such crystallisation and to be able to inhibit it if so 
desired.
At the point when Tg drops to the experimental temperature T, most amorphous 
(glass) materials have a viscosity of 1012-10 14 Pa.S (Levine et al, 1988). In reality, 
this viscosity is too high to allow crystallisation to occur rapidly. Thus, it is more 
usual to see crystallisation when Tg has been significantly reduced below the 
experimental temperature.
Shalaev described the softening temperature as being the point at which collapse 
of structures under gravity will occur within a short period of time (Shalaev et al, 
1995). Subsequent to the collapse event, the material will crystallise. Again the
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rate of onset of crystallisation is dependent upon the extent to which Tg has been 
reduced below T. Crystallisation from the amorphous state is primarily governed by 
the same factors that determine crystallisation from the melt. For any amorphous 
system the temperature at which optimal nucleation, and hence crystallisation, 
should occur will depend primarily on the degree of super-cooling below Tm , and 
where the temperature lies relative to Tg. The closer to Tg the greater the degree of 
super-cooling and the lower the molecular mobility.
Gerhardt et al. (1993) showed that the crystallisation temperature for amorphous 
sugars is reduced by the presence of absorbed water in direct proportion to the 
plasticizing effects of water on Tg, and raised by the incorporation of high Tg 
additives. This has led to a general conclusion that crystallisation from amorphous 
state over practical time scale can be prevented by keeping the operating 
temperature below Tg (Jolley et al, 1970), by reducing the water content, or by 
raising the Tg of the system using additives with high Tg values (Yoshioka et al, 
1995) (e.g. PVP with a Tg of about 180°C). These strategies have been advocated 
by many workers, but a clear understanding of the molecular basis for such 
stabilising effects has not yet been achieved (Yoshioka et al, 1995).
Amorphous systems are expected to exhibit greater chemical reactivity (Pikal et al, 
1978), possibly at different rates below and above Tg (Yoshioka et al, 1994).
In conclusion, amorphous materials are thermodynamically unstable and therefore 
liable, under certain circumstances such as elevated temperature or relative 
humidity (RH), to undergo changes in its amorphous structure, or to revert to the 
stable crystalline form.
1.1.5.7 Characterisation of the amorphous state
Upon passing into the super-cooled liquid state or through the glass to rubber 
transition it is possible to observe changes in a multitude of material physical 
properties including density, viscosity, heat capacity, X-ray diffraction, and diffusion 
behavior.
Techniques which measure these properties (directly or indirectly) can be used to 
detect the presence of an amorphous material (glass or rubber), and some of
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these methods are sensitive enough to allow quantification of the amount of 
molecular order or disorder (amorphous content) in a partially crystalline system.
Diffraction Techniques
As there is no long range three dimensional molecular order associated with the 
amorphous state, the diffraction of electromagnetic radiation (e.g. X-rays) is 
irregular compared to that in the crystalline state. Diffraction techniques are 
perhaps the most definitive method of detecting and quantifying molecular order in 
any system, and conventional, wide angle and small-angle diffraction techniques 
have all been used to study order in systems of pharmaceutical relevance 
(Gerhardt et al, 1994).
The specificity and accurate quantitative nature of these nondestructive techniques 
make them first line choices for studying partially crystalline pharmaceutical 
materials. Conventional X-ray powder diffraction measurements can be used to 
quantify non-crystalline material down to levels of about 5% (Gerhardt et al, 1994), 
and with temperature and environmental control can also be used to follow the 
kinetics of phase transformations, or to quantify the presence of a crystalline drug 
in an amorphous excipient matrix (Ward et al, 1995).
Small angle X-ray measurements have been used to study subtle structural 
(density) changes in polymers in the glassy state upon annealing (Murase et al, 
2004), and neutron scattering is gaining wider use in the characterisation of short- 
range two-dimensional order in amorphous materials.
Gas Displacement Technique
The use of gas displacement pycnometry for quantifying the amorphous content of 
partially crystalline pharmaceutical systems has been described by (Saleki- 
Gerhard et al, 1994), and the accuracy achieved was about ± 10%. Liquid 
displacement pycnometry has also been used to determine the crystallinity of 
several mannitol samples (Chew et al, 1999). This approach has proved useful for 
quantifying low levels of disorder in crystalline pharmaceutical samples.
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Transport Phenomena
The most characteristic property of the amorphous state is its viscosity 
(approximately < 1012 Pa.s above Tg and > 1012 Pa.s below Tg). The greater free 
volume, lower density, and higher molecular disorder of an amorphous material 
compared to its crystalline counterpart, result in the mechanical properties of 
amorphous systems, (viscosity, elastic modules) being much more like those of a 
liquid than those of a solid.
As a consequence of the greater free volume in amorphous materials, diffusive 
transport processes are usually significantly more rapid than in crystals. Often 
different diffusion rates are observed above and below Tg, with significantly faster 
diffusion occurring above Tg. This phenomenon can be used to identify the glass 
transition temperature in some amorphous systems (Duddu et al, 1995). Despite 
being very difficult to make general predictions about diffusion behavior in 
amorphous systems because of the large number of system specific variables 
which can have an effect upon transport properties, it is possible to rank the rates 
of diffusion in the order liquid > rubber > glass > crystal, assuming all other factors 
to be approximately equal. Transport properties of amorphous pharmaceutical 
materials are important because they can be exploited to control drug release in 
modified release dosage forms (e.g. transdermal patches).
The methods used to study transport phenomena in amorphous pharmaceutical 
systems include diffusion cells, NMR measurements, and molecular dynamics 
simulations (Oksanen et al, 1993).
Scanning Probe Microscopy
The development in recent decades of scanning probe microscopy (SPM) 
techniques such as atomic force microscopy (AFM) has made visualization of 
surface structures on a nano to micrometer scale feasible (Shakesheff et al. 1996; 
Craig et al. 2002). In AFM, a tip attached to a cantilever (a spring) is scanned over 
a surface, while the deflection of the cantilever is monitored by the aid of a laser, 
as the tip moves over the sample. In this way, the nanoscale topography of the 
sample can be imaged. Moreover, modern SPM instruments can be run in different
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modes to derive indications of surface related properties such as friction and 
rheology.
AFM has found applications in many areas, such as biology and polymer and 
materials sciences, and the technique also has considerable potential in the field of 
pharmaceutics. It offers a unique means of scanning unprepared samples in 
different environments, including liquids, and at controlled temperature and relative 
humidity. A possible application could thus be the examination of solid systems 
during phase transformation, for example, crystallisation of amorphous materials. 
AFM can be a valuable tool for monitoring properties of pharmaceutical materials 
and the measurements can be performed directly, for example on compacts, film 
coatings, and single particles.
In recent publications, AFM has been used to study different crystal forms of 
Cimetidine (Danesh et al, 2000), friction, and adhesive forces of lactose (Sindel et 
al. 2001; Louey et al. 2001) crystallisation of films of amorphous Felodipine, and 
surface roughness in relation to friction (Berard et al. 2002; Bogdanovic et al.
2002).
A recently developed type of AFM, the microthermal analysis, has also been used 
to analyze and identify amorphous and crystalline materials (Bond et al. 2002; 
Royall et al. 2001). However, the AFM technique is restricted to flat sample 
surfaces, and the height range of the scanner is often limited to approximately 
10pm or less. The tip is also sensitive to lateral forces, which can be a problem 
when scanning rough surfaces. One way to circumvent this problem is to use AC 
mode, in which the sample is tapped by oscillation of the tip at the sample surface. 
Information is then extracted from the change in the amplitude of oscillation, rather 
than from the deflection as in contact mode.
The literature on the use of AFM for the quantification of crystallisation processes 
is limited. Trojak et al. (2001) reported that the surface roughness increased 
significantly as a film of amorphous felodipine crystallized. Beekmans et al. (2002) 
used AFM to study the kinetics of crystal melting of polyethylene oxide.
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Spectroscopic Techniques
Spectroscopic techniques are valuable for the characterisation of amorphous 
systems because of their high structural resolution. Nuclear magnetic resonance 
(NMR), Raman, infrared (IR) and electron spin resonance (ESR) studies of 
amorphous pharmaceutical systems have all been described (Taylor et al, 1997). 
These methods can be used to determine the glass transition temperature, 
quantify the presence of amorphous content and determine mean molecular 
relaxation times as a function of temperature (Taylor et al, 2001).
While there are some advantages in being able to follow the molecular mobility of 
specific chemical groups within molecule (e.g. resolution of different modes of 
motion), the conclusions drawn are open question unless supporting evidence can 
be obtained using complementary techniques (Fevotte et al, 2004). Samples 
ranging from simple powders or solutions to entire dosage forms can be studied 
using these nondestructive techniques, and this makes them especially useful for 
characterising pharmaceutical systems. Dielectric relaxation and dynamic 
mechanical spectroscopy have also been widely used to study amorphous 
pharmaceutical materials (Craig et al, 2001). These techniques are especially 
sensitive to the glass transition event and to secondary thermal transitions which 
reflect lower order molecular motions. Buckton had shown that it is possible to 
monitor the crystallisation of amorphous lactose in real time through examination of 
NIR spectra at certain wavelength (Buckton et al, 1998-a).
Recent studies by Seyer et al. (1997) have indicated that second derivative Near 
Infra-Red spectroscopy (NIR) spectra are able to quantify small amounts of 
amorphous materials in crystalline samples, this technique is extremely good at 
showing the state of water in the sample but not as good as calorimetry methods in 
quantifying the amorphous content.
Lusting et al. (1997) have shown that solid state NMR has a similar detection limit 





Thermal calorimetric analytical methods have been widely used to characterise 
amorphous pharmaceutical systems, and several comprehensive reviews of their 
use have been published (Giron et al, 1998). These methods can obviously be 
used to determine fundamental thermodynamic properties (e.g. heat capacity, 
enthalpy changes) of the amorphous state.
The heat capacity of an amorphous material is always higher than that of its 
crystalline state, and a change in the rate of heat capacity change with 
temperature defines its calorimetric glass transition temperature (Weuts et al,
2003). This change in heat capacity at the glass transition temperature ACP can be 
related to the fragility of the amorphous material (Angell et al, 1995).
Glasses are thought to be frozen into an unstable state on normal experimental 
times scales, but on longer time scales they slowly relax back to the metastable 
super-cooled liquid state. The enthalphic changes associated with this process 
was measured using DSC (Hancock et al, 1995). Such relaxation processes were 
also studied by thermomechanical analysis (TMA) for some sample configurations 
(Fukuoka et al, 1989). DSC method involves heating or cooling of a sample and 
reference and the measurement of the differential heat flow (power) between them 
with respect to temperature.
Hains described two principal approaches of DSC measurements (Hains et al, 
1995). Heat flux DSC which involves the measurement of the temperature 
differential between the sample and reference and the subsequent calculation of 
the equivalent heat flow according to Eq.1.3:
AQ = (Ts~Tr* ........................................... Eq. 1.3
Rt
where Q is heat, Rt is the thermal resistance of the cell and Ts and Tr are the 
sample and reference temperatures. Hence at a given scanning rate the heat flow
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is displayed against temperature. Power compensation DSC involves the 
application and measurement of a compensatory power input (P) to one or other 
pan in order to maintain both at the same program temperature.
Thus, DSC measurements provide qualitative and quantitative information as a 
function of time and temperature regarding transitions in materials that involve 
endothermic or exothermic processes, or changes in heat capacity. Some of the 
advantages contributing to the widespread usage of DSC are the ease of sample 
preparation, the applicability to both solids and liquids, fast analysis time and wide 
temperature range.
On the other hand, DSC does have some important limitations. It is often difficult to 
interpret the heat flow from a DSC experiment if multiple processes are involved 
over the same temperature range.
In a single component material, different types of transitions can overlap such as, 
for example, melting and recrystallisation in a semi-crystalline material. In a 
multicomponent material, transitions of the different compounds can overlap. 
Moreover it is not always straightforward to identify the nature of a transition, an 
enthalpic relaxation peak superimposed on the heat capacity variation at the glass 
transition temperature can be so large that the transition is confused with a melting 
transition, this renders identification and quantification of Tg extremely difficult 
(Verdonck et al, 1999). In addition to the above, there are also a number of 
practical considerations associated with the measurement of glass transitions 
using DSC. The baseline shifts may be small, particularly for strong glasses, 
rendering differentiation from baseline noise a non-trivial problem. However, a true 
glass transition will be reproducible and should be seen on both heating and 
cooling. Furthermore, it is essential that adequate baseline calibration is performed 
to ensure as flat a baseline as possible.
Craig et al. (1999-a) mentioned that the relaxation endotherm arises as a result of 
one of two processes. Firstly, it may reflect a mismatch in the rate of cooling and 
subsequent heating of the sample. When cooling is slow the glass that forms has
43
long relaxation times ‘frozen in’. Subsequently, when this material is heated 
quickly, with a faster rate through the glass transition than was the case on cooling, 
the relaxation times are slow with reference to the heating rate, thereby producing 
an overshoot in the enthalpy curve. In other words, the molecules within the glass 
cannot achieve the motion required for the glass transition within the time scale of 
the heating rate and the glass briefly superheats (Wunderlich et al, 1990). Once 
the relaxation times lower to the order of the heating rate the superheated glass 
reverts quickly towards the liquid line in the enthalpy curve. This overshoot and 
subsequent recovery in the enthalpy curve produces the characteristic 
endothermic peak in the ACP (or power) curve.
The second reason for the appearance of the endothermic relaxation is that 
because glasses are not in an equilibrium state. They can relax over time, thereby 
decreasing the enthalpy and volume of the material and increasing the structural 
relaxation time. Consequently, such annealing also produces a relaxation 
endotherm at the glass transition for the same reasons as above, the magnitude of 
which may be used to calculate relaxation times for the sample (Hancock et al, 
1995).
To increase the sensitivity (i.e. signal-to-noise) for the detection of a weak 
transition, either the sample mass or the scan rate can be increased. For obtaining 
a better resolution in separating transitions occurring at close temperatures, either 
smaller samples are used or the scan rate is lowered. Thus, an increased 
sensitivity is at the expense of the resolution and vice versa.
Besides, the detection of weak transitions is also strongly influenced by the 
baseline curvature and stability. The determination of a small jump in heat capacity 
for example, is much more difficult when it is superimposed on a curved baseline 
then if the baseline is straight. Often the baseline is not straight due to, for 
example, moisture evaporation from the sample, variations in thermal contact 
between the sample and the DSC pans during the scan and the overall baseline 
characteristics of the specific DSC cell.
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Some quantities such as the absolute value of a materials heat capacity and its 
thermal conductivity cannot be determined straightforwardly with DSC and require 
multiple experiments. Moreover, the heat capacity cannot be determined in an 
isothermal experiment with DSC.
Modulated Temperature DSC (MTDSC) overcomes these limitations and therefore 
provides new insight into the materials properties (Royall et al, 1998). A number of 
instruments are available under the category of MTDSC. The development of 
MTDSC has removed or reduced some of the difficulties associated with 
characterising glass transitions (Giron et al. 1998, Craig et al. 1999-c). This 
technique involves the application of a sinusoidal heating signal superimposed on 
the linear temperature ramp. Hence, information may be derived from both the sine 
wave response and the Fourier transformed total heat flow output (equivalent to 
conventional DSC) (Royall et al, 1988). The advantage of the technique is that 
changes in heat capacity (i.e. glass transitions) may be seen in isolation from other 
events, particularly relaxation endotherms, with a considerably enhanced signal-to- 
noise ratio (Hill et al, 1998).
In the MTDSC sample preparation conditions must be carefully controlled (and 
stated), particularly in terms of the choice of pans and level of residual moisture or 
other solvents, as changes to the sample either during or prior to analysis may 
have a profound influence on the measured Tg. An investigation by Hill et al. 
indicated that the measured Tg of spray dried lactose may vary by -  35°C 
depending on pan type (Hill et al, 1998). This is due to the retention of water in 
hermetically sealed pans, which acts as a plasticizer, thereby reducing Tg 
compared to non-hermetically sealed or open pans from which water is lost during 
the heating run.
Glass transition temperature measurements are ideally performed in cooling rather 
than heating cycles, as in the former the sample starts from the equilibrium liquid 
state before entering the nonequilibrium glass, which is a reproducible route 
compared to starting from the glass in a heating cycle (Wunderlich et al, 1990). 
However, many pharmaceutical systems such as drugs and freeze dried systems
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are heat sensitive and may not withstand cycling. Similarly, other systems are 
multi-component; hence heating through the Tg of one component may result in 
irreversible changes in the structure of the system as a whole. Consequently, most 
pharmaceutical studies have involved measuring Tg upon heating.
Operating principle of MTDSC
In MTDSC a sinusoidal modulation is overlaid on the linear ramp. As a result of the 
temperature modulation, the heating rate is no longer constant, but varies in a 
periodic (modulated) fashion. The average heating rate, corresponding to the rate 
for a conventional DSC experiment, is called the underlying heating rate. The 
modulated heating rate varies between a minimum and a maximum value; these 
are determined by the value of the underlying heating rate, the period (or 
frequency) and the amplitude of the superimposed temperature wave. Depending 
on the combination of these three parameters, the minimum modulated heating 
rate is positive (heat-only), zero (heat-isothermal), or negative (heat-cool).
The resultant heat flow between the sample and reference in a DSC or MTDSC 
experiment is described by the general Eq.1.4:
^  = C pb+ /(T ,t)................................................Eq. 1.4
at
Where dQ/dt is the resultant heat flow, Cp is the heat capacity of the sample, b is 
the rate of temperature change (dT/dt) and /(T,t) is heat flow from kinetic 
processes. For an MTDSC experiment, the resultant heat flow is periodically 
varying and termed the modulated heat flow.
From the general equation, it follows that the resultant heat flow is composed of 
two components: one component is a function of the samples heat capacity and 
rate of temperature change, and the other is a function of absolute temperature 
and time. In conventional DSC only the sum of the two components is determined 
and is called the total heat flow. In MTDSC the total heat flow and the two 
individual components can be distinguished as the heat capacity component (Cpb)
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or reversing heat flow and the kinetic component (/(T,t)) or non-reversing heat flow 
(Cser et al, 1997).
All of these signals are calculated from three measured inputs: time, modulated 
temperature, and modulated heat flow. The total heat flow in MTDSC is calculated 
from the average of the modulated heat flow; this average corresponds to the total 
heat flow in a conventional DSC experiment at the same underlying heating rate. In 
conventional DSC, Cp can be calculated from the difference in heat flow between 
two runs on an identical sample at two different heating rates. In MTDSC, Cp can 
be determined in a single experiment because of the periodical variation in heating 
rate: the heat capacity is calculated from the ratio of the modulated heat flow 
amplitude and the modulated heating rate amplitude by discrete Fourier 
transformation. The reversing heat flow is then calculated by multiplication of Cp 
with the negative heating rate b. the kinetic component or non-reversing heat flow 
is the arithmetic difference between the total heat flow and the reversing heat flow.
Solution calorimetry
Solution calorimetry has also been used to a small extent to assess powder 
crystallinity. This approach works on the basis that the heat of solution will be 
different for the crystalline and the amorphous states of a sample. Previous studies 
by Ward and Shultz (1995) showed clear differences in the heat of solution of 
micronised and crystalline salbutamol sulphate samples. These differences were 
attributed to changes in surface energy.
Thompson et al. (1994) have shown that solution calorimetry can be an effective 
way of differentiating between drug samples with different degrees of crystallinity. 
They also showed good agreement between heat of solution and thermal activity 
measured in an isothermal microcalorimeter over the range 0 -  100% crystallinity. 
Salvetti et al. (1996) have demonstrated that different physical forms of 
carbohydrates can be differentiated by measuring heat of solution. Pikal et al. 
(1978) used heat of solution measurements to correlate the extent of crystallinity to 
the chemical stability of antibiotics.
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Microcalorimetry
Microcalorimetry can be used in a non-isothermal mode to detect glass transition 
events and secondary transitions in amorphous pharmaceutical solids. It has also 
been used in several studies to detect physical and chemical instabilities in 
formulations containing amorphous drugs or excipients (Heidemann et al. 1991; 
Buckton etal. 1995-c).
A further innovation has been the introduction for microthermal analysis, a 
technique that combines the principles of atomic force microscopy (AFM) with 
calorimetry. In essence the tip of the AFM is replaced by a Wollaton wire whereby 
the platinum sheath is etched away to leave a high resistance tip. On application of 
a voltage the tip heats in a controlled manner, thereby allowing one to perform 
thermal analysis on highly specific regions of a sample. For example, one may 
land the tip on a specific region of a complex material and heat, usually at very 
rapid rates in the region of 10-20°C/sec. In this manner specific components may 
be identified and characterised, such as the mixed amorphous and crystalline 
regions. By landing the tip on these different regions, it becomes possible to 
identify the material by the temperature at which the material either softens if 
glassy or melts if crystalline (craig et el, 2002).
Other calorimetric approaches include the gas flow, this approach uses a 
calorimeter cell in which the powder is housed, which has been constructed to 
allow a constant flow of humid air. The humidity can be altered in steps or as a 
ramp. As the powder crystallises, there will be a clear exotherm and also an 
endotherm associated with the water loss. A number of studies on the use of these 
gas flow cells in calorimeters have been published, e.g. (Sheridan et al. 1995; 
Puddipeddi et al. 1996; and Sokoloski et al. 1997).
Vapour Sorption Techniques
Bulk analytical techniques, such as differential scanning calorimetry, powder X-ray 
diffraction and IR spectra, will measure the properties of the sample as a whole. 
The detection limits for amorphous content with such techniques can vary, but will 
generally have a lower cut off of 5-10% (Gerhardt et al, 1994). This detection limit
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is related to the fact that these techniques measure the entire sample; thus, the 
amorphous content becomes a small part of the total signal, and consequently it is 
difficult to detect with confidence. It may be more appropriate to preferentially 
investigate the properties of the powder surface only, where amorphous material 
may predominate.
A powerful way of investigating surface properties is by using the vapour sorption 
studies, which preferentially probe amorphous (over crystalline) regions due to 
absorption behavior. As the vapour sorption by amorphous and crystalline 
pharmaceutical materials is usually quite different, thus it can be used to precisely 
distinguish between them (Zografi et al, 1994). Typically, crystalline materials 
adsorb vapours in small quantities at their surfaces in contrast amorphous 
materials absorb vapours in relatively large amounts. Rubbery amorphous 
materials usually sorb considerably greater quantities of vapour than their 
respective glasses, and this phenomenon can be used to identify the state of an 
amorphous material (Oksanen et al, 1990).
Hancock et al. (1997) described water sorption studies as the preferred means of 
studying pharmaceutical systems containing low levels of amorphous material. 
Water sorption has been used in the study of many amorphous and partially 
amorphous powders. A few examples in the pharmaceutical literature include 
sucrose by (Gerhardt et al, 1994); Lactose by (Buckton et al, 1996); raffinose by 
(Gerhardt et al, 1995); and salbutamol sulphate by (Ward et al, 1995).
Another vapour sorption technique is the inverse phase gas chromatography 
(IGC), in which the powder is packed in a column and known liquid vapours 
(usually at infinite dilution in a carrier) are passed into probes (Ticehurst et al, 
1994). It is possible to assess the surface nature of the material in the column. In 
keeping with the calorimetric and gravimetric techniques, it is to be expected that 
this vapour sorption approach will also be able to detect differences in samples 
due to small amount of amorphous content.
49
In summary, there are many precise and accurate methods suitable for studying 
and characterising amorphous pharmaceutical materials in all their configurations, 
including final dosage forms. As with any scientific method, the use of multiple 
complimentary techniques which measure the properties most relevant to the 
problem or material under consideration is preferred. The most notable difference 
between the techniques described is in their ability to quantify the amount of order 
or disorder in partially amorphous systems, and in their ability to monitor molecular 
level processes over a wide range of temperatures (ideally above and below Tg), 
(Buckton etal, 1998-b).
1.1.5.8 Physico-mechanical factors which influence the behaviour of 
amorphous systems
In the processing and handling of solid pharmaceuticals there are a number of 
situations where rheological or mechanical properties are critical for product 
manufacturability, stability, and performance. Most crystalline materials tend to 
exhibit high levels of elasticity and brittleness upon exposure to an external stress. 
In contrast, molecules in the amorphous state tend to exhibit varying degrees of 
viscoelasiticity, depending on their temperature in relation to the Tg.
Such viscoelastic behavior provides solids with the ability to flow under conditions 
of mechanical stress and to provide a number of important excipient functionalities. 
Relief of mechanical stresses through flow would appear to be important in 
creating tablet bonds after compression of powders (Elamin et al, 1994), and in 
preventing mechanical failure of polymeric film coats on tablets because of stress 
relaxation (Sinko et al, 1991).
The use of plasticizers, including water, to lower the Tg of various cellulose and 
acrylic polymers utilized in film coating is based on this principle, as is the use of 
spray dried lactose (about 15% amorphous content), or microcrystalline cellulose 
(about 30% amorphous content) as direct compression tableting excipients. For 
example, a critical level of about 4-6% water provides a significant change in the 
viscoelasitic properties of microcrystalline cellulose (Amidon et al, 1995), and is at 
a level below which direct compaction properties are lost.
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Chemical reactivity
Chemical degradation of drugs in the solid state, particularly at elevated 
temperatures and relative humidities, is a fairly common occurrence with drugs 
exhibiting susceptibility for degradation when in solution (Byrn et al, 1982). In the 
amorphous state, the reacting molecules have sufficient free volume and molecular 
mobility to chemically react. One would expect a comparison of reaction rates of 
crystalline and amorphous forms of a drug under otherwise identical conditions to 
reveal greater rates with the amorphous forms than with the crystalline forms, and 
this has been shown to be the case for a number of systems (Carstensen et al, 
1993).
Stability and manufactureability
Polymorphic forms of a pharmaceutical ingredient may have different physical and 
solid state chemical (reactivity) properties (Byrn et al, 1995). The most stable 
polymorphic form of a drug substance is often used because it has the lowest 
potential for conversion from one polymorphic form to another, while the 
metastable form may be used to enhance bioavailability. Thermodynamic activity 
and solubility provide a definitive measure of relative polymorphic stability under 
defined conditions of temperature and pressure.
The relative polymorphic stability may be determined by the examination of the 
relative apparent solubility of supersaturated solutions of polymorphic pairs. Since 
the rate of conversion to the more stable form is often rapid when mediated by the 
solution phase, the less stable polymorph with the greater apparent solubility 
dissolves, while the more stable polymorph with the lower apparent solubility 
crystallises out.
Solid-state reactions include solid-state phase transformations, dehydration 
/desolvation processes and chemical reactions. One polymorph may convert to 
another during manufacturing and storage, particularly when a metastable form is 
used.
Since an amorphous form is thermodynamically less stable than any crystalline 
form, inadvertent crystallisation from an amorphous drug substance may occur. As
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a consequence of the higher mobility and the ability to interact with moisture, 
amorphous drug substances are also more likely to undergo solid-state reactions. 
In addition, phase conversions of drug substances are possible when exposed to a 
range of manufacturing processes (Brittain et al, 1999). Milling and micronisation 
operations may result in polymorphic form conversion of a drug substance (Ward 
et al, 1995). In the case of wet granulation processes, where the usual solvents are 
aqueous, one may encounter a variety of transformations between anhydrous and 
hydrates, or between different hydrates. Spray-drying processes have been shown 
to produce amorphous drug substances and specially proteins (Pikal et al, 1993).
1.2 CEFUROXIME AXETIL 
1.2.1 Activity
Cefuroxime is a second generation cephalosporin antibiotic, which has a broad 
spectrum of activity against both gram-positive and gram-negative 
microorganisms. It is generally more active against gram- negative bacteria than 
first generation cephalosporins, but has a narrower activity in this aspect than the 
third generation cephalosporins.
Cefuroxime exerts its bactericidal effect by binding to an enzyme or enzymes 
referred to as penicillin binding proteins (PBPs), involved in bacterial cell wall 
synthesis. This binding results in inhibition of bacterial cell wall synthesis and 
subsequent cell death. Specifically, it shows high affinity for PBP3, a primary target 
for cefuroxime in gram negative organisms such as E.coli., and it has bactericidal 
activity against a wide range of common pathogens, including many beta- 
lactamase-producing strains. It is stable to many bacterial beta-lactamases, 
especially plasmid-mediated enzymes that are commonly found in 
enterobacteriaceae (De Sommers et al, 1984).
1.2.2 Bioavailability
The compounds use is limited to injectable administration because it is poorly 
absorbed from the gastro-intestinal tract following oral dosing, where sodium salt of 
cefuroxime after oral administration is absorbed in less than 1% of applied dose 
(Ridgway et al, 1991).
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Higher bioavailability values are obtained only with cephalosporins that are taken 
up by carrier systems, or when the polarity of the carboxylic acid group in the 
4 position is reduced by esterification (Stoeckel et al, 1995). Therapeutically active 
drug can, however, be obtained only if the absorbed prodrug ester is readily 
converted back to the active drug. The success of the prodrug ester approach 
depends vitally on the solubility and lipophilicity of the prodrug ester as well as its 
stability to chemical and enzymatic ester cleavage. Crisp et al. (1989) described 
the synthesis of the 1-acetoxyethyl ester of cefuroxime, now referred to as 
cefuroxime axetil (CA).
Cefuroxime axetil is a prodrug of cefuroxime which can be orally administered, 
thereby permitting more convenient and wider therapeutic use of cefuroxime. 
Esterification of the carboxyl group of cefuroxime renders the molecule more 
lipophilic and, in contrast to the parent substance, a significant proportion is 
absorbed after administration.
Chemically, cefuroxime axetil, is (RS)-l-hydroxyethyl (6 R, 7R)-7-[2-(2furyl) 
glyoxylamido]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2 
carboxylate, 72-(Z)-(0-methyl-oxime), 1-acetate 3-carbamate. Its molecular formula 
is C20H22N4O10S, and it has a molecular weight of 510.48. The structural formula of 






Figure 1.2: Structural formula of cefuroxime axetil
The major structural differences between cefuroxime and other commercially 
available cephalosporins is that cefuroxime contains a methoxyimino group at
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position 7 on the beta -  lactam ring and a carbamate group at position 3 on the 
ring. The methoxyimino group results in stability against hydrolysis by many beta- 
lactamases and the carbamate group results in metabolite stability.
Cephalosporin prodrug esters exhibit oral bioavailabilities of approximately 50%, 
after oral administration, CA is absorbed from the gastrointestinal tract and rapidly 
hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to 
cefuroxime. Cefuroxime is subsequently distributed throughout the extracellular 
fluids. The axetil moiety is metabolized to acetaldehyde and acetic acid (Ginsburg 
et al, 1985).
Cefuroxime axetil suffers from being rapidly hydrolyzed in the intestine, leaving 
substantial unabsorbable cefuroxime. This premature hydrolysis in the intestine 
before absorption has been discussed as a possible reason for their incomplete 
bioavailability (Saab et al, 1988). Hydrolysis can proceed either by enzyme- 
catalyzed direct hydrolysis to the parent cephalosporin (Mosher et al, 1992), or via 
a reversible base-catalyzed isomerization yielding the A 2-cephalosporin ester 
which is rapidly cleaved to give the biologically inactive A2-cephalosporin (Richter 
et al, 1990). Both pathways will remove some of the cephalosporin available for 
absorption. The result is incomplete bioavailability of the oral prodrug ester. On the 
other hand, direct hydrolysis to the non absorbable but biologically active 
cephalosporin in the gut lumen could affect the gut flora, causing undesirable 
intestinal side effects (Cullmann et al, 1995). Campbell et al. (1987) reported the 
isolation and partial characterisation of an esterase enzyme which is said to be 
responsible for converting CA to cefuroxime in the gut.
The ester portion of CA, namely the 1-acetoxyethyl group, contains an asymmetric 
carbon atom at the 1-position. Accordingly CA exists in the form of a mixture 
(mainly 1:1) of two diastereomers designated as R (1R, 6R, 7R) and S (1S, 6R, 
7R). Little is known concerning the relative availability of cefuroxime from each 
isomeric form. Barrett et al. (1997) used a Caco-2 cell monolayer model to 
examine the possible stereo selectivity of absorption of CA. This was done by 
measuring the accumulation and epithelial transport rate in the apical to
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basolateral direction of cefuroxime and CA, following application of a mixture or 
individual diastereomers. Cefuroxime appearance in the basolateral chamber was 
in the order of mixture> R > S following application of the prodrug. The 
accumulation of unchanged CA was higher for S than for R, irrespective of the 
form applied, i.e. individual diastereomer or the mixture. Such stereoselective 
differences in both absorption and/or hydrolysis may contribute to the observed 
oral bioavailability (30 -  50 %) of cefuroxime in vivo (Barrett et al, 1997).
Mosher et al. (1991) reported that the individual S-isomer of cefuroxime axetil is 
hydrolyzed in animals much more rapidly than the R-isomer. Accordingly, an R- 
isomer substantially free of the S-isomer was prepared. The selective 
administration of the R-isomer was reported by Mosher to cause a surprisingly 
greater bioavailability of cefuroxime. The latter was said to be readily absorbed in 
the stomach and intestine well before the esterase enzymes located there are able 
to hydrolyze the axetil portion of the molecule. Accordingly, oral administration of 
R-cefuroxime axetil was expected to result in good absorption of antibiotic from the 
stomach and gut, resulting in drug levels of cefuroxime in the blood sufficient for 
rapid and effective control and irradiation of the bacterial infection throughout the 
animal system (Mosher et al, 1991). Just as important, however, is the low 
incidence of hydrolysis in the intestine, and thus low concentration of cefuroxime 
as the free acid, which is essentially not absorbed from the gut, and the presence 
of which results in undesired intestinal irritations.
In concordance to this, Stoeckel et al. (1998) studied the compounds cefetamet 
pivoxil, cefuroxime axetil, and cefpodoxime proxetil. They found that there occurred 
a rapid hydrolytic cleavage to the biologically active A 3-cephalosporin in the 
intestinal juice, without the concomitant formation of significant amounts of the A 2  
isomers. Spontaneous base-catalyzed isomerization to the A  2 ester was 
significantly slower than hydrolytic cleavage to the A 3  acid. The isomerization 
process is, therefore, not efficient enough to compete with enzymatic ester 
cleavage. The incomplete bioavailability of the prodrug esters was related to the 
efficient enzymatic hydrolysis and not to the A  3 to A  2 isomerization and 
spontaneous hydrolysis of a 2 esters.
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A further relevant observation by Stoeckel et al. is the high stereoselectivity of the 
enzymatic cleavage reaction. With cefuroxime axetil and cefpodoxime proxetil, 
both as diastereoisomer mixtures, the S diastereoisomer was hydrolyzed faster 
than the R, by factors of 2.5 and 5.5, respectively (Stoeckel et al, 1998). Thus, by 
using the most stable diastereoisomer of the prodrug ester instead of a mixture, 
higher bioavailabilities can be achieved. Furthermore, elimination of the more 
rapidly hydrolyzed isomer should reduce the amount of biologically active 
cephalosporin formed in the gut, leading to improved intestinal tolerability.
Balaguer et al. (1997) studied the intestinal transport of CA in rats. Studies were 
performed using three CA solutions (11.8, 118 and 200 pM) in three selected 
intestinal segments, and one CA solution (118pM) in colon of anaesthetized rats. 
First-order absorption rate pseudo constants, kap and effective permeability 
coefficients, Pem were calculated in each set. Absorption of CA was apparently 
described as a carrier-mediated transport, which obeys Michaelis-Menten and first 
order kinetics in the proximal segment of the small intestine, and a passive 
diffusion mechanism in the mean and distal segments. In situ intestinal absorption 
of CA in the proximal segment of the rat, in the presence of variable concentrations 
of cefadroxil has been also investigated by Balaguer (1997), in order to examine 
the inhibitory effect of cefadroxil on CA transport. The data suggested that both 
compounds shared the same intestinal carrier.
As a requirement in the official compendia (USP, BP and JP), CA has been 
specified as a diastereoisomer of A and B (R and S) of which A should constitute 
48 -  55% of the mixture.
1.2.3 Physical Forms
It is reported in the literature that CA exists in its amorphous (CAA) and crystalline 
(CAC) forms. Oszczapowicz et al. (1995) reported that CAC does not exhibit 
adequate bioavailability upon oral administration. The amorphous form of CA 
which has higher bioavailability had been prepared by Crisp et al. (1985), as 
essentially free from the crystalline form. Different processes for preparation of 
amorphous cefuroxime axetil were reported in the literature, these include spray 
drying (Crisp et al, 1989) and recovering of CA by drying (Handa et al, 2002).
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It was reported by Oszczapowicz et al. (1995) ; Woo et al. ( 2000) ; Guk et al. 
(2002) that CA shows polymorphism of three forms detected by DSC. Sasinoswka 
et al. (1995) reported that CA concentration after oral administration to rats 
depends to a considerable degree on the form as well as on the particle size.
1.2.4 Stability
Cefuroxime axetil is a relatively stable compound under normal ambient conditions. 
Fabre et al. (1993) studied the effect of light on CA, where the photoisomerization 
kinetics of aqueous solutions of CA under irradiation at 254 nm was studied by 
HPLC. They reported that the overall degradation is the result of a competition 
between the isomerization of the alkoxyimino group to A 2 isomer and the 
photolysis of the p-lactam ring. The two diastereomers were found to react at 
different rates. That was true not only for the photoisomerization step but also for 
ground-state hydrolysis in alkaline conditions. Photoisomerization of the 
alkoxyimino group was also observed for the anti isomer of CA and for some of its 
degradation products. Results of the study indicated that in comparison to the 
other cephalosporins, bearing the alkoxyimino group, CA was most sensitive under 
irradiation at 254 nm.
Stoeckel et al. (1996) compared the levels of degradation of cefetamet pivoxil (CT), 
CA and cefpodoxime proxetil (CD) in 0.6 M phosphate buffer (pH 7.4), and human 
intestinal juice (pH 7.4) at 37°C over 24 h. Significant differences in the time courses 
of degradation and in the patterns of degradation products were observed. The 
relative proportions of the A2- and A3-cephalosporins were roughly reversed in the 
two incubation media. In phosphate buffer, the major degradation product was A2- 
cephalosporin while in the intestinal juices it was A3-cephalosporin. Generally, the 
degradation of the prodrug esters progressed faster in intestinal juice than in 
phosphate buffer. The two diastereoisomers of CA and CD degraded at different 
rates in intestinal juice.
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1.2.5 Pharmaceutical Formulations
Cefuroxime axetil is formulated into tablets and dry suspension dosage forms. 
Ceftin® tablets are administered for the treatment of patients with mild to moderate 
infections caused by susceptible strains of the designated microorganisms.
Ceftin® for oral suspension is administered for the treatment of pediatric patients 
from 3 months to 12 years of age with mild to moderate infections caused by 
susceptible strains of the designated microorganisms in the conditions of 
pharyngitis/tonsillitis, acute bacterial otitis media, and impetigo.
Ceftin® for oral suspension was found not to be bioequivalent to Ceftin® tablets 
when tested on healthy adults. Thus, the tablet dosage forms and the powder for 
oral suspension formulations are not substitutable on a mg/mg basis. The area 
under the curve for the suspension averaged 91% of that for the tablet, and the 
peak plasma concentration for the suspension averaged 71% of the peak plasma 
concentration of the tablets. The safety and effectiveness of both the tablet and 
oral suspension formulations had to be established therefore in separate clinical 
trials (Finn et al, 1987).
Absorption of the tablet is greater when taken after food, where the absolute 
bioavailability increases from 37% to 52% (Finn et al. 1987; Donn et al. 1994). 
Cefuroxime axetil has an extremely bitter taste which is long lasting and which 
cannot be adequately masked by the addition of sweeteners and flavors to 
conventional granules presentations. Tablets are film coated to reduce the bitter 
taste of the drug.
The tablet core was formulated such that it disintegrates immediately following 
rupture of the film coat (Deutsch et al, 1990-a). This was achieved by using 
disintegrants, which provide the desired disintegration properties. The tablet core 
conveniently contains a disintegrant at high concentrations of 4 to 10% by weight.
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Another problem arises from the tendency of CA both in the crystalline and the 
amorphous form to form a gelatinous mass when in contact with the aqueous 
media. This gelling effect is temperature dependent, and occurs at temperatures at 
about 37°C (James et al, 1989). Such gelling would lead to poor dissolution of CA, 
and hence poor absorption from the gastrointestinal tract, i.e. low bioavailability. In 
the case of granule formulations, the use of particles of small diameter and high 
surface area is desirable to avoid gelling (James et al, 1989).
In the formulation of CA powder for dry suspension, it is highly important to avoid 
the release of the drug into any liquid suspension prior to administration. This has 
been achieved by formulating CA as lipid coated particles, the coat of which has a 
limited permeability to water and remains integral (James et al, 1989).
The integral lipid coat has a melting point of 45 -  60°C and is substantially 
insoluble in water, but readily dispersed or dissolved in gastro-intestinal fluid. The 
formulated coated particles, while not releasing the bitter CA in the wet 
environment of the mouth, break down upon contact with gastro-intestinal fluid, 
thus allowing rapid dispersion and dissolution in the gastro-intestinal tract.
1.3 FORMATION OF TASTE MASKED API PARTICLES
1.3.1 Taste masking approaches
For ease and safety of administration, most drugs are formulated as tablets or 
capsules for oral administration. However, children and the elderly often 
experience difficulty in swallowing solid oral dosage forms. For these patients, 
drugs are commonly provided in liquid dosage forms such as solutions, emulsions 
and suspensions. These dosage forms usually permit perceptible exposure of the 
active drug ingredient to the taste buds, which can be a problem when the drugs 
have an unpleasant taste or are extremely bitter.
Conventional taste masking techniques such as the use of sweeteners, and 
flavoring agents are often unsuccessful in masking the taste of highly bitter drugs 
and other techniques have been and continue to be exploited for the effective taste
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masking of such drugs. Extremely bitter drugs, like, quinine, ciprofloxacin, 
clarithromycin and cefuroxime axetil have been formulated as a fairly acceptable 
range of products even for pediatric use.
Palatability of oral suspensions is important and may be a substantial factor in 
determining compliance in young pediatric patients. Dagan et al. (1994) studied 
acceptance and compliance of such oral antibiotic suspensions. During a 4-month 
period, lists of children receiving oral antibiotic suspensions were obtained from 
three major pediatric ciinics, and parents were contacted 10 to14 days after 
initiation of therapy, at which time information on age, sex, main disease, 
prescribed drugs and duration of treatment was obtained.
Information regarding acceptance, side effects and compliance were obtained from 
11 questions with graded scores. In the study 546 children received one of the 
following drugs: amoxicillin (n = 222); cefaclor (n -142); cefuroxime axetil (n = 107); 
trimethoprim / sulfamethoxazole (n = 75). More than 50% of each group had acute 
otitis media. The result of the study was that 73% of the cefaclor group reported 
acceptance of the drug with a pleasurable experience versus 60, 55 and 20% for 
amoxicillin, trimethoprim / sulfamethoxazole and cefuroxime axetil respectively.
These data demonstrated that marked variations exist in acceptance and 
compliance of oral antibiotic suspensions with children. The findings influenced the 
choice of drugs for young pediatric patients with common infections (Dagon et al, 
1994).
Taste sensation is presented by taste transduction, which is how the taste cells 
detect the presence of pleasant-tasting nutrients and bitter-tasting toxins, and store 
this information in the taste cell. Taste transduction involves the interaction of 
molecules with taste receptor cells, which reside in specialized structures known 
as taste buds (Margolskee et al, 1993). Taste buds are located in the papillae of 
the tongue and are the end organ of taste. The function of taste buds is to relay 
information to the CNS on the positive (nutrient-rich) and negative (bitter-poison) 
content of foods. Recent advances in molecular biology and biochemistry of taste
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have shown that each taste modality affects receptor cells through a distinct 
mechanism. The transduction of most bitter and sweet compounds is mediated via 
G protein coupled receptors (GPCRs), while salty and sour tastes depend on ion 
channels (McLaughlin et al, 1992).
The G proteins are a class of heterotrimeric proteins that amplify signals generated 
at the cell surface by ligand-activated receptors. More than 50% of bitter 
substances activate one or more taste receptors, which catalyze the activation of 
the taste specific G protein gustducin. Gustducin is homologous to transducin, the 
G protein of the visual system. Gustducin and transducin have been localized to 
taste buds and co-localize with taste GPCRs (McLaughlin et al, 1992; 1995).
When gustducin is activated, it dissociates into alpha and beta-gamma subunits. 
Alpha-gustducin activates intracellular phosphodiesterases leading to decreased 
cAMP levels (Birnbaumer et al, 1990). Lower cAMP concentrations cause 
activation of ion channels resulting in a change in the taste cell potential. The beta- 
gamma subunits are thought to activate phospholipase C, which can generate the 
second messengers IP3 and DAG. IP3 can then mobilize intracellular stores of 
calcium modulating the taste cell membrane potential. This complex cascade of 
biochemical events results in taste cells sending a signal to the brain that is 
interpreted as bitter and unpleasant.
Most of the non-gustducin mediated bitter substances are thought to traverse the 
taste cell membrane and directly modulate downstream signal transduction 
enzymes or ion channels. The bitter taste of caffeine is transduced by inhibition of 
the taste cell phosphodiesterase (PDE) (Ming et al, 1999).
There is a wealth of information about formulations and processes, including 
materials and equipment for producing active pharmaceutical ingredient (API) 
particles designed for taste masking applications. Of these, a review of taste 
masking in liquid dosage forms was published (Sun et al, 1998), which covered the 
sensory approaches, chemical approaches, complexation/adsorption approaches 
and barrier approaches.
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Other reviews written by Roy et al. (1994 ; 1997) covered specific formulations and 
ingredients used for producing taste masked API particles including flavors, 
sweeteners, amino acids, lipids, lecithin-like substances, surfactants, hydrophilic 
substances, and polymers/resins (including ion exchange). These studies 
presented a comprehensive review of the taste masking literature up to the early 
1990s.
A review on encapsulation technology focusing on drug delivery applications had 
been published by Sparks et al. (1999). It comprehensively covered important 
characteristics of the core particle, selection and formulation of coating materials, 
equipment and coating procedures, scale up and problems related to 
microencapsulation.
Gibbs et al. (1999) review on encapsulation in the food industry provided an 
alternative perspective on materials, processes and equipment used for 
encapsulation of liquids and solids for purposes of controlled release, stabilisation, 
physical separation of ingredients and masking of taste and odor.
Tyle et al. (1990) addressed an important issue related to solid oral application of 
taste masked API through encapsulation. Namely, sensory attributes of 
particulates including texture and palatability. Although they specifically addressed 
size, shape and hardness of particles in suspension, the results were said to be 
applied to solid oral forms as well. The results showed significant differences in 
sensory perception between different samples based on size, shape and hardness. 
Aside from particle size, the important discovery from this work is that other particle 
physical characteristics (shape and hardness) can also affect textural perceptions.
In general, in the pharmaceutical industry, taste-masking science covers 
physiological and physicochemical approaches to prevent active pharmaceutical 
ingredient (API) or drugs from interacting with taste buds; thereby eliminating or 
reducing negative sensory response.
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Physiological approaches consist of inhibiting or modifying an API-mediated 
bitterness response by incorporating agents into a pharmaceutical formulation. 
Agents like sodium chloride (Breslin et al, 1997), phosphatidic acid, and 
peppermint flavor (Katsurgi et al, 1997) are known to inhibit bitterness of select API 
molecules via a mechanism that takes place at the bitterness receptor in the taste 
buds. Other approaches include the physical approach, presented by 
encapsulating the API with a coat or barrier material that physically separates the 
API from the water in saliva, the chemical approach, which is to complex or 
electrostatically bond the API with another chemical compound.
In the scientific literature, the above approaches were categorized into the 
following particle configurations: substrate, coated substrate, matrix particulate, 
drug resinate, microencapsulated API crystal, coated microencapsulated API 
crystal, and coated matrix particulate.
One challenge is to achieve acceptable human bioavailability while maintaining 
acceptable sensory attributes. When a barrier approach is used, poor API 
bioavailability can be averted by judicious selection of a barrier material having 
suitable properties that allows the API to dissolve in the stomach and intestine.
Another challenge when using a barrier is to prevent or minimize the barrier from 
becoming physically damaged during the compaction process. Since chewable 
and orally disintegrating tablets are compacted, the physical barrier material must 
withstand the stress and strain of the compaction process and chewing without 
significantly fracturing. Fracturing could be a major cause in API leaking through 
the barrier prematurely in the mouth, severely reducing the taste masking 
effectiveness.
Considering the substrate, some can be API crystals alone of which the physical 
and chemical properties directly relate to its taste masking processing. Ideally, a 
one step process is required to directly envelop an API crystal with a physical 
barrier. However, the morphology, crystal size distribution (CSD) and mechanical
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strength of most API crystals preclude direct envelopment without an intermediate 
step to improve these properties.
Significant technological advances are being made to obtain the 
thermodynamically stable crystal form while simultaneously controlling the API 
morphology and CSD by employing molecular modeling techniques and novel 
crystallisation processes (Sridhar et al5 2000).
The shape and size most amenable to the envelopment process is a spheroid with 
a narrow size distribution. Spherical crystallisation techniques have been reported 
by Kawashima et al. (1989, 1991 and 1998); Pich et al. (1986); and Espitalier et al. 
(1997-a, b). These techniques are known as spherical crystal agglomeration (SCA) 
processing. The unique feature of this technique is that crystal growth and 
agglomeration occur simultaneously. By manipulation of the process variables, 
agglomerates are formed with desirable mechanical properties as well as a well- 
defined CSD and optimal particle morphology. Desirable mechanical properties 
include high fracture toughness and wearability in withstanding the high-shear 
forces that occur in typical particle coating processes (e.g. Wurster coating). The 
ideal CSD was a narrow distribution, with a nominal average particle size equal to 
75 to 150 microns.
In the SCA methods, the API is dissolved in a solvent, and the API solution is 
added to a second anti-solvent which contains a third solvent, called a “bridging” 
liquid. The API precipitates into fine crystals, which agglomerate through the action 
of the capillary forces of the bridging liquid and the shear forces/hydrodynamics of 
the agitation system. Hasan et al. (2001) investigated the effect of bridging liquid 
composition and concentration on SCA of salicylic acid (SA), and studied the 
kinetics of SCA of SA through on-line particle size analysis. They concluded that 
bridging liquid composition and concentration significantly affected the size and 
shape of agglomerated particles.
The physical properties of the bridging liquid, i.e. solubility, interfacial tension and 
polarity, correlated with its ability to form SCA particles. Further, based on a shear-
64
dependent-model, bridging liquids with higher surface tensions produced larger 
crystal agglomerates, due to formation of stronger liquid bridges during 
agglomeration (Kawashima et al, 1998). Further, other techniques were developed 
for controlling and understanding API crystallisation. These included using 
molecular simulation, solute/solvent control of crystal morphology/crystal size 
distribution, and spherical crystallisation (Sridhar et al, 2000).
A substrate or core particle may also be a mixture of API with non-taste masking 
excipients, whose sole purpose is to be subsequently coated. Examples of the 
substrate particle configuration include: the formulation of spherical particles from 
theophylline, microcrystalline cellulose, using Glatt GPCG-1 (Pereira et al, 1997). 
The differences between raw materials in the formulation of the spherical particles 
and effects of increasing level of drug loading on their quality has also been 
studied.
For coated substrates the main example, related to this study, is applying a taste- 
masking layer to the very bitter tasting material .cefuroxime axetil. James et al. 
(1989) reported that wax coating of cefuroxime axetil by using suitable lipids . The 
most common lipids include the high molecular weight (C10-30) straight chain 
saturated or unsaturated aliphatic acid, such as stearic acid or palmitic acid (as in 
Zinnat® commercial preparation). The triglyceride tested was a glyceryl ester of a 
high molecular weight (C10-30) aliphatic acid, such as glyceryl trilaurate or glyceryl 
trimyristate. The partially hydrogenated vegetable oil tested was cottonseed oil or 
soyabean oil. While the wax was beeswax or carnauba wax, and the high 
molecular weight (C10-30) straight chain aliphatic alcohol was stearyl alcohol or cetyl 
alcohol, or a mixture thereof.
Further advancement in the coating process was achieved by improvements in the 
methodology and apparatus used for coating or microencapsulating solid particles 
or viscous liquid droplets. This was found applicable to a wide range of particle 
sizes, and done by using gelatin and glutaraldehyde materials, and by applying 
microencapsulation process using a heated rotating disc equipment (Spark et al, 
1987).
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Mauger et al. (1998) used triglycerides in combination with a polymer as a coat for 
masking the taste of orally administered drugs. The triglyceride tested melt at body 
temperature, while the polymer was chosen to dissolve at a pH of 5.5. Upon oral 
administration, the coating remained intact during the brief transit in the mouth but 
then released the active upon reaching the gastric fluid of the stomach.
Another example of coated substrate particle configuration was undertaken by Holt 
et al. (2000). They used rapid release spacing layer between core and taste 
masking layer, which included effervescent agents, EC, poly vinyl pyrrolidone 
(PVP), and aminoalkyl methacrylate copolymer material. Fluid bed and a wurster 
were used for such purposes.
The matrix particulate is a mixture of API and taste masking excipients or agents, 
which may not be subsequently coated. Examples of the matrix particulate 
configuration include the preparation of clarithromycin with polyvinylacetyl diethyl 
aminoacetate (AEA) and sodium lauryl sulphate (SLS) (Shimano et al, 1995). The 
matrix was obtained by dispersion of the drug in AEA solution and spraying it into 
liquid droplets, followed by subsequent drying into spherical particles.
Another example of matrix particulate particle configuration is via the use of cation 
exchange resins, which have more effective ion exchange due to the nature of 
most actives. Ion exchange resin materials have been used with 
granulation/coating processes using an extruder, fluid bed, spray dryer, and rotary 
granulation equipments (Hiroshi et al, 1994).
A drug resinate is a drug/resin complex, formed when an ionizable drug reacts with 
a suitable ion exchange resin for the purpose to taste mask some APIs. Because 
the drug resinate is insoluble it has virtually no taste, so that even very bitter drugs 
are masked when converted into a drug resinate (Agarwal et al, 2000). With the 
correct selection of the ion exchange resin, the drug resinate can be made 
sufficiently stable such that it does not break down in the mouth, avoiding the 
unpleasant taste. However, when the drug resinate comes into contact with the 
gastrointestinal fluids, usually the acid of the stomach, the complex is broken down 
quickly and completely. The drug is released from the resinate directly into solution
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and then absorbed in the usual way. The resin passes through the Gl tract without 
being absorbed. Examples where this technique has been successfully 
demonstrated include chloroquine phosphate (Agarwal et al, 2000).
Mukherji et al. (2003) prepared a taste masked matrix comprising the process of 
dissolving the bitter tasting drug, a methacrylic acid copolymer, and a phthalate 
polymer in a suitable organic solvent, followed by the recovery of the said taste 
masked matrix from the solution by conventional methods. The optimal taste 
masking effect was found achieved at total polymer to drug ratio of at least 1:4.
Microencapsulation is the general technology for forming microcapsules, and is 
divided into two classes known as physical methods and chemical methods (Bakan 
et al, 1992). The physical methods include spray coating (Fluid bed coating) and 
wurster coating. These processes rely upon a bottom positioned nozzle spraying 
the coating material up into a fluidized bed of core particles.
Other physical methods include the annular jet technology, which relies upon two 
concentric jets (Bakan et al,1992). The innerjet contains the liquid core material, 
and the outer jet contains the liquid coating material, generally molten, that 
solidifies upon exiting the jet. This dual fluid stream breaks into droplets much as 
water does upon exiting the spray nozzle.
Spinning disk is another technique which relies upon a spinning disk and the 
simultaneous motion of core material and coating material exiting from that disk in 
droplet form.
In the spray cooling method, a molten matrix material containing minute droplets of 
the core materials is spray cooled.
Spray chilling process relies on spray-chilling the coat around an atomized core. 
The resulting capsules move countercurrent to a flow of tempered air and are 
collected in a large container below the spray nozzle.
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The number of methods for chemical encapsulation is actually far less. Two 
methods are known as water-in-oil and oil-in-water. The oil-in-water process is 
known as complex coacervation.
A novel process for encapsulating water-insoluble or slightly water-soluble drug 
was based on to evaporating method in liquid vehicle developed by Morishita et al. 
(1973).This method provided a process for encapsulating various water-insoluble 
or slightly water-soluble medicaments, regardless of their physical properties. It is 
based on dissolving or dispersing a water-insoluble or slightly water-soluble 
medicament into a solution of a hydrophobic coating material in at least one 
organic solvent, poorly miscible with water. This was followed by dispersing the 
resulting solution or dispersion to form fine droplets in a vehicle, and then 
vapourizing the organic solvent. It was found that when two or more organic 
solvents are used in the admixture, more fine and excellent encapsulated particles 
are obtained (Morishita et al, 1973).
Microencapsulation of API crystals has been achieved by the application of a 
physical barrier directly onto an API crystalline solid to cover the vast majority of 
solid forms observed in the pharmaceutical industry. Examples of the 
microencapsulated API crystal particle configuration include microincapsulation of 
chloroquine diphosphate (CHD), using Eudragit® RS100, tetrahydrofuran (THF), 
cyclohexane, polyisobutylene (PIB) by non-solvent coacervation. Drug crystals 
were coacervated with Eudragit® RS100, using PIB as a well known anti­
aggregation agent used during coacervation process (Ndesendo et al, 1996).
Microencapsulated API crystal and coated microencapsulated API crystal particle 
configurations were applied as taste-masked particles for a variety of dosage forms 
using EC and MacP, cellulose acetate phthalate (CAP), and hydroxypropylmethyl 
cellulose phthalate (HPMCP) materials, using phase separation process with fluid 
bed and microencapsulation tank (Phillip et al, 2001).
Coated substrates, coated matrix particulate and coated microencapsulated API 
crystal contain an additional coating layer, functioning as a physical barrier. The
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coating layer usually consists of polymer, lipid, or carbohydrate chemical classes. 
An example of coated microencapsulated API crystal is clarithromycin which was 
first coacervated using gelatin and glutaraldehyde and then subsequently coated 
by a phase separation technique using methacrylate resins. Friend et al. (1992) 
concluded that application of the methacrylate resin using a fluid-bed spray 
process would probably be a better method to use based on the appearance of the 
coated microencapsulated product.
For simultaneous API crystal growth, agglomeration and encapsulation Cuna et al. 
(1996 ; 1997-a,b) reported the use of solvent evaporation and solvent extraction to 
co-crystal I ise drug and polymer. Mauger et al. (1998) described a pharmaceutical 
coating for taste masking oral medications which includes a unique combination of 
triglycerides and a polymer. The triglyceride mixture melts at body temperature and 
the copolymer causes the coating to dissolve upon reaching the acidic 
environment of the stomach.
A further flavor masking method for badly tasting pharmaceuticals, which is 
likewise based on the use of lipids was described as a method for flavor masking 
based on the embedding of the active ingredient in a mixture of lipids (Paradissis 
et al, 1988).
1.3.2 Evaluation of taste masked API particles
The ultimate performance tests for taste masking API particles are to conduct 
human sensory and bioavailability studies. While these tests are pivotal and 
conclusive, they are costly and time-consuming. Several in vitro tests are usually 
performed prior to the human confirmatory testing (Reo et al, 2001).
Drug release testing can be performed to evaluate the sensory effectiveness and 
bioperformance. One example of a drug release test for sensory effectiveness has 
been reported by Shirai et al. (2000). The authors described mixing the processed 
API in a relatively small volume of water (10 ml) contained in a syringe.
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The mixture is gently mixed for 30 seconds, filtered and assayed for API 
concentration. Bioperformance-indicating drug release tests are usually based on 
official compendial dissolution testing. Modifications to these tests are frequently 
implemented to account for drug solubility and particle size of the processed API.
Some common modifications include the chemical composition of the dissolution 
media and reducing the size of the dissolution basket opening size to prevent 
particles from escaping. Recently, a novel system has been developed to test in 
vitro taste masking effectiveness. The commercial instrument is called an 
electronic tongue and consists of several (five to seven) coated potentiometric 
probes that are immersed into a liquid containing dissolved solids (Reo et al, 
2002).
It has been used to assist in optimizing the taste of liquid formulations and may 
have application to solid dosage forms. Potentiometric response data from all 
probes for active formulations and placebo formulations are compared using 
principal component analysis mapping. Formulations having the best taste most 
closely match the placebo on the map.
Visual assessments of processed API are probably the most common tests 
performed to determine how the formulation and/or process can be optimized to 
achieve the desired outcome. Optical microscopy is the oldest test and still 
prevalently used today. It is quick, easy and can be done during the process. 
Scanning electron microscopy (SEM) and environmental SEM (ESEM) are 
commonly used when fine detail of the process API surface is needed.
The most common technique to evaluate the location of the drug in a coated 
substrate is to combine (ESEM) with energy dispersive X-ray analysis (Gordon et 
al,1986). This technique can also be a very useful one in evaluation of the 
efficiency of taste masking of drugs by coating.
Energy dispersive X-ray analysis is limited to elements, if the drug contains an 
element that is not part of other chemical compounds in the formulation, then it is
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highly useful for locating the drug to a resolution region of 3 pm by 3 pm (Gordon 
et al, 1986). However, when elemental analysis is not appropriate, ESEM can be 
combined with Time-of-Flight Secondary Ion Mass Spectrometry (TOF-SIMS) for 
determining drug location, (Patel et al. 2001; Belu et al. 2000).
The TOF-SIMS process involves bombarding a sample surface with a beam of 
primary ions. When the primary ions collide with atoms and molecules in the 
surface, they are emitted. Either the positive or negative ions are measured using 
a mass spectrometer. Some of the key features of TOF-SIMS are sub-micron 
resolution and parts per million sensitivity. TOF-SIMS can be used to produce a 
chemical image of a surface by scanning a defined region and recording a 
spectrum at each pixel within the scan, i.e, a chemical mapping of the surface can 
be accomplished.
Another imaging technique is Atomic Force Microscopy (AFM). The AFM is a high- 
resolution surface imaging and surface property mapping technique (Erlandsson et 
al, 2000). Samples can be studied neat or in a liquid environment. It can be used to 
detect domains (due to chemical structure) and therefore, location, of one polymer 
component of a polymer blend when the polymer blend is used as a barrier 
coating. This type of data could also provide insight to the compatibility of the 
polymer blend in situ. A related technology of AFM, called Scanning Thermal 
Microscopy, has enabled polymorphic forms of cimetidine to be identified in ultra 
small volume on the surface of a sample (Sanders et al, 2000).
1.4 ENHANCING DISSOLUTION AND BIOAVAILABILITY OF POORLY 
SOLUBLE DRUGS
1.4.1 Approaches
In recent years, an increasing number of active agents which possess low aqueous 
solubility have come through the discovery laboratories. However, oral delivery of 
such poorly water-soluble drugs often results in low bioavailability, since the rate- 
limiting step for absorption from the gastrointestinal tract is the dissolution rate. 
Several commercial products of these hydrophobic drugs are available, and
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different methods had been applied trying to enhance in vivo performance. Some 
of which are described below.
1.4.1.1 Size reduction
Particle size reduction effectively increases the surface area to volume ratio, 
thereby increasing the dissolution rate in the GIT and promoting absorption of 
poorly soluble substances (Kawashima et al, 2001). Various technologies were 
used for particle size reduction, this include micronisation, nano-ionization and, 
most recently, supercritical fluid technology (Kerc et al, 1999), which deposits 
nanometer sized drug particles on a pharmaceutically acceptable support matrix. 
Particle size reduction must include a method for preventing aggregation, which 
commonly occurs after milling, and effectively negates any improvement in 
dissolution gained by particle size reduction.
A common way for reducing the particle size is the disruption of previously formed 
larger particles by milling techniques, such as jetmilling, milling in a pearl-ball-mill, 
or high-pressure homogenization (Parrot et al, 1990). However, these methods 
have several disadvantages resulting from the mechanical disruption process. The 
micronisation process using mills is inefficient, because of the high-energy input 
that can alter the surface properties as a thermodynamically activated surface is 
created. Even a small amount of activated material at the surface can affect the 
drug substance properties, such as the blending characteristics (Mackin et al, 
2002) or flow properties (Feely et al, 1998). Example of this is when the partially 
amorphous surface recrystallises, leading to changes in the physical properties of 
the drug (Roberts et al, 1994), where the conversion of crystalline solid surfaces 
into partially amorphous solid surfaces leads to a dynamic nature of the micronised 
drug.
Thus, this surface will dominate the size reduced particles and the milled powder is 
characterised by their surface properties. In the case mentioned above the surface 
will show poor wetting properties, therefore, because of agglomeration, the 
increase in the dissolution rate is not as high as calculated from the increase in 
surface area.
72
Nanosuspensions are milled by high pressure homogenizers (Jacob et al, 2000). 
The high pressure used cause changes in the crystal structure, and as a result, the 
amorphous fraction in the particle increases.
Thus, milling affects several physical properties of the drug, such as powder flow, 
agglomeration behavior, or electrostatic behavior. Beside these effects, the 
chemical reactivity or degradation can also be affected (Shalaev et al, 2002). The 
particle size can also change during storage after micronisation because of stress 
relaxation processes (Joshi et al, 2002). Beside these problematic properties, a 
further disadvantage especially of jet-milling processes is a broad size distribution 
(Muller et al, 1996). On the other hand, because of abrasion, the product can be 
afflicted with metallic impurities that can affect the chemical stability as a result of 
catalytic activity.
Due to these disadvantages of milling processes, techniques have been developed 
that produce the drug directly in the optimal particle size. However, the preparation 
and stabilisation of small particles is not easy because of their tendency to grow. 
Because of the high surface that must be created, the established methods need 
high amounts of stabilising excipients leading to amorphous products.
The most important examples are the so-called hydrosols developed by Gapmann 
et at (1994). Hydrosols are colloidal aqueous suspensions containing drug 
nanoparticles of poorly water soluble drugs for intravenous administration. They 
are prepared by a precipitation process as the drug solution is mixed with a 
relatively high volume of water (96-98% water after mixing) in the presence of 
stabilising agents such as poloxamer and modified gelatins, which act as short 
term stabilisers (Gapmann et at, 1994). Hydrosols contain the drug in a particle 
size of approximately 200 nm and are thus suitable for parenteral application. An 
example is cyclosporine, which can be formed as a hydrosol in a ratio of drug to 
gelatin of 1 : 20.
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1.4.1.2 Using solid carriers
Another approach of enhancing solubility was described by Mahesh et al. (2003), 
with the idea of using solid carriers. This includes a substrate and an encapsulation 
coat on the substrate. The encapsulation coat can include different combinations of 
pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and 
triglycerides. The composition of the carrier improves the delivery of hydrophilic 
and hydrophobic drugs and offers potential advantages over micronised drugs, 
emulsions or solubilized formulations. Solid carriers can easily pass through the 
stomach, thus making the performance less prone to gastric emptying variability. 
Further, the problems of leakage and other disadvantages of liquid formulations 
are not present in solid carrier formulations (Mahesh et al, 2003).
1.4.1.3 Salt formation
Hanss et al. (2001) reported a method for improving the absorption of ionizable 
compound through the salt formation. Salts of poorly soluble compounds typically 
dissolve more quickly in the GIT, thus improving absorption, which is typically 
limited by the slow dissolution of the parent free acid or base compound. 
Limitations to this approach involve identifying a counter-ion that will yield a 
pharmaceutically acceptable salt. Additional salt requirements include the ability to 
prepare, in sufficient yield, a chemically stable, non or minimally hygroscopic 
product of sufficiently high melting point to withstand formulation processing.
1.4.1.4 Prodrug formation
This is a less frequently employed method for improving the solubility and involves 
attaching a solubilizing moiety to form a prodrug which is cleaved by an 
endogenous enzyme subsequent to absorption, thereby regenerating the active 
parent molecule. The added complexity of the prodrug development, which 
requires additional studies for verifying bioconversion and demonstrating lack of 
toxicity, has limited the application of this approach (Hanss et al, 2001).
1.4.1.5 Stabilisation of amorphous forms of the drugs
An infrequently used method for improving the bioavailability of poorly soluble 
compounds involves stabilising the drug in the amorphous, or high energy solid
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state, thereby facilitating its dissolution relative to that of the stable crystalline form 
(Robinson et al, 1993).
Various stabilising methods have been reported, including the use of polymer 
excipients having high glass transition temperature (Tg). Crystallisation of 
amorphous sucrose and indomethacin was inhibited by preparing solid dispersion 
with a small amount of polyvinylpyrrolidone (PVP) (Zografi et al, 1999). Similarly, 
addition of alginate inhibited the crystallisation of amorphous lactose prepared by 
spray drying (Takeuchi et al, 2000). The stabilising effect of these excipients was 
attributed to their antiplasticization effect as well as their ability to interact with 
sucrose, indomethacin, or lactose. Drug excipient interactions leading to the 
stabilisation of amorphous drugs have also been reported for the systems of 
excipients with a pyrrolidone ring (PVP and polyvinylpyrrolidone-co-vinyl acetate) 
and drugs with hydrogen donor groups (indomethacin, lacidipine, nifedipine, and 
tolbutamide) (Forster et al. 2001; Aso et al, 1995).
In this same aspect, crystallisation of acetaminophen (ACTA) in solid dispersions 
with PVP and polyacrylic acid (PAA) has been studied by Miyazaki et al. (2004) to 
determine the role of drug polymer interaction in the inhibition of crystallisation as 
well as the effect of moisture on the interaction.
Other examples of stabilising amorphous solids include: the stabilisation of labile 
biomolecules (e.g. proteins and peptides) through additives. The prevention of the 
crystallisation is achieved by maintaining the amorphous form within specification 
on the appropriate storage temperatures to achieve acceptable shelf life, and the 
prevention of chemical degradation and microbial growth through anti-oxidant, pH 
buffer, preservatives, etc.
Lyophilisation and spray drying are essential steps in the preparation of protein 
and peptide formulations (Pikal et al, 1994), and in the preservation of organisms 
(Crowe et al, 1998). Such treatments can be detrimental to these naturally 
hydrated species. It has been observed that the proteins, peptides and organisms 
can be effectively protected against freezing and drying when they are co­
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processed with certain excipients, typically carbohydrates and derivatives 
(sucrose, trehalose, mannitol, sorbitol, etc) (Sun W. et al, 1998). Although the 
mechanism of stabilisation is not firmly established, it is thought to involve both 
vitrification and direct interactions.
Vitrification based stabilisation relies on the immobilization and isolation of labile 
substances in rigid glasses of inert stabiliser molecules. Vitrification is expected to 
reduce the potential for protein aggregation and diffusion of small molecules 
required to initiate hydrolysis, oxidation, etc (Lai et al, 1999). The general 
assessment of the vitrification hypothesis seems to be that vitrification is necessary 
but insufficient for stabilising labile substances and that direct interactions also are 
required (Crowe et al, 1998).
In vitrification based stabilisation strategies, the Tg provides a concrete guide to the 
selection of stabilisers and storage temperatures. By eliminating plasticizers (e.g. 
water) and introducting antiplasticizers, one increases Tg and reduces structural 
mobility. Shamblin et al. (1998, 2000) showed that antiplasticizers effectively 
reduce structural mobility in amorphous sucrose. A more sophisticated analysis 
takes into account of both Tg and fragility, using the “zero mobility” temperature T0 
as the parameter for ranking the relative stability of potential formulations (Hatley 
et al, 1999).
Besides vitrification, direct drug excipient interactions are important for stabilisation 
(Crowe et al, 1998). An example of such interactions is the selective hydrogen 
bonding between stabilising excipients and the drug molecules. These interactions 
may resemble the way in which water molecules are integrated into the structures 
of proteins and peptides (the water replacement hypothesis).
A well developed concept is that conformational change of proteins during freeze- 
drying is generally detrimental and should be avoided (Carpenter et al, 1994). This 
is a sound strategy so long as the conformational change is irreversible. In the 
crystallisation of carbohydrates and other small molecule organics conformational 
changes upon solidification are common, but often reversible upon dissolution
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(Bernstein et al, 1987). If such cases, conformational changes on freezing and 
drying would not be indicative of structural damage.
It is generally accepted that in order to act as stabilisers, an excipient must mix 
homogeneously with the drug to be stabilised (Pikal et al, 1994). However, certain 
excipients (e.g. mannitol) have strong tendency to crystallise, leading to phase 
separation and loss of stabilising powder. Crystallisation can also lead to the 
formation of slow dissolving particles, causing slow reconstitution of parenteral 
products. Despite potential crystallisation problems, excipients with strong 
tendency to crystallise can sometimes make suitable stabilisers. In the case of 
mannitol, the crystallisation tendency is compensated by a superior chemical 
stability against oxidation and hydrolysis in comparison to disaccharides. For 
example, mannitol is stable at low or high pH where disaccarides undergo 
hydrolysis. Amorphous sucrose can undergo acid-catalyzed inversion even at very 
low levels of residual water (Shalaev et al, 2000). In some cases, the “flaw” of 
mannitol as a poor glass former can be remedied by proteins and peptides 
themselves, which effectively inhibit crystallisation (Kim et al, 1998).
Molecular mobility that allows physical aging and crystallisation of glasses below 
Tg implies that Tg is unsatisfactory as an indicator for the temperature below which 
molecular motions cease for practical purposes (Yoshioka et al, 1994). If the 
parameter T0 represents the temperature at which the relaxation time goes to 
infinity (zero mobility), then T0 rather than Tg is to be used as a practical guide for 
selecting storage temperatures. For many fragile glasses, T0 is approximately 
50 K below Tg .The Tg -  50 K rule is an important reminder of the finite structural 
mobility below Tg. For strong materials, T0 will lie significantly below Tg -  50K 
(Hancock et al, 1997).
1.4.1.6 Lipid matrix systems
Other ways of enhancing dissolution and bioavailability include formulations which 
solubilize a drug in a lipid or water-miscible co-solvent matrix system. This can 
provide dramatic improvements in bioavailability by eliminating the need for pre- 
absorptive dissolution in the GIT (Muller et al, 2001). Due to their immiscibility with 
water, lipids can maintain a poorly soluble drug in solution, unlike water miscible
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co-solvent systems, which often precipitate the drug following dilution in the 
predominantly aqueous Gl fluids. Lipid systems can also be formulated to have 
self-emulsifying properties, which provides further enhancement to absorption by 
increasing the surface area of the lipid dispersion presented to the GIT (Muller et 
al, 2001).
1.4.1.7 Inclusion complex formation
Cyclodextrins, which are water-soluble molecules containing a hydrophobic pocket, 
have also been used to form a dissociable inclusion complex with a hydrophobic 
drug molecule. This resulted in an improvement in the water solubility and 
bioavailability for poorly water-soluble drugs. The application of this approach is 
limited by the ability of the cyclodextrin to form the inclusion complex, which is 
strongly dependent on the molecular characteristics of the drug molecule (Mura et 
al, 1999).
1.4.1.8 Solid dispersions
Another common approach to improve the dissolution rate of poorly water-soluble 
drugs, and, therefore, improved oral bioavailability is by formation of a solid 
dispersion with a water soluble rate enhancing polymer, such as polyethylene 
glycol (Chiou et al. 1971; Serajuddin et al. 2004). Typical methods for fabricating 
solid dispersions include solution methods (Mura et al. 1996 ; Doshi et al. 1997) 
and melt methods (Mura et al. 1996 ; 1999). These techniques are not readily 
scalable and have the disadvantages of solvent use and potential drug degradation 
at elevated temperatures. Broman et al. (2001) described a novel method to 
fabricate solid dispersions utilizing compression moulding, but this technique also 
utilized elevated temperature and a thermoplastic polymer.
In another study, cellulose excipients were used to form solid dispersions of 
enhanced dissolution. Example of this is the use of HPMC (K3L V Premium), by 
Mitechell et al. (2003), to enhance the rate of dissolution for naproxen, nifedipine 
and carbamazepine. Three different means of combining HPMC and drug were 
utilized: dry blending of drug and polymer to produce a simple physical mixture, 
and compacting the blends by either roller compaction or slugging with subsequent 
milling. Both the roller compaction and the slugging processes resulted in
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enhanced dissolution rate for the poorly water-soluble drugs compared to the drug 
as received, and the corresponding physical mixture.
The roller compaction and slugging methods produced comparable rate and extent 
of drug dissolution. Dissolution enhancement by the compaction process was 
comparable when different types of HPMC, specifically K3LV Premium, E3LV 
Premium, and E5LV Premium, were used (Mitechell et al, 2003).
The mechanism for how the compaction/milling process yields enhanced 
dissolution properties was believed to be a microenvironment surfactant effect 
whereby HPMC dissolution creates a local surfactant concentration in the 
boundary layer surrounding the drug particles, providing a lower energy pathway 
for drug dissolution. The compaction processes are believed to be particularly 
effective at enhancing the rate of drug dissolution because the drug particles are 
maintained in direct contact with the HPMC particles during drug dissolution. This 
is in contrast with a physical mixture, where the drug and HPMC particles may 
quickly disperse and be separated in the dissolution medium.
It was also demonstrated that HPMC presence is critical to the dissolution 
enhancement mechanism. Samples of the drugs alone subjected to the same 
slugging and milling procedure did not exhibit faster drug dissolution. Rather, 
slugged and milled naproxen alone had a dissolution rate that was slower than the 
drug as received. The compaction and milling procedures did not alter the bulk 
thermal properties or the X-ray diffractograms of the drugs. Differences were 
observed between the endotherms for the drug powders compared to the 
HPMC/drug mixtures. However, in each case the endotherm was unchanged by 
the compaction and milling processes (Mitechell et al, 2003).
1.4.2 Bioavailability Enhancers
Bioavailability of drugs is affected by many factors, such factors include the nature 
of the form of the drug, the physical state, particle size and surface area, presence 
or absence of adjuvants with the drug, type of dosage form in which the drug is
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administered, and pharmaceutical processes used to make the dosage form 
(Cadwallader et al, 1971).
Manipulations of many of these parameters have been reported in the literature as 
effective means for increasing drug absorption and bioavailability. As regards to 
the physical state of the drug, increasing bioavailability of digoxin was achieved by 
administering the drug in capsule form (Crseswell et al, 1978). Blume et al. (1983) 
prepared special granular bioavailable formulations of active ingredients, 
particularly Triamterene and Hydrochlorothiazide. Crisp et al. (1985) reported an 
amorphous form of cefuroxime axetil with improved bioavailability.
With respect to the use of adjuvants, the use of polyglycerol esters of unsaturated 
fatty acids enhanced solubility of active drugs (Kaushal et al, 2004). Brickel et al. 
(1984) reported the use of acid salts of the drug to enhance bioavailability of 
dipyridamole. Dhanarajn et al. (1998) reported the use of cyclodextrin to enhance 
the bioavailability of griseofulvin.
Surfactants have also often been used to enhance bioavailability. Examples 
include the the use of water-soluble polymers and wetting agents to enhance 
solubility of drugs (Kawata et al, 1983). Tsuji et al. (1974) reported Penicillin 
prodrugs as having enhanced bioavailability. Ther et al. (1971) discussed the 
dependence of intestinal drug absorption on blood flow. Cadawallader (1971) 
suggested that Reserpine and Guanethidine could increase the rate of absorption 
of orally administered drugs by increasing the blood flow to the Gl tract.
Mclean et al. (1978) attempted to explain, via computer modeling, increased 
bioavailability of drugs such as propranolol or metoprolol after a meal. They 
predicted that the vasodilator Hydralazine should enhance the bioavailability of 
Propranolol or similar drugs which require metabolism through the liver to be 
effective. This prediction was borne out by Schreck et al. (1984), where the authors 
concluded that the increased bioavailability can be due to hemodynamic effects.
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1.5 Objectives
It is known in general that the amorphous drugs are metastable and may convert 
back to its crystalline state (less soluble and absorbable form), during processing 
and storage. The objective behind this study was to stabilise an amorphous drug, 
cefuroxime axetil (CAA) upon processing such as compression, crushing and 
coating, and to protect it from transforming to the crystalline form (CAC).
It is known in the literature that cefuroxime axetil (CA) exists in its amorphous and 
crystalline states, of which the former is the most soluble and absorbable. The latter 
was found in this study to be commercialised as a mixture of two polymorphs.
CAA was proved to be sensitive to operation conditions of compression and coating. 
Compression of the amorphous material led to its partial transformation to the 
crystalline polymorph of the high melting point, consequently the intestinal 
absorption rate of the drug was significantly reduced.
On the other hand, wax coating of CA done to mask its very bitter taste in dry 
suspension formulation, was found to cause complete transformation of CAA to the 
crystalline polymorphs, thus dramatically reduced its intestinal absorption. This gave 
bioavailability of CA that is lower than that obtained from the drug in its tablet dosage 
form.
The concept utilised for stabilising the amorphous CA in this study was based on 
mixing and processing of CAA with excipients that were expected to deplasticize the 
amorphous CA, and reduce its molecular mobility, thus inhibiting crystallisation 
under compression and coating.
Techniques and methods used for testing CAA and its mixtures with excipients were 
DSC, MTDSC, XRPD, DVS, dissolution in vitro gut absorption and bioequivalence. 
All indicated that the objective of the study was achieved, and that CAA mixed with 




GENERAL MATERIALS AND METHODS
Different methods had been utilised to characterise and compare physical and 
chemical properties of different forms and preparations of cefuroxime axetil (CA) 
used in this study. These methods are described below.
2.1 DIFFERENTIAL SCANNING CALORIMETRY (DSC)
2.1.1 Introduction
Thermal analyses is a term used to describe the analytical techniques that 
measure the physical and chemical properties of a sample as a function of 
temperature or time (Brown et al, 1998). This physical technique along with 
complementary analytical structural techniques such as spectroscopy, and, 
chromatographic methods have become increasingly important in the development 
of modern day pharmaceuticals. A number of thermo-analytical techniques are 
currently widely used in the pharmaceutical industry. These include 
thermogravimetric Analyses (TGA), differential scanning calorimetry (DSC), and 
thermomechanical Analyses (TMA) (Gallagher et al, 1997). Of these techniques, 
DSC is the most popular due to its wide applicability, ease of preparation and 
interpretation (Haines et al, 1995). It provides thermodynamic information that is 
essential for preformulation studies of pharmaceuticals and the subsequent 
development of a stable and effective dosage form (Brown et al, 1998). The 
performance of DSC is dependant on a number of experimental factors. Some of 
the important factors to be considered are the sample size, the heating rate, the 
atmosphere, and crucible type (Roy et al, 2003).
This technique is useful to characterise physical properties of raw materials, 
mixtures of materials or the medical products. A calorimeter measures heat flow 
into (endothermic) or out of (exothermic) a material as it undergoes a phase 
change. Examples of thermal transitions measured by DSC are melting, 
polymorphism, crystallisation, decomposition, out-gassing, glass transition, 
compatibility, sublimation and thermal stability (Worthington et al, 1999 and 
Wissing et al, 2000).
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It also measures the transition onset and ending temperatures, as well as, the 
temperature at maximum transition. DSC is useful in monitoring materials to 
assess their similarities or differences or the effects of additives on the thermal 
properties of a material. Differential scanning calorimetry is one of the best 
methods to characterise crystal polymorphism (Haines et al, 1995).
This technique monitors heat effects associated with phase transitions and 
chemical reactions as a function of temperature. In a DSC the difference in heat 
flow to the sample and a reference at the same temperature, is recorded as a 
function of temperature. The reference is an inert material such as alumina, or just 
an empty aluminum pan. The temperature of both the sample and reference are 
increased at a constant rate (Brown et al, 1998). A schematic representation of the 
differential scanning calorimeter is shown in Figure 2.1.
Since the DSC is operated at constant pressure, heat flow is equivalent to enthalpy 
changes:
^  dH ...................................................................................  Eq. 2.1
vdt/p dt
The dH/dt is the heat flow measured in mJ sec '1. The heat flow difference between 
the sample and the reference is:
A dH f dH i f dH
dt v dt / samp|e V dt y
i\
.......................................................  Eq. 2.2
reference
and can be either positive or negative. In an endothermic process, such as most 
phase transitions, heat is absorbed and, therefore, heat flow to the sample is 
higher than that to the reference. Hence heat flow (AdH/dt) is positive. Endothermic 
processes which include melting, dehydrations, reduction reactions, and some 
decomposition reactions. For exothermic process, such as crystallisation, some 
cross-linking processes, oxidation reactions, and some decomposition reactions, 
the heat flow (AdH/dt) is negative.
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The information which is readily obtainable from a DSC curve is the temperature at 
which a certain process occurs, for example, the melting point. The temperature at 
which a reaction, such as decomposition, may start is another important 
parameter. The peak temperature is associated with the temperature at which 
maximum reaction rate occurs (Mcedo et al, 2001). The enthalpy of a reaction can 
also be quantified if a known mass of the active is weighed into the pan. 
Thermodynamic information regarding the process can therefore be determined. 










Figure 2.1: Schematic representation of a differential scanning calorimeter (DSC).
2.1.1.1 Glass transition temperature (Tg)
In the case of glass-forming materials, for example, when the cooling process is 
too rapid for crystallisation, the precipitated material forms a super cooled liquid. 
Upon further cooling a point is reached at which the material forms a glass, this 
transition is referred to as the glass transition temperature (Tg) (Angell et al, 1995). 
At this temperature, the bonding between molecules remains the same as in the 
liquid, but their translational and rotational motions are dramatically reduced. 
Hence the glass transition is dependent on molecular mobility with no associated 
heat transfer for the process. It is also rate dependent, with slower cooling rates 
resulting in lower Tg values (Craig et al, 1999-a). On the other hand, as a material 
(e.g. an amorphous polymer) goes from a glassy state to a rubbery state there 
occurs a change in the heat capacity (Hancock et al, 1997; Angell et al, 1995).
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2.1.1.2 Crystallisation temperature (Tc)
Above the glass transition of an amorphous material, the increase in free volume 
between molecules will increase the degree of molecular mobility. If there is 
sufficient mobility and energy to form a critical nucleus, crystallisation will 
subsequently occur (Royall et al, 2001). As the material undergoes 
recrystallisation, the excess energy (the enthalpy) gives rise to an exothermic peak 
in the thermogram.
2.1.1.3 Melting temperature (Tm)
Heat may allow crystals to form, but upon continued ramping of the temperature, 
the crystallised material will either undergo melting or decomposition. At the 
melting temperature the long range order of the crystalline lattice is lost, increasing 
the degree of molecular freedom. Melting is a first order transition, indicating that 
at the melting temperature, the temperature of the sample pan will not rise until all 
the material has undergone the phase transition (Ahlneck et al, 1990). This relates 
to the need for an increase in the heat flow to the sample pan to melt the crystals 
and to maintain the temperature rising at the same rate as that of the reference 
pan. Upon calibration of the system (e.g. with indium) the measured heat flow 
required during melting provides a quantitative measurement of the 
thermodynamic process of the melting transition.
A typical DSC thermogram of the thermal transitions of an amorphous substance 





Figure 2.2: A DSC thermogram of an amorphous substance
2.1.2 Materials and methods
DSC test procedure:
The sample pan and lid were weighed on the balance and the balance zeroed. 
After the pan had been put on the movable piece of DSC punch, 10.0 -12.0 mg 
weight of the material (unless otherwise mentioned) was put in the standard 40pl 
aluminum crucible with a pinhole in the lid (unless otherwise mentioned) to allow 
removal of any residual water. The punch was pressed and the closed crucible 
was weighed again, the weight was recorded.
The instrument (Mettler® TA 4000 series) was initially calibrated for temperature 
and enthalpy values using pure indium. The following parameters were chosen for 
the ramp: starting temperature 10°C, end temperature 200°C, ramp rate 25°C/min 
or 10°C/min. Each material was analysed as triplicates.
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2.2 MODULATED TEMPERATURE DSC (MTDSC)
2.2.1 Introduction
2.2.1.1 History
Modulated temperature DSC (MTDSC) is a recently developed extension of 
standard DSC. It was first presented by Reading et al. at the 1992 NATAS 
conference (Sauerbrunn et al, 1992; Reading et al, 1993-a, 1993-b). The technique 
has subsequently been extensively studied (Gill et al, 1993; Boiler et al, 1994; 
Reading et al, 1994; Schawe, 1995-a, 1995-b, 1996-a; Varma-Nair, 1996) and 
applied to the characterisation of materials such as inorganic glasses (Schawe, 
1996-b; Tomasi et al, 1996), polymers (Reading et al, 1994; Boiler et al, 1995; 
Hourston et al, 1995; Sauerbrunn et al, 1995; Boiler et al, 1996) and more recently 
to pharmaceutical and food systems (Barnes et al, 1993; Alden et al, 1995; 
Coleman et al, 1996; Izzard et al, 1996; Craig et al, 1998; Hill et al, 1998; Bustin et 
al, 1999).
In an MTDSC operation, a modulated sinusoidal wave is superimposed over the 
conventional linear (or isothermal) heating or cooling temperature program. 
MTDSC confers to the same theory as standard DSC in which the heat flow signal 
is a combination of the specimen heat capacity (heat rate dependent component) 
and of any temperature dependent, often irreversible, ‘kinetic’ component. The 
resultant heat flow can be represented by (Saklatvala et al, 1999):
—  = Cm — +f(t,T ).............................................................. Eq. 2.3
dt dt '  ' H
where Q is the heat flow absorbed by the specimen, CPit the specimen heat 
capacity, T the absolute temperature, t the time and f (t,T) the kinetically-limited 
heat flow rate (i.e. it represents the contribution to the total heat flow rate given by 
the reversible events taking place with a kinetics that is slow when compared to the 
experimental time-scale). In MTDSC, the applied temperature program can be 
expressed as:
T(t) = T0 + bt + Bsin (cat).....................................................  Eq. 2.4
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where T0 is the starting temperature, b the underlying or average heating rate, B 
the amplitude of the oscillation and u  the frequency of the oscillation. Assuming 
that for a small temperature modulation the response of the rate of the kinetic 
process to temperature is linear over a modulation interval, the heat flow can be 
written as (Craig et al, 1999-b):
—  = CPit(b + Bu) cos(ut)) + f  (t,T) + C sin(ut)................... Eq. 2.5
dt
where f  (t,T) represents the contribution to the total heat flow rate given by true 
irreversible events; C is the amplitude of the kinetic response to sine wave 
modulation and the term (b + Bu cos(ut)) is the derivative modulated temperature.
The cyclic component of the heat flow signal depends on the value of b, u  and C. 
In most kinetically-controlled processes, C may be approximated to zero such that 
the response to the cyclic perturbation originates from the thermodynamic heat 
capacity contribution only, resulting in:
— =Cp.,(b + Bw cos(wt)) + f  (t,T )..................................... Eq. 2.6
dt
A discrete fourier transform (DFT) algorithm is then used to separate this cyclic 
response of the specimen from its response to the underlying heating rate and to 
quantify these two signals separately.
The heat capacity Cp,t may be determined from the measurement of b, u  and B. 
The product of CP)t and the underlying heating rate may then be calculated to yield 
the cyclic heat flow component, also called the reversing heat flow. The non­
reversing heat flow is obtained by simply subtracting the reversing heat flow 
component from the calculated total heat flow.
It is worthy to note that, by applying this procedure, all short-term noise is removed 
from the deconvoluted signals and the heat capacity, which is calculated using 
modulation amplitudes, is not affected by instrumental baseline curvature. Thus, 
thermal events such as glass transition and some melting events will be distributed 
in the reversing heat flow whereas the non-reversing heat flow will refer to
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enthalpic relaxation, evaporation, crystallisation, thermal decomposition, cure and 
some melting events.
MTDSC is nowadays a widely recognised technique yielding particular advantages 
over conventional DSC. One of the major advantages of MTDSC is that the 
technique allows direct measurement of the glass transition in the first heating 
scan when an associated enthalpic relaxation is also present (Craig et al, 1999-b). 
The enthalpic relaxation may arise over the glass transition region either due to a 
difference in the cooling and heating rates used in the preparation and 
characterisation of an amorphous material, or by stress relaxation on storage 
(Moynihan et al, 1996). The presence of this thermal feature is frequently 
problematic as it occurs over the same temperature range as the glass transition, 
thereby rendering visualization of the latter difficult. Furthermore, the similarity in 
appearance between the relaxation endotherm and a melting response may result 
in confusion with regard to whether a melting or glass transitional event is taking 
place.
On the other hand, the presence of water, which lowers the Tg of amorphous 
systems, has concomitant implications for product stability. The relationship 
between water content and Tg has been explored in a number of publications in the 
pharmaceutical literature (e.g. Hancock et al, 1994). However, if one is attempting 
to quantitatively model the relationship between Tg and water content, the errors in 
Tg measurement arising due to the presence of the relaxation endotherm may be 
considerable. It is possible to temperature cycle the sample in order to minimize 
the relaxation endotherm, although this may alter the sample in relation to the 
original system under study either due to changes in water distribution or to non- 
reversible alterations in structure such as collapse of freeze dried products.
There are, therefore, significant advantages in measuring the Tg during the first 
temperature cycle, in isolation from the relaxation endotherm. All the benefits listed 
make MTDSC a powerful technique provided that the choice of the experimental 
parameters as well as the Cp calibration of the calorimeter are carried out properly.
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2.2.1.2 Choice of MTDSC parameters
The general precautions that are necessary to ensure reliable and accurate results 
include careful specimen preparation, appropriate specimen size, use of adequate 
pans and purge gas, selection of appropriate purge gas flow, and calibrations 
carried out under conditions identical to those used for specimen measurement 
(Craig et al, 1999-a).
Other general recommendations which apply for all types of thermal events is to 
select an optimized set of MTDSC parameters. This includes the underlying linear 
heating rate (R), which should be 1-5°C/min; a value of 5°C/min should not be 
exceeded to allow for the specimen to follow the modulation; values below 1°C/min 
should be preferred whenever possible to ensure enough oscillations (at least 5-6 
cycles) across the thermal event studied. The modulation period (P) should be 40- 
100s, a value of 60s is generally recommended when using standard aluminium 
crimped pans and nitrogen purge gas. The temperature modulation amplitude (A) 
is better to be ±0.1 -  ±3°C for a given linear heating rate. Larger period values 
enhance sensitivity, while smaller values enhance resolution. In the specific case 
of the glass transition which involves Cp measurement, the following additional 
recommendations also apply, the use of large modulation period values (80-100 
s), which allows for a maximum time for heat transfer across the specimen and is 
necessary to yield precise heat capacity values. For weak glass transition signals, 
a larger value of the amplitude should be preferred, typically around 1.5-2°C 
(working in ‘heat-and-cool’ instead of in ‘heat only’ mode is not a problem when 
dealing with reversible events such as a glass transition). However, this value 
should not be too large to prevent the modulation from over-spanning the transition 
width.
A general approach for selecting appropriate experimental parameters would be to 
first run the specimen in standard mode to evaluate the possible need for MTDSC, 
then choose the temperature modulation period and the underlying linear heating 
rate and finally select the temperature modulation amplitude.
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2.2.1.3 Heat capacity (Cp) calibration and measurement
The heat capacity is obtained by continuously dividing the amplitude of the heat 
flow by the amplitude of the modulated heating rate, as expressed in the following 
equation (Craig et al, 1999-b):
Cp = K(cp) 4 ^ ^ ................................................................. Eq-2.7
A m pM H R
where K(cP) is the heat capacity constant, AmpMHF the amplitude of the modulated 
heat flow and A m p MHR the amplitude of the modulated heating rate. Once the 
appropriate set of MTDSC parameters has been chosen, the calorimeter must be 
calibrated by both performing a Cp baseline run and determining the heat capacity 
constant, K(Cp), a multiplying factor which allows for the quantitative measurement 
of the heat capacity. These calibrations must be carried out under the same 
experimental conditions as those chosen for specimen analyses using closely 
mass matched DSC pans, (Varma-Nair et al, 1996).
The heat capacity constant, K(cP), is given by the ratio of the theoretical heat 
capacity of a reference material to the measured heat capacity of the material 
studied ,as expressed in Eq. 2.8:
K(Cp) =   Eq. 2.8
Cp, measured
As the MTDSC parameters can significantly affect the K<Cp) value, it is compulsory 
to be in the so-called plateau zone of the three-dimensional (K(cP), period, 
amplitude) graph. A safe-operating zone that ensures reliable determination of the 
heat capacity constant. This zone corresponds typically to period values comprised 
of between 60 and 100s (a value of 100s should be preferred for best accuracy) 
and amplitude values ranging from 90.1 to 92s. By doing so, acceptable values of 
K(cP) can be obtained, typically less than 1.1, by using either helium or nitrogen 
purge gas.
Several approaches can be applied for heat capacity measurements. These 
include isothermal (Jin et al, 1993; Boiler et al, 1994) and non isothermal methods
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(Varma-Nair et al, 1996), with the choice being dependant upon the degree of 
accuracy required and the time which can be devoted to the measurements. The 
quasi-isothermal MTDSC method (Boiler et al, 1994) is a unique way of performing 
Cp measurements with an average heating rate value of zero, thus keeping the 
specimen continuously close to equilibrium. It involves measuring the specimen 
heat capacity at a given temperature for 20-30 min while applying a fixed 
modulation period and temperature amplitude.
This procedure is repeated for several temperatures within the studied temperature 
range. The quasi-isothermal MTDSC method allows for obtaining highly precise Cp 
values and is advantageous when dealing with specimens that are sensitive to fast 
temperature changes. This method, however, is time consuming.
The MTDSC dynamic method is fast and easy. Over the temperature range of 
interest, there should only be, however, a small variation in K(CP) values, on the 
order of less than 93% of the average value (within the experimental precision 
limits of the technique).
2.2.2 Materials and methods
MTDSC analyses were undertaken with Mettler® DSC 822 Module, equipped with 
a refrigerated cooling accessory. The DSC was calibrated for baseline using empty 
pans of matched masses, and for temperature and enthalpy using indium 
standards. For purging of the samples nitrogen gas was used, and measurements 
were made using pairs of samples and standard aluminum pans.
Analyses was performed using lids with 50pm pinhole in order to work under self 
generated atmosphere. Accurate samples weights of 3.0 - 5.0 mg were taken, and 
measurements were done at heating rate of 1°C/min, amplitude of 0.5°C, at period 
of 48 seconds for the range of 30°C - 100°C. These conditions were chosen to 
obtain 5 - 6  cycles across the thermal event studied.
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2.3 LASER PARTICLE SIZE ANALYSES
2.3.1 Introduction
Particle sizing is an important aspect of pharmaceutical development and 
validation processes, particularly as the particle size of active ingredients strongly 
affects their solubility and, thus, bio-availability. There are many methods available 
for particle size and distribution determination. In general, these techniques can be 
divided into three basic categories: ensemble methods, counting methods, and 
separation methods (Syvitsia et al, 1991).
An ensemble method takes a snap shot of a sample and then elucidates the 
distribution of particles sizes based on the physical properties revealed by the 
measurement. A counting method characterises the sample one particle at a time 
in a more direct manor. The accumulative account of the particle provides the size 
distribution. A separation method, on the other hand, first physically separates the 
sample according to their particle size, then various techniques are applied to 
determine the relative amount of each fraction. The advantages and disadvantages 
of each technique are presented below.
2.3.1.1 Ensemble techniques
Common ensemble techniques include Low Angle Laser Light Scattering (LALLS), 
Photon Correlation Spectroscopy (PCS), and Back-Scattering Spectroscopy, 
(Jillaven-Katesa et al, 2002).
Laser Diffraction
This is more correctly called Low Angle Laser Light Scattering (LALLS). This 
method has become the preferred standard in many industries for characterisation 
and quality control. The applicable range according to ISO13320 is 0.1- 3000pm.
Instrumentation has been developed in this field over the last twenty years or so, 
the method relies on the fact that diffraction angle is inversely proportional to 
particle size.The laser particle size analyser instruments consist of a laser as a 
source of coherent intense light of fixed wavelength. He-Ne gas lasers (A=0.63 pm) 
are the most common as they offer the best stability (especially with respect to 
temperature) and better signal to noise than the higher wavelength laser diodes.
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The instrument also includes some means of passing the sample through the laser 
beam. In practice it is possible to measure aerosol sprays directly by spraying 
them through the beam. Particles in suspension can be measured by recirculating 
the sample in front of the laser beam.
The latest instruments use the Mie theory which solves the equations for 
interaction of light with matter. This allows accurate results over a large size range 
typically (0.02 -2000pm) (Cooper et al, 1998; Rame et al, 2002). Refractive indices 
of the material and medium need to be known and the absorption part of the 
refractive index known or approximated. These values are either generally known 
or can be measured.
Laser diffraction has the following advantages over other methods. It is an absolute 
one set in fundamental scientific principles, hence there is no need to calibrate an 
instrument against a standard. Equipment can be validated, to confirm that it is 
performing to certain traceable standards. It works in a wide dynamic range, the 
best laser diffraction equipment allows the user to measure in the range from 0.1 to 
2000 microns. Smaller samples 1nm -  1pm can be measured with the photon 
correlation spectroscopy technique as long as the material is in suspension and 
does not sediment.
An important feature of the instrument is its flexibility. It has extensive application in 
pharmaceutical and agricultural industries. Dry powders can be measured directly, 
although this may result in poorer dispersion than using a liquid dispersing 
medium. However, in conjunction with a suspension analyses it can be valuable in 
assessing the amount of agglomerated material in the dry state.
Particle properties in liquid suspensions and emulsions can be measured via a re­
circulating cell, which gives high reproducibility and allows dispersing agents (e.g. 
0.1% Calgon, sodium hexametaphosphate solution for Ti02) and surfactants to be 
employed to ascertain the primary particle size. The preferred method would be to 
measure in liquid suspension (aqueous or organic). Another important feature is 
that the entire sample is measured, thus all the sample passes through the laser 
beam and diffraction is obtained from all the particles.
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Photon Correlation Spectroscopy (PCS)
For smaller particles, a dynamic light scattering system is preferred. A PCS 
method uses laser light with well defined properties, (wavelength, polarisation, etc) 
(Brown et al, 1993), to determine the velocity distribution of particles by measuring 
dynamic fluctuations of scattered light intensity. The typical scattering angel is 90 
degrees. To avoid multiple scattering, high dilution is required. The main 
disadvantage is that small particles can get lost in the crowd of larger particles.
Back Scattering Spectroscopy
To overcome the difficulties encountered in conventional dynamic light scattering 
system, back scattering spectroscopy has been developed to utilise the information 
at high scattering angle (Brokovec et al, 2000). One such system involves the use 
of a single fiber optics that provides both the probing and scattering beam. The 
most important advantage of this technique is the ability to measure particle size 
and distribution for concentrated samples without dilution (Allegra et al, 1972).
2.3.1.2 Counting Techniques
In a counting technique, each particle is identified and counted at a time. Among 
the popular counting methods are electrozone counter, optical counter, time of 
flight, and microscope.
Electrozone Measurement (Coulter Counter)
This technique was developed in the mid 1950’s for sizing blood cells. The 
principle of operation is that a glass vessel has a hole or orifice in it, and a dilute 
suspension is made to flow through this orifice with a voltage applied across it. As 
particles flow through the orifice the capacitance alters and this is indicated by a 
voltage pulse or spike (Allen et al, 1992).
The method is not an absolute one but is more of a comparative nature. For real 
industrial materials .there are a number of fundamental drawbacks in this 
technique. It is, for example, difficult to measure emulsions, sprays and dry 
powders which need to be suspended in a medium and cannot be measured 
directly. Using this technique one must measure in an electrolyte; for organic 
based materials this is difficult. On the other hand this method requires calibration
95
standards which are expensive and change their size in distilled water and 
electrolyte (Allen et al, 1992).
Optical Counter
In this technique particles are forced through a counting chamber (Gouesbet et al,
1988), where a focused laser beam is partially blocked as the particle passes. The 
light counter has resolution and accuracy comparable to electrozone and LALLS 
methods.
Time of Flight (TOF) Counter
In a time of flight counter a very dilute particulate suspensions in water is first 
“nebulized”. After the evaporation of water, particles are carried by airflow through 
two adjacent detectors. The advantages of this technique include high resolution 
and reasonable dynamic range. The disadvantage is that particle may aggregate 
during the evaporation of solvent.
Microscopy
Using this, relatively cheap, technique the shape of the particles can be seen, it is 
not .however, suitable as a quality or production control technique as only few 
particles are examined, and there is the real danger of unrepresentative sampling.
2.3.1.3 Separation Techniques
A separation method exerts an external force to a sample and physically groups 
the particles according to size. Once the particles are separated, the 
characterisation of individual groups of particles can be conducted using either a 
counting method or an ensemble method. Common separation techniques include 
sieves, gravitational sedimentation, disc centrifuge, capillary hydrodynamic 
fractionation, packed column chromatography, and sedimentation field flow 
fractionation.
Disc Centrifuge Methods
A disc centrifuge method uses a rotating optically clear disc that is filled with slurry 
to be analysed (Fitz-patrick et al, 1995). The particles suspended in the liquid 
move at rates that depend on particle size, large particles move much faster than
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small ones. A light beam detector is used to monitor the amount and the size of 
particles that pass through the edge of the disc.
Capillary Dynamic Fractionation
In capillary hydrodynamic fractionation (CHDF) system, a very dilute suspension of 
particles flows through a very thin capillary. A parabolic velocity profile is 
developed for each particle size group (Barth et al, 1984). The method is capable 
of measuring particles in the range of 0.01-2 microns, and the resolution is usually 
poor.
Gravitational Sedimentation
The applicable range for this method is 2-50 microns (Allen et al, 1992).The 
principle of measurement is based on the Stokes’ Law. The viscosity factor 
indicates that it is needed to control temperatures very accurately (Beckers et al,
1989). On the other hand, measurements with this technique tends to be extremely 
slow and repeat measurements are tedious.
Sedimentation Field Flow Fractionation
In this instrument a rotating disc provides a flow chamber for the particle 
suspension to be analysed (Schimpf et al, 2000). The method can provide 
extremely good resolving power for particles that are less than 3-5 microns, but is 
based on the highly convoluted separation mechanisms, thus, the run time is 
typically long (1 hour or more).
Packed Column Chromatography
In this technique, the capillary is packed with chromatographic materials that 
create many tiny channels for the suspended particles to flow through. An 
advantage of the technique is the increased resolution for particles with small size 
difference.
Sieving
Is an old technique but has the advantage that it is cheap and is readily usable for 
large particles. Allen et al. (1992) discussed the difficulties of reproducible sieving, 
but the main disadvantages are that by sieving it is difficult to measure sprays, 
emulsions, and dry powders under 400# (38p).
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In this study; Laser particle size analyses was the method of choice for samples 
testing.
2.3.2 Materials and methods
Particle size analyses was performed using Analysette®22 (Fritsch, Germany) 
Laser particle sizer, together with a liquid dispersing unit for small quantities of 
suspended material. The instrument was tested using the “Fritsch” starch standard, 
berore being used for samples testing.
The liquid dispersing unit was filled with small quantities of Benzene (it has been 
found the most suitable dispersing liquid for the material to be tested, as water and 
other organic solvents dissolved it).
A background measurement was performed before starting analyses. The sample 
was gradually added until the absorption was between 7% and 15%. The 
measurement was started automatically as the specified value was reached. When 
the measurement was finished, the raw data were stored and the particle size 
distribution was calculated from these data.
2.4 X-RAY POWDER DIFFRACTION
2.4.1 Introduction
X-ray powder diffraction (XRD) has been used extensively in pharmaceutical 
industry for a number of years. Historically, diffraction started with the development 
of film methods, where the intensity of the diffracted beams was measured by the 
blackening on a photographic film (Kenkins et al, 1996). The 1940s saw the advent 
of the powder diffractometer which contained a detector designed to scan across 
the area previously occupied by the film (Klug et al, 1974). Until recently, 
instrument development has focused mainly on detector technology and sample 
environment.
In recent years, however, the introduction of sources that can focus an x-ray beam 
into a small area and two dimensional detectors for rapid data collection have 
opened new horizons for x-ray powder diffraction.
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The XRPD technique takes a sample of the material and places a powdered 
sample in a holder, then the sample is illuminated with x-ray of a fixed wave-length 
and the intensity of the reflected radiation is recorded using a goniometer (Erko et 
al ,1996). This data is then analysed for the reflection angle to calculate the inter­
atomic spacing (D value in Angstrom units-10"8 cm). The intensity (I) is measured 
to discriminate (using I ratios) the various D spacings and the results are 
compared to identify possible matches (Nielsen et al, 2001).
2.4.1.1 X-Ray generation and properties
X-rays are electromagnetic radiation with typical photon energies in the range of 
100 eV -  100 keV. For diffraction applications, only short wavelength x-rays (hard 
x-rays) in the range of a few angstroms to 0.1 angstrom (1 keV -  120 keV) are 
used. Because the wavelength of x-rays is comparable to the size of atoms, they 
are ideally suited for probing the structural arrangement of atoms and molecules in 
a wide range of materials. The energetic x-rays can penetrate deep into the 
materials and provide information about the bulk structure (Warren et al, 1990).
X-rays are produced generally by either x-ray tubes or synchrotron radiation. In an 
x-ray tube, which is the primary x-ray source, x-rays are generated when a focused 
electron beam accelerated across a high voltage field bombards a stationary or 
rotating solid target. As electrons collide with atoms in the target and slow down, a 
continuous spectrum of x-rays are emitted, which are termed Bremsstrahlung 
radiation (James et al, 1982). The high energy electrons also eject inner shell 
electrons in atoms through the ionization process.
When a free electron fills the shell, an x-ray photon with energy characteristic of 
the target material is emitted. Common targets used in x-ray tubes include Cu and 
Mo, which emit 8 keV and 14 keV x-rays with corresponding wavelengths of 1.54 A  
and 0.8 A, respectively (Chritopher et al, 1997). The energy E of an x-ray photon 
and it’s wavelength is related by the equation E = hc/A, where h is Planck’s 
constant and c the speed of light.
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In recent years synchrotron facilities have become widely used as preferred 
sources for x-ray diffraction measurements. Synchrotron radiation is emitted by 
electrons or positrons travelling at near light speed in a circular storage ring 
(Authier et al, 2001). These powerful sources, which are orders of magnitudes are 
more intense than laboratory x-ray tubes, have become indispensable tools for a 
wide range of structural investigations and brought advances in numerous fields of 
science and technology.
The diffracted beam may be detected by using a moveable detector such as a 
Geiger counter, which is connected to a chart recorder. In normal use, the counter 
is set to scan over a range of 20 values at a constant angular velocity.
Routinely, a 20 range of 5 to 70 degrees is sufficient to cover the most useful part 
of the powder pattern. The scanning speed of the counter is usually 20 of 2 
degrees min-1 and therefore, about 30 minutes are needed to obtain a trace.
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Figure 2.3: Scheme of an X-ray powder diffractometer 
2.4.1.2 Lattice Planes and Bragg’s Law
X-rays primarily interact with electrons in atoms. When x-ray photons collide with 
electrons, some photons from the incident beam will be deflected away from the
100
direction in which they were originally travelling. If the wavelength of these 
scattered x-rays did not change (meaning that x-ray photons did not lose any 
energy), the process is called elastic scattering (Thompson Scattering) in that only 
momentum has been transferred in the scattering process (Guinier et al, 
1994).These are the x-rays that are measured in diffraction experiments, as the 
scattered x-rays carry information about the electron distribution in materials.
In an inelastic scattering process (Compton Scattering), x-rays transfer some of 
their energy to the electrons and the scattered x-rays will have different 
wavelength than the incident x-rays (Guinier et al, 1994).
Diffracted waves from different atoms can interfere with each other and the 
resultant intensity distribution is strongly modulated by this interaction. If the atoms 
are arranged in a periodic fashion, as in crystals, the diffracted waves will consist 
of sharp interference maxima (peaks) with the same symmetry as in the 
distribution of atoms. Measuring the diffraction pattern therefore allows us to 
deduce the distribution of atoms in a material.
The peaks in an x-ray diffraction pattern are directly related to the atomic 
distances. For a given set of lattice plane with an inter-plane distance of d, the 
condition for a diffraction (peak) to occur can be simply written as 2dsin0 = nA. It is 
presented in Figure 2.4, and is known as the Bragg’s law , after W.L. Bragg.
Where A is the wavelength of the x-ray, 0 the scattering angle, and n an integer 
representing the order of the diffraction peak. Bragg’s law is one of most important 
laws used for interpreting x-ray diffraction data (Zachariasen et al, 1997).
2dsin0 = A
Figure 2.4: Bragg’s Law
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2.4.2 Materials and methods
X-ray powder diffraction (XRPD) patterns were obtained with a Phillips analytical 
X-ray powder diffractometer (Bath, UK) utilizing a CuKq source at 1.5418 A. Each 
sample of approximate weight of 1gm was analysed by a single 20 sweep, with a 
step size of 0.027 step and step time of 13 s.
2.5 DYNAMIC VAPOUR SORPTION
2.5.1 Introduction
Many amorphous materials are able to crystallise by the process of water 
absorption, which lowers the Tg and gives sufficient molecular mobility to allow 
crystallisation to proceed rapidly. The availability of microbalance assemblies with 
good temperature and humidity control (as in the dynamic vapour sorption 
apparatus) makes it rather simple to detect changes in crystallinity gravimetrically 
(Buckton et al, 1999).
Water sorption has been used in the study of many amorphous and partially 
amorphous powders. A few examples in the pharmaceutical literature include 
sucrose (Gerhardt et al, 1994), lactose (Buckton et al, 1995-b), raffinose (Gerhardt 
et al, 1995) and salbutamol sulphate (Ward et al, 1995).
Vapour sorption by amorphous and crystalline pharmaceutical materials is usually 
quite different and can be used to precisely distinguish between them (Buckton et 
al, 1995-b). Typically, crystalline materials adsorb vapors in small quantities at their 
surfaces. In contrast, amorphous materials absorb and adsorb vapors in relatively 
large amounts. Vapor sorption in glassy and rubbery amorphous systems have 
been widely studied experimentally and modeled extensively, particularly with 
polymers (Vrentas et al, 1993). The models most applicable to pharmaceutical 
materials are based on solution theories and assume no specific interactions 
between sorbent and sorbate.
Rubbery amorphous materials usually sorb a considerably greater quantity of 
vapour than their respective glasses, and this phenomenon can be used to identify 
the state of an amorphous material (Oksanen et al, 1990). Many sorbent vapours 
plasticize the amorphous material into which they absorb, and thus at a critical
102
partial vapor pressure the glass to rubber transition can be induced at a constant 
temperature. Temperature effects on vapour sorption tend to be small, usually with 
an increased level of sorption with decreasing temperature .
Water vapor sorption has been most widely used in the study of amorphous drugs 
and excipients, and the predominant techniques are the vacuum microbalance and 
desiccator-saturated salt solution gravimetric methods. Other Volumetric and 
potentiometric methods have also been used (Kontny et al, 1985).
The sensitivity of water vapor sorption techniques to amorphous material is of the 
order of a few weight percent, and thus these techniques are the preferred means 
of studying pharmaceutical systems containing low levels (<10%) of amorphous 
material. The plasticizing effects of water vapor on amorphous pharmaceutical 
materials have been described in some details (Oksanen et al, 1990), and can 
potentially induce unwanted effects such as spontaneous phase transitions and 
lyophile collapse. Isothermal microcalorimetric techniques can be used in 
conjunction with water vapor sorption methods to study such phase transitions 
from the amorphous state (Angberg et al, 1988). The influence of additives on the 
kinetics of amorphous to crystalline phase transition in lactose has been widely 
investigated (Buckton et al, 1998-b), as has the physical stability of amorphous 
drugs.
2.5.2 Materials and methods
The moisture sorption profile was determined by dynamic vapor sorption (DVS; 
DVS-1 from Surface Measurement Systems Ltd., Bath, UK). Approximately 10 mg 
of sample was weighed into the DVS sample cell and subjected to a sorption- 
desorption cycle using 10% RH increments between 0 and 90% RH. Equilibrium 
mass, at each RH, was determined with a dm/dt of 0.0005% min'1.
2.6 SCANNING ELECTRON MICROSCOPY
2.6.1 Introduction
Electron microscopes use a beam of highly energetic electrons to examine objects 
on a very fine scale. This examination can yield information on topography (surface 
features), and crystallography (how the atoms are arranged in the object) (Mohanty
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et al, 1982). Electron microscopes were developed due to the limitations of light 
microscopes (Watt et al, 1997), which are limited by the physics of light to 500x or 
1000x magnification and a resolution of 0.2 pm.
The transmission electron microscope (TEM) was the first type of electron 
microscopes to be developed and is patterned exactly on the light transmission 
microscope except that a focused beam of electrons is used instead of light. It was 
developed by Max Knoll and Ernst Ruska in Germany in 1931.
The scanning electron microscope generates a beam of electrons in a vacuum. 
That beam is collimated by electromagnetic condensor lenses, focused by an 
objective lens, and scanned across the surface of the sample by electromagnetic 
deflection coils. The primary imaging method is by collecting secondary electrons 
that are released by the sample (Chapman et al, 1986). The secondary electrons 
are detected by a scintillation material that produces flashes of light from the 
electrons. The light flashes are then detected and amplified by a photomultiplier 
tube (Chapman et al, 1986). The intensity of the electrical current induced in the 
specimen by the illuminating electron beam is used to produce an image (Lyman et 
al, 1990).
Scanning electron microscopes are often coupled with x-ray analysers. The 
energetic electron beam-sample interactions generate x-rays that are characteristic 
of the elements present in the sample (Reimer et al, 1985).
The instrumentation of an electron microscope, and X-ray ejected from electron 
















Figure 2.5: Electron microscopy instrumentation
2.6.1.1 Scanning process
In a typical SEM configuration, electrons are thermo-ionically emitted from a 
tungeston or LaB6 cathode filiment towards an anode (Chesco et al, 1990).The 
beam then passes through the objective lens, where pairs of scanning coils deflect 
the beam over a rectangular area of the sample surface. As the primary electrons 
strike the surface they are inelastically scattered by atoms in the sample (Reimer 
et al, 1985).
Interactions with the surface lead to the subsequent emission of electrons and x- 







Figure 2.6 Electrons and X-rays ejected from electron beam hitting the samples
2.6.1.2 Detection of secondary electrons
The most common imaging mode monitors low energy (<50 eV) secondary 
electrons (Heywood et al, 1971). Due to their low energy, these electrons must 
originate within a few tenths of a nanometer from the surface. The electrons are 
detected by a scintillator-photomultiplier device and the resulting signal used to 
modulate the intensity of a cathod ray tube that is rastered in conjunction with the 
raster-scanned primary beam. Because the secondary electrons come from the 
near surface region, the brightness of the signal depends on the surface area that 
is exposed to the primary beam (Crang et al, 1988).
Because the SEM utilises vacuum conditions and uses electrons to form an image 
(Chapman et al, 1986), special preparations must be done to the sample. All water 
must be removed from the samples because the water would vaporize in the 
vacuum. All non-metals need to be made conductive by covering the sample with a 
thin layer of conductive material (e.g. gold). This is done by using a device called a 
sputter coater.
2.6.2 Materials and methods
Instrument used was 6310 Cryo System, and samples were coated with gold for 
measurement. For the cooling system with liquid nitrogen, SEM cold stage and 
anticontaminator were purged with nitrogen gas at a pressure of 0.5kg/cm2 (7psi) 
for 1-2 minutes. Particles examined under electron microscope were inittialy 




The measurement of dissolution rate is utilised for the functionality and 
characterisation of bulk drug substances and products. The dissolution rate and 
bioavailability of a drug substance is influenced by its solid state properties, i.e 
crystallinity, polymorphism, hydration, solvation, particle size, and particle surface 
area (Banakar et al, 1992). It is also influenced by extrinsic factors, such as 
hydrodynamics (e.g. test apparatus, shaft rotation speed) and test conditions (e.g. 
temperature, fluid volume and viscosity, pH, and buffer strength in the case of 
ionizable compounds) (Byrn et al, 1995). The official approved dissolution 
apparatus for testing dissolution include, apparatus I (Basket), apparatus II 
(Paddle), apparatus III (reciprocating cylinder), and apparatus IV (flow through the 
cell).
In these, testing of pharmaceutical dosage forms typically calls for using a buffer 
solution or a hydrochloric acid (HCI) solution as the dissolution medium. Usually 
basket speed is 100 rpm, while the paddle speed is 50 rpm. Both tests require 
sampling of the solution after specific intervals, called time points. These are 
usually 15, 30, 45, and 60 minutes when testing immediate-release products. The 
compendial time points are usually a single point of either 30 or 45 minutes.
A discriminating dissolution procedure yields data that distinguishes important 
differences in composition and/or method of manufacture between dosage forms 
(Junginger et al, 2003). The discriminatory power of the dissolution method 
depends on the method’s ability to detect changes in the drug product (Banakar et 
al, 1992). Of these, manufacturing variables which can come from many sources, 
e.g. the drug substance (different particle sizes, crystal habits, solvation, surface 
areas, or synthetic pathways) (Mauger et al, 1996), the drug product’s formulation, 
and/or the drug product’s process of manufacturing.
The method sensitivity to drug product formulation changes can be challenged by 
testing products with different amounts of excipients or by testing formulation 
changes (Rohrs et al, 2001). If the data show a measurable difference for the key
107
variables, then the method may be considered as a discriminating test for critical 
manufacturing variables.
With regard to stability, the dissolution test should appropriately reflect relevant 
changes in the biopharmaceutical performance caused by temperature, aging, 
humidity, and photosensitivity.
On the other hand, the implementation of similarity analyses is becoming important 
for demonstrating formulation equivalencies among semi-solids, immediate release 
and extended release oral solid dosage forms. Test methods for these analyses 
involve the use of the USP apparatus I and II (Fares et al, 1995). For active 
pharmaceutical ingredients (API) “sameness” analyses became possible by the 
development of the intrinsic dissolution test (Viegas et al, 2001).The evaluation of 
the intrinsic dissolution of an API is a way to demonstrate chemical purity and 
equivalency, after changing the synthesis final crystallisation steps, the particle 
size and the surface area. Polymorphism and scale up issues regarding batch size 
and manufacturing site can also be assessed by intrinsic dissolution (Viegas et al, 
2001).
The intrinsic dissolution rate is defined as the rate of dissolution of a pure 
pharmaceutical active when conditions such as surface area, temperature, 
agitation-stirring speed, pH and ionic strength of the dissolution medium are kept 
constant, (Mauger et al, 2003). The intrinsic dissolution apparatus is shown in 
Figure 2.7. The assembly is immersed, pellets side up, into the bottom of a flat- 
bottom dissolution vessel containing 900 ml dissolution medium at 37°C.The 

























Figure 2.7: The apparatus for intrinsic dissolution test (Vigas et al, 2001).
2.7.2 Materials and methods
2.7.2.1 Intrinsic dissolution
Disc preparation: 6 Discs were prepared from each material, compressed at 
pressure of 2000 -  3000 psi for 2 minutes and 30 seconds at weighs of around
0.125 gm.
Standard preparation: 35.0 mg of cefuroxime axetil reference standard (CARS) 
was transferred to 100 ml volumetric flask containing 10 ml methanol. The solution 
was sonicated for 10 minutes and then completed to volume with the dissolution 
media. 4 ml of the solution was transferred to 100 ml volumetric flask and diluted to 
volume with the same media.
Sample preparation: Each disk was placed in a dissolution vessel, as shown in 
figure 2.7, and the dissolution test was started as the conditions mentioned below. 
At the specified time intervals (5,10, 20, 30 & 45 min), 20 ml samples were 
withdrawn from the dissolution vessels, filtered using 0.45pm filter previously 
saturated with 10 ml of the dissolution media, and then analysed.
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Dissolution conditions: Dissolution conditions mentioned under CA tablets in BP 
2000 were applied. These are, dissolution apparatus II used together with the 
intrinsic dissolution disks (Erweka DT 60), 900ml 0.1N HCI medium maintained at 
37°C±1 °C. The speed of the paddle was set at 50 rpm.
Measurements: the absorbances of the standard preparation and the samples 
taken were measured at 278 nm using “Varian Cary I” UV spectrophotometer. The 
dissolution media was used as a blank.
2.7.2.2 Dissolution using apparatus II
Dissolution conditions adopted were those mentioned in BP 2000 monograph for 
CA tablets. These include the use of apparatus II (Erweka DT 60), set at 50 rpm 
speed, and 900ml 0.1 N HCI, maintained at 37°C ± 1°C.
Standard preparation: 34.0 mg CARS was transferred to a 100 ml volumetric flask, 
10 ml methanol was added and sonicated for 10 minutes, then volume was 
completed with the dissolution media. 4ml of the solution was transferred to 100 ml 
volumetric flask, then volume was made up with the same media.
Sample testing: a weight from the sample preparation equivalent to 125mg 
cefuroxime was transferred to each of the 6 dissolution vessels at the beginning of 
the test. At the time intervals of 5, 10, 15, 20 & 30 minutes samples (10 ml each) 
were withdrawn. Substitution with 10ml media was done gently and directly, 
samples were then filtered through 0.45microns filter, diluted with the same 
dissolution media (if necessary), and analysed for the amount of dissolved CA.
Measurements: the absorbances of the standard preparation and the samples 
tested were measured at 278 nm using “Varian Cary I” UV spectrophotometer. The 
dissolution media was used as a blank.
The % release of CA was calculated at each time interval using the following 
equations:
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Abs of sample ^ Qonc 0f q a r § = Cone, of CA in the sample  Eq. 2.9
Abs of standard
Cone. Of CA mg/ml x 900ml = amount of CA released to the media  Eq. 2.10
Amount of CA released . . . . .  .. _ . , A A1_ .  . .-------------------------------- x100% = % Release of CA to the media  Eq. 2.11
125/0.8
2.8 RAT INTESTINAL ABSORPTION MEASUREMENTS
2.8.1 Introduction
The intestinal epithelium is a gatekeeper, i.e. it controls the entry of nutrients and 
active pharmaceutical ingredients. Knowledge of the absorption and metabolism of 
these substances at the intestinal mucosal level is, thus, of great importance. Drug 
absorption is considered to be a complex transfer process across the intestinal 
lining, which includes passive diffusion through the paracellular space and/or 
membranes of absorptive cells, vesicular uptake (endocytosis / pinocytosis), and 
release at the basolateral space, transcytosis (Lennerans, 1998). This transport 
may or may not be receptor-mediated, entailing uptake across the apical domain 
with subsequent passive diffusion into the basolateral space.
Each transport mechanism depends on the physico-chemical properties of the 
absorbed compound, such as its stereochemistry, partition into membranes, 
molecular weight and/or size, molecular volume, pKa, solubility, chemical stability 
and charge distribution. Physiological factors such as gastric emptying, 
gastrointestinal motility, intestinal pH, blood flow, lymph flow, pathological state, 
drug interactions, nutrition, and mucus dissolution, also need to be considered 
when evaluating absorption (Pade et al, 1998; Wikman et al, 1993).
Possible routes and mechanisms of transport of molecules across the intestinal 








Figure 2.8: Routes and mechanisms of transport of molecules across tne intestinal epithelium 1) 
Paracelluiar; 2) transcellular passive diffusion; 3) transcytosis; 4) carrier-mediated uptake at the 
apical domain followed by passive diffusion across the basolateral membrane.
Upon ingestion, compounds have to be liberated from their dosage form, which 
includes dissolution into a complex medium containing numerous compounds (bile 
salts, ions, lipids, cholesterol and enzymes) (Welling et al, 1984). This medium can 
vary considerably, depending on the individual, the intestinal segment, the diet, 
etc.
Measurements of absolute solubility and dissolution are performed routinely during 
drug development, however, knowledge of intestinal drug dissolution is limited, due 
to the non-physiological aspects of in vitro systems. For example, instead of using 
intestinal fluid, buffer systems are commonly employed, which may result in an 
overestimation or underestimation of the actual events in vivo (Galia et al, 1998; 
Dressman et al, 1998). Since the intestinal fluid is rich in enzymes derived from 
dying enterocytes and/or the intestinal flora, gastrointestinal stability includes both 
physico-chemical and enzymatic stability.
The intestinal cell lining is covered with a viscous and elastic gel produced by the 
goblet cells of the villous epithelium. The physico-chemical properties of this gel 
can influence the rate of diffusion from the bulk to the site of absorption. 
Furthermore, metabolic enzymes could be associated with the mucus layer.
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Thus, the gel is considered to be the first in a series of absorptive barriers (Winne 
et al, 1979). The enzymatic barrier to oral absorption could consist of several 
layers, depending on the physico-chemical properties of the active compound.
As well as the enzymes within the intestinal lumen, there are additional enzymes 
located in the absorptive cells themselves, such as several cytochrome P450 
(CYP) isoforms. In combination with P-glycoprotein (P-gp), these enzymes are 
responsible for the intestinal first-pass effect.
The intestinal mucosa is characterised by the presence of villi that constitute the 
anatomical and functional unit for nutrient and drug absorption (Pacha et al, 2000). 
The presence of villi and microvilli provides enormous surface area for absorption 
(approximately 250m2 in a human). The mucosa consists of the epithelial layer, the 
lamina propria (collagen matrix containing blood and lymphatic vessels) and the 
muscularis mucosa. Therefore, any drug entering the bloodstream has to pass 
through the epithelial layer, part of the lamina propria, and the wall of the 
respective vessel.
A series of methods have emerged for investigating the principal mechanisms of 
absorption in animals, namely, in vivo, in situ and in vitro methods. The choice of 
model depends totally on the questions to be answered with respect to the test 
compound being studied.
2.8.1.11n vivo models
The main advantage of in vivo models is the integration of the dynamic 
components of the mesenteric blood circulation, the mucous layer and all the other 
factors that can influence drug dissolution (Amidon et al, 1988).
The most frequently used animal model is the rat, since it better reflects the human 
situation with respect to paracelluiar space and metabolism than the dog, which is 
significantly different to the human, particularly in relation to metabolism, and 
overestimation of the absorption of paracellularly restricted compounds (Kararli et 
al, 1995). However, oral studies in rats also have limitations, and tend to provide
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false-positive results. It has therefore been stated that “the only real model for man 
is man” (Wilding et al, 2000).
The disadvantage of in vivo models is that it is impossible to separate the variables 
involved in the process of absorption, i.e. it is not possible to identify individual 
rate-limiting factors.
2.8.1.2 In situ models
The development of stable , vascularly perfused preparations of the small intestine 
has provided a powerful research tool for the investigation of intestinal transport 
and metabolism. In this approach, the abdominal cavity of an anaesthetised animal 
is exposed by laparotomy. The intestinal segment into which the drug solution is 
introduced can be either a closed loop or an open loop.
In situ methods have significant advantages over in vivo models. This includes 
bypassing the stomach, which means that acidic compounds are not likely to 
precipitate, so dissolution rates do not confuse intestinal drug concentrations and 
therefore plasma levels. Furthermore, in situ tests allow the experimentalist to 
assess formulation-independent breakdown in the stomach under acidic 
conditions. Although the animal has been anaesthetised and surgically 
manipulated, mesenteric blood flow remains intact.
Rat single-pass intestinal perfusion is an in situ technique wherein the blood 
supply, innervation and clearance capabilities of the animal remain intact. Input of 
drug can be closely controlled in terms of concentration, pH, osmolality, 
composition, intestinal region and flow rate (Thomas et al, 1992). The drug is 
measured in buffer or perfusate, thus facilitating assay of drug by specific 
chromatographic means. This technique has been used extensively in establishing 
a database for permeabilities with correlation to human absorption data, as well as 
to elucidate absorption mechanism (Amidon et al, 1988). The basic principle of 
perfusion experiments is that the absorption is calculated from the disappearance 
rate of the drug from the perfused segment.
The value of effective permeability (Pef f ) provides the best description of the 
transport process across the intestinal barrier (Lennerans et al, 1992, 1995-a and
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1995-b). Calculation of Peff is dependent on the hydrodynamics within the segment, 
which in turn is determined by the perfusion technique, its rate, and the degree of 
intestinal motility.
The intestinal Petf represents a direct measurement of the local absorption rate in 
man and reflects the transport velocity across the epithelial barrier. Intestinal 
perfusion models, which measure the clearance disappearance of the drug from 
the perfusion solution, directly describe uptake into the epithelial cell.
Intracellular metabolism in the enterocyte, for instance CYP 3A4, does not occur in 
the vicinity of the outer leaflet and is therefore considered less likely to influence 
the disappearance rate (P e tr )  (Lande et al, 1994; 1995). Intracellular metabolism is, 
however, a part of the first-pass effect and can therefore be a further limitation to 
the bioavailability of the drug. In contrast to intracellular metabolism, metabolism in 
the lumen and/or at the brush-border will interfere directly with the determination of 
the Peff (Langguth et al, 1994; Krondahl et al, 1997).
In vivo studies permit the determination of absolute or relative bioavailability, but 
are also more complex in terms of plasma assay development and assessing 
where rate limiting processes occur. In vitro or in situ models are of particular utility 
if they project when absorption is rate limiting to systemic availability and 
permeability is rate limiting to absorption.
There are few publications (Artursson et al, 1991; Conradi et al, 1993; Kim et al, 
1993) that compare the three widely used intestinal absorption models, possessing 
individual strengths and weaknesses. They show that each absorption model rely 
on a different mean of determining membrane transport. The rat in situ single-pass 
intestinal perfusion system base permeability calculations on steady state 
disappearance of the compound from the intestinal lumen (Conradie et al, 1993).
The rat everted intestinal ring method use the tissue accumulation of compound in 
vitro to determine drug uptake rate (Kim et al, 1993). The human colon 
adenocarcinoma cell line (Caco2) is grown on membrane filters mounted in
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diffusion chambers, the rate of compound appearing in the receiver compartment 
is the basis of the permeability measurement (Artursson et al, 1991).
There are factors that add weight in selecting the appropriate in vitro or in situ 
methods for evaluating drug absorption. These factors include the ease and cost of 
preparation, maintenance, control of experimental conditions, reproducibility and 
ease of drug analyses.
2.8.1.3 In vitro models 
Organotypic models
All intestinal cell types (for example, enterocytes, caliciform cells and lymphocytes) 
are present in organotypic models, which are used to study formulation effects, 
intestinal metabolism/stability, and regional differences in permeability. Some 
studies have shown that permeability to various marker molecules varies along the 
intestinal canal. In general, permeability decreases in the order jejunum > ileum > 
colon (Davis et al, 1982). The half-lives of these models are short (1-3 hours).
Everted gut sacs
The everted gut sac of the rat small intestine can be used to determine kinetic 
parameters with high reliability and reproducibility (Barthe et al, 1999). Oxygenated 
tissue culture media and specific preparation techniques ensure tissue viability for 
up to 2 hours. The technique can be used to study drug transport across the 
intestine and into the epithelial cells, provided that sensitive detection methods are 
employed.
This technique has been previously used to study the transport of macromolecules 
and liposomes. More recently, it has mainly been used to quantify the paracelluiar 
transport of hydrophilic molecules and to estimate the effects of potent enhancers 
on their absorption (Ceppert et al, 1994). Molecules that cross the epithelial barrier 
by transcellular route have a much higher permeability, which can also be 
accurately quantified by using the everted sac system.
This kind of model (everted or not) is suitable for measuring absorption at different 
sites in the small intestine (Chowhan et al, 1977), and for performing preliminary
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experiments on the colon (Brathe et al, 1999).
It is also useful for estimating the first-pass metabolism of drugs in intestinal 
epithelial cells. A potential disadvantage of this approach is the presence of the 
muscularis mucosa, which is not usually removed from everted sac preparations. 
This model, therefore, does not reflect the actual intestinal barrier, because 
compounds under investigation pass from the lumen into the lamina propria (where 
blood and lymph vessels are found) and across the muscularis mucosa. Thus, the 
transport of compounds with a propensity to bind to muscle cells might be 
underestimated.
The rat everted gut sac system was first reported for the study of the transport of 
glucose and amino acids (Wilson et al, 1954). In the original method, and all 
subsequent reports of the use of the method, sacs were incubated in simple salts- 
containing media/buffers, sometimes with the addition of glucose. Viability of the 
intestinal tissue was doubtful under such conditions. In histological studies Levine 
et al. (1970) showed that after 30 min incubation in a salt-buffered medium, 50- 
75% of the normal epithelium had disappeared, and at 1 h there was total 
disruption of the epithelial border.
In a histological study of various gut preparations Plumb et al. (1987) observed that 
when everted gut sacs were incubated for 20 min in simple media, there was 
severe interstitial oedema and disruption of the villus epithelium. Similar 
observations were made by Bridges (1980). As a result, the basic method was 
modified to an organ culture system by using tissue culture medium (TC 199), in 
place of simple salt buffers. The use of tissue culture medium greatly enhances the 
viability of the tissue and the system was successfully used to quantify in vitro the 
intestinal uptake of macromolecules (Rowland et al, 1981). This modified method 
has been used in uptake studies of liposomes, synthetic polymers (Blundell et al,
1993), and to precisely quantify the paracelluiar transport across the rat intestine.
Stewart et al. (1994) showed the histology at the electron microscope level, of 
everted sacs incubated for 1h in TC 199. It was shown that the general cell 
structure and tissue morphology were well preserved. A simple biochemical test of 
sac integrity was in the ability of the tissue from the duodenum and proximal
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jejunum to transport glucose via active transport and to maintain a glucose 
concentration gradient inside the sacs (serosal side) up to 3.7 times higher than 
the outside (mucosal) concentration.
The active transport of glucose requires metabolic energy and so clearly if the sacs 
were not biochemically active, or if they were not physically intact, such a 
concentration gradient would not be maintained.
From the recovery of total glucose in the system, it was clear that the cells were 
metabolically active, with approximately 20% - 30% of the total glucose in the 
system being utilised by the sacs during 60 min of incubation. During these studies 
it was also observed that the sacs actively transported H+ ions (Stewart et al,
1994).
The in vitro gut experiments tissue culture medium contained a colored indicator 
that facilitated a visual estimation of the pH of the medium. Careful and gentle 
handling of the tissue during preparation was found to be very important. The 
intestine needs to be removed as quickly as possible from the animal and the sacs 
prepared with the entire intestine are bathed in warmed TC 199 medium with 
constant oxygenation.
In vitro gut intestinal absorption offers a relatively quick and inexpensive technique 
for measuring uptake of drug into tissue. These considerations are important in 
comparing the methods, as the everted ring technique does not entail the 
considerable time and expense of start-up and maintenance of the Caco2 cells, nor 
does it require the greater number of animals, with associated husbandry costs 
needed for statistical power with the perfusion method. Rings can be prepared 
from virtually any segment of intestine, permitting study of axial differences in 
uptake.
Techniques used in the study
In this study two techniques were used to test absorption of CAA, the intestinal in 
situ perfusion and the in vitro gut sac absorption.
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In situ perfusion was conducted to determine the Kabs (absorption rate constant) 
and t0.5 of absorption of CA across the rat intestinal membrane. Calculation was 
then done to determine the rate of absorption in the human intestine.
Only one concentration was tested, because the mechanism of CA absorption is 
well known and reported as via an active transport mechanism (Balaguer et al, 
1997). Further, absorption in only one region of the intestine was studied (jujenum, 
first 15 cm), as the proximal part of the intestine was determined as the major site 
of absorption (Balaguer et al, 2002).
In this study cefuroxime axetil drug was tested for in situ and in vitro absorption. It 
is known that the parent drug (cefuroxime) is not absorbed, whereas the prodrug 
CA showed absolute bioavailabilities in human of 36% and 52% in the fasted and 
fed states respectively (Carretro et al, 2000). It had also been shown that during 
absorption from the GIT, CA was rapidly hydrolyzed by non-specific mucosal 
esterases to cefuroxime (C ) and acetaldehyde (Balaguer et al, 1997).
As mentioned above, the mechanism of CA absorption is via a carrier mediated 
transport, which obeys Michaelis-Menten and first order kinetics in the proximal 
segment of the small intestine, and a passive diffusion mechanism in the mean 
and distal segments of the intestine. In another study, using Caco2 cells, it was 
reported that CA enters the Caco2 cells by simple diffusion (Dantzig et al, 1999).
In the in vitro gut tests, the gut sacs were not everted and were taken as sacs of 50 
cm long from proximal and mean parts of the small intestine, they were filled with 
the drug dispersed in 0.01 N HCI, and then isolated at both sides. Each sac was 
soaked in 50 ml TC 199 media in a flask at 37°C with oxygen aeration. A 0.01 N 
HCI solution was chosen in accordance with the published literature which states 
that CA undergoes gelling in water (Deutsch et al, 1990-b and James et al, 1989). 
No evidence of gelling occured in 0.01 N HCI (pH < 4). Also CA was stable in the 
solution for more than 3 hours as the stability of CA in this media revealed. The 
drug which was transported from inside the intestine to outside was withdrawn 
from the media at constant time intervals (every 15 min for 120 min), and analysed 
for the concentration of transported C.
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The efficiency of the transport system was controlled by monitoring the followings:
1. Changes in the pH of the TC 199 media in the flask. This could be immediately 
noticed by changes in the color of the media if any leakage of 0.01 N HCI from 
inside intestine to outside occured, as the media is pink and it changes to 
yellow under acidic conditions.
2. CA analyses in the media, as if any destruction or leakage from the intestinal 
membrane occurred, CA would be found in the withdrawn samples from the 
media. For this purpose stability of CA in the TC199 media at 37°C was studied 
for 2 hrs, and it was found that > 85% of CA was recovered. Thus CA could be 
detected in the release media, if presented.
3. The viability of the membrane .this was assured by the linear transport of the 
drug to the release media with respect to time.
Each in vitro gut absorption test (in this study) was conducted in triplicates.
2.8.2 Materials and methods
2.8.2.1 In situ perfusion
The in situ perfusion test was conducted according to methods previously
published by Fagerholm et al. (1996).
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10.32 gm
Table 2.1: Materials used for the in situ perfusion media 
Media preparation method
The materials mentioned in Table 2.1 were transferred to a 2L volumetric flask and 
the volume was made up with Milli-Q water to 1500 ml volume with stirring. The pH 
was adjusted to 6.5 using NaOH or H3PO4 solutions. Volume was adjusted with 
Milli-Q water to 2L.
Solution preparation
A solution of CA in the perfusion media was prepared at a concentration of 
0.1 mg/ml C. The drug was solubilised with the aid of sonication for 10 min upon 
cooling. CA was analysed initially using the HPLC method mentioned under 
section 2.9.2.2, and the results were recorded as the initial assay. The 
concentration in the perfusion study was chosen as (0.1 mg/ml), based on the fact 
that the dose of the drug given to the rat should be equivalent to the dose given to 
human. The equivalent dose was determined using the following equation.
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Dose (RAT) = — ^  r a t —  x  Dose of human at a specified w eight...............Eq. 2.12
wt of human
Dose (RAT) = 300 gm x125= 2.5 mg Cefuroxime 
15000
The volume of the in situ perfusion solution was 24 ml. This relates to the media 
flow rate previously reported of 0.2 ml/min for 2 hrs (120 min) (Fagerholm et al, 
1996).Thus, a 0.1 mg/ml drug (C) concentration was needed for the in situ 
perfusion experiments.
In situ perfusion procedure
A rat of weight 250g -  350g, fasted for 24 hr, was anaesthesised using ether 
compartment, followed by administration of 1M Ketamine (1ml). Labatomy was 
done starting from the large intestine and upwards. The intestine was traced to 
take the first segment from the jujenum(15 cm).
A partial cut was done away from the mysentry to allow the tip of infusion tube (1) 
to be entered, and the same was done at the end of the segment to put another 
infusion tube tip (2). Both were tied tightly to the intestine.
A 50 ml syringe filled with saline was flushed through the sealed intestine at a rate 
of 1 ml/min. The intestine was subsequently purged with air to remove any saline 
residue. A wet gauze was fitted on the exposed part of the stomach trying, as 
much as possible, to retain intestine parts inside.
Another syringe filled with filtered drug solution (using a saturated 0.45pm filter), 
was connected to the syringe pump at a rate of 0.22 ml/min. A long tube was used 
to heat the solution via a water bath, to 37°C, before entering to the intestine. The 
timer was started from the moment the drug solution entered the intestine. 
Meanwhile an ice bag was placed above the syringe to minimize CA hydrolysis, 
while a second tube and a clean graduated cylinder 10 ml were fitted to other end 
of the intestine.
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Samples were collected every 10 min, for 100 min. The collected samples were 
immediately filtered using 0.45pm nylon filter, and stored in eppendorfs at -20°C. 
Samples were subsequently withdrawn and analysed using the method described 
under section 2 .9.2 .2 .
2.8.2.2 In vitro gut absorption
Preparation of the test media:
The content of TC 199 bottle (1 Og) was placed in a 1L volumetric flask, 0.35g 
NaHC03 were added, and volume was completed with purified water. The media 
was kept cool.
Rat Preparation:
Rats of weight around 0.3 kg were fasted for 24 hr, then anaesthetized by ether 
until death. The abdomen was incised, the intestine was traced from the beginning 
of the large intestine upward, and with avoiding the 15 cm of the ileum it was cut. 
About 50 cm from the small intestine was taken (length was measured accurately). 
The intestine was washed with 20 ml of saline water and squeezed gently to 
empty.
The intestine was assured to be viable by keeping it all time in the media and not 
allowed to dry. This was done either by putting the intestine on a spread media 
over a tray or in a beaker filled with the media.
After washing, the empty intestine was weighed and then one end of the intestine
was tied up using a medical thread. Using a syringe, the drug suspension was 
loaded slowly, while avoiding any spillage. The second end of the intestine was 
then tied up and weighed upon loading. The drug remaining in the syringe and the 
volumetric flask were analysed for CA content.
A volume of 50 ml of TC 199 media was placed in a conical flask, which was pre­
healed to 37°C and aerated with Carbogen gas (95% 0 2) 5% C02). The intestine
was then soaked in the media and timing of the measurements started.
Measurements were undertaken after the initial immersion and then every 15 min 
for 120 min. Total of 2ml volume was withdrawn from each measurement and
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substituted immediately with another fresh 2 ml media. Aeration of the conical flask 
was undertaken after each sampling, flasks were stoppered, and the samples 
taken were filtered and stored at -20°C for post analyses using the HPLC method 
described under section 2.9.2.3.
After 120 min, the intestine was removed from the flask, weighed after drying its 
surface with a guaze, and emptied in a test tube with squeezing. Washing of the 
inner surface of the intestine was done with 10 ml of saline water (Wash Sample), 
and the intestine gently squeezed. The samples were stored at -20°C for analyses 
using the HPLC method described under section 2.9.2.3.
To digest the intestine (for the purpose to obtain the residual cefuroxime) it was 
soaked in 2.5N NaOH for 2 hrs at 37°C in a water bath. This, however, led to 
complete destruction of the cefuroxime structure as confirmed by analyses of CA 
upon exposure to the same conditions.
Drug suspension preparation
A quantity of CA, equivalent to 25 mg cefuroxime, was transferred to a 10 ml 
volumetric flask. Prior to each experiment, the volume was made up with 0.01 N 
HCI, with shaking to ensure complete wetting.
Cefuroxime dose was based on a 10X dose of the drug, which was chosen for 
easy quantitation of the material during analyses. The dose for the study was 
calculated as follows:
30 kg ch ild  ►the dose is 250 mg cefuroxime.
0.3 kg rat *  the dose is 2.5 mg cefuroxime.
10 X = 25 mg cefuroxime dose given to the rat.
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2.9 HPLC ASSAY METHODS
2.9.1 Introduction
The USP, British and European pharmacopeia current editions issued monographs 
for testing of CA raw material . All HPLC assay methods mentioned inthere 
included the same method conditions, parameters, instrumentation and materials. 
This indicated a reliable and valid method for analyses of CA. Because of this, it 
has been adopted in this study for the analyses of CA and C, and was tested for its 
suitability for detection and quantitation of C in the samples of the in situ perfusion 
and in vitro gut tests.
Changes in the method were needed to eliminate the interference of the tissue 
culture media (TC 99) with CA and C analyses, such changes were accompanied 
with validation to ensure the method suitability and validity.
A few non-pharmacopeial HPLC methods had been developed and published for 
analyses of CA. Of these, a simple reversed phase HPLC method for detection of 
C in the serum has been developed by Koot at al (1992). This method was based 
on cleaning up the serum with 93.3% solution of perchloric acid in water, and 
analyses using cefuroxime as an internal standard. Detection was made using a 
UV detector, at a wavelength of 275 nm.
Holt et al. (1990) reported a simultaneous assay method for some additional 
antibiotics found in combination in clinical samples. No interference was detected 
between these in urine, serum or cerebrospinal fluids. In another published 
method, an HPLC method for analyses of CA was described for the study of 
comparative pharmacokinetics of 2 brands of CA following a single intramuscular 
injection. The detection was based on UV method at 280 nm (Irshiad et al, 1995).
Rossel et al (1997) established a sensitive and selective method for determination 
of C in bronchoalveolar lavage fluid. The HPLC method included a UV detection at 
280nm,a C18 column and a mobile phase of acetonitril 0.05M and ammonium 
phosphate buffer pH 3.2 (15 : 85) v/v. The method was found to be sensitive, 
selective and linear.
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Another method reported by Klaus et al. (1998) was used for detecting the stability 
of CA in human intestinal fluid. The method utilised a C18 column maintained at 
room temperature, mobile phase I (0.002M Perchloric acid), mobile phase II 
(Acetonitril),a flow rate of 1 ml/min and a detector at wavelength of 265 nm. The 
separation eluent consisted of 84.0% mobile phase I for the first 6.5 min, and then 
it was changed to 62.0% for the 28.5 min, followed by washing with 84.0% mobile 
phase I for the 40 min.
Another assay method published by Sasinowska et al. (1995) described the use of 
the HPLC chromatography for the permeability determination of CA across the 
biological membrane, which included monitoring the absorbance at 280 nm.
2.9.2 Materials and methods
2.9.2.1 HPLC assay method for testing CA content and homogeneity in 
mixtures
For the analyses of the homogeneity of distribution and the content of CA in the 
mixtures prepared, the following assay of CA according to BP 2000 was applied .
Reference solutions:
Reference solution (a): 1 ml of the test solution was diluted to 100.0 ml with the 
mobile phase.
Reference solution (b): 5 ml of the test solution was heated at 60°C for 1 hr to 
generate the A3-isomers.
Reference solution (c): 5 ml of the test solution was exposed to ultraviolet light at 
254 nm for 24 hr to generate E isomers.
Standard solution: The solution was prepared immediately before use. 40.0 mg of 
cefuroxime axetil reference standard (CARS ) (BP, batch no. 2024) was dissolved 
in 20 ml of the mobile phase and then diluted to 200.0 ml with the same solvent.
Sample preparation (test solution): the solution was prepared immediately before 
use. A known mass of the material, equivalent to 40 mg cefuroxime, was 
transferred to a 200 ml volumetric flask containing 10 ml of methanol. The solution 
was cooled and sonicated for 10 minutes. The volumetric was subsequently filled
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with the mobile phase, and upon complete dissolution of the drug, the solution was 
filtered using a 0.45pm filter that had been previously saturated with 20 ml 
standard solution. It was then stored at 2°C -  8°C.
The chromatography was carried out using the HPLC system (Waters 2690 
Separations Module “Alliance”), column 0.25m long and 4.6 mm internal diameter, 
packed with trimethylsilyl silica gel for chromatography (L13) (5 pm), and the 
mobile phase was a mixture of 36% v/v of methanol R and 64% v/v of a 23 g/L 
solution of ammonium dihydrogen phosphate R. The flow rate was at 1.0 ml/min. 
The photodiode array detector was set at a wavelength of 278 nm. 20pl of each of 
reference solutions a, b, c and the standard solution were injected.
When the chromatograms were recorded in the prescribed conditions, the retention 
times relative to CA diastereoisomer A (second peak) were approximately 0.9 for 
CA diastereoisomer B, 1.2 for the CA A3 -  isomers, and 1.7 and 2.1 for the E 
isomers. The test was not considered valid unless in the chromatogram obtained 
with the standard solution, the resolution between the peaks corresponding to CA 
diastereoisomers A and B was at least 1.5. In the chromatogram obtained with 
reference solution b, the resolution between the peaks corresponding to CA 
diastereoisomers A and CA A3 -  isomer was at least 1.5.
The standard solution was injected six times. The assay was not considered valid 
unless the relative standard deviation of the sum of the peaks corresponding to CA 
diastereoisomers A and B was at most 2.0%.
The percentage content of C20H22N4O10S was calculated from the sum of areas of 
the two diastereoisomer peaks and the declared content of C20H22N4O10S in 
CARS.
2.9.2.2 HPLC assay method for testing CA and C content in the in situ 
perfusion test
Since CA undergoes hydrolysis in the intestinal conditions and is converted to 
cefuroxime sodium (C), both compounds CA and C were analysed .The method 
used was based on the BP 2000 monograph for analyses of CA, and its suitability
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for analyses of both CA and C was confirmed by its validation for C analyses, as 
mentioned under 2.9.3.
Standard preparation -  about 40 mg weights of cefuroxime, as cefuroxime axetil 
reference standard (CARS, batch no. 2024, BP) and cefuroxime working standard 
(CWS, batch no. CUC 05512, Orchid), were transferred to a 200 ml volumetric 
flask. 20 ml methanol was added, sonicated with cooling, and the volume was then 
completed with the mobile phase. The standard preparation was diluted with 
mobile phase to obtain standards with concentrations of 0.02, 0.005 and 0.002 
mg/ml.
Sample preparation: each sample of the in situ perfusion test was taken from the 
freezer 30min before analyses, and sonicated for 7 minutes with cooling. The 
solution was then filtered using 0.45pm nylon filter that had been previously 
saturated with 30 ml standard preparation.
Reference solutions:
Reference solution (a). 1.0 ml of the standard preparation was diluted to 100.0 ml 
with the mobile phase.
Reference solution (b). 5 ml of the standard preparation were heated at 60°C for 
1 h to generate the A3-isomers.
Reference solution (c). 5 ml of the standard preparation were exposed to ultraviolet 
light at 254 nm for 24 hr to generate E isomers.
The chromatographic test was carried out using the HPLC system (Waters 2690 
Separations Module “Alliance”). A 0.25m column with a 4.6 mm internal diameter 
packed with trimethylsilyl silica gel for chromatography (5 pm) was used. The 
mobile phase -  at a flow rate of 1.0 ml/min -  was prepared as a mixture of 36% v/v 
of methanol R and 64% v/v volumes of a 23 g/L solution of ammonium dihydrogen 
phosphate R. The photodiode array detector was set at a wavelength of 278 nm.
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20|jl of each of reference solutions (a), (b), (c) and the standard solution were 
injected. When the chromatograms were recorded in the prescribed conditions the 
retention times relative to CA diastereoisomer A (second peak) were approximately 
0.9 for CA diastereoisomer B, 1.2 for the CA A3 -  isomers, 0.35 for C and 1.7 and
2.1 for the E isomers.
The test was not considered valid unless in the chromatogram obtained with the 
standard solution, the resolution between the peaks corresponding to CA 
diastereoisomers A and B was at least 1.5. In the chromatogram obtained with 
reference solution (b), the resolution between the peaks corresponding to CA 
diastereoisomer A and CA A3 -  Isomer was at least 1.5.
The standard solution was injected six times. The assay was not considered valid 
unless the relative standard deviation of the sum of the peaks corresponding to CA 
diastereoisomers A and B is at most 2.0%, and the relative standard deviation of 
the peaks corresponding to C is at most 5% for the 0.005 mg/ml standard solution.
Volumes of 20pl sample preparation were injected into the chromatograph, the 
chromatograms were recorded, and the responses for the major peaks were 
recorded. The concentration of cefuroxime (mg/ml) present in each sample was 
calculated in the form of CA , and C as shown in equations 2.13 and 2.14 
respectively:
Sum peak area of diastereoisomers A + B in the sample _ o o  --------------------------------------------------------------—  x Cone, of CA RS Eq.2.13
Sum peak area of diastereoisomers A + B in the CARS
Peak area of C in the sample _ f 0 r- o -n---------------------------------- -— xConc.ofCWS ...............................  Eq. 2.14
Peak area of the C in the WS
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2.9.2.3 HPLC assay method for testing CA and C content in the in vitro gut 
absorption tests
Since CA undergoes hydrolysis in the intestine and is converted to C, both 
compounds CA and C were analysed using the same HPLC method. Method used 
for in situ perfusion samples analyses mentioned under section 2.9.2.2, was tested 
for suitability for the analyses of in vitro gut sac samples, but was found to be not 
suitable , due to the interference of the test medium having TC 199 with the C 
peak. Thus, the method was altered as described below, and was validated to 
confirm its suitability and validity for in vitro gut samples analyses ( as shown under 
section 2.9.3).
The mobile phase contained a filtered and degassed mixture of 0.2M monobasic 
ammonium phosphate and methanol (64 : 36). The 0.2M Monobasic ammonium 
phosphate was prepared by dissolving 23.0 g of monobasic ammonium phosphate 
in 1000 ml water.
Standard solutions were prepared by adding 40mg weights of cefuroxime, as 
CARS and as CWS in a 200 ml volumetric flask. 20 ml methanol was added, 
sonication with cooling was done and volume was completed with mobile phase. 
Standard preparation was diluted with the mobile phase to obtain standards of 
0.02, 0.005 and 0.002 mg/ml concentrations with the mobile phase. CARS and 
CWS standards used for in vitro gut analyses were the same as those mentioned 
under section 2.9.2.2.
The liquid chromatography (Waters 2690 Separations Module “Alliance”) HPLC 
system was equipped with a 320 nm (Waters 996 Photodiode Array) detector and 
a 4.6 mm * 25 cm column containing 5 pm packing L13. The flow rate was about 
1.0 ml per minute. The resolution (R) between the CA diastereoisomer A and B 
peaks was not less than 1.5, the column efficiency was not less than 3000 
theoretical plates when measured using the CA diastereoisomer A peak. The 
relative standard deviation for replicate injections was not more than 2.0%, and the 
relative standard deviation of the peaks corresponding to C was at most 5% for 
0.005 mg/ml standard solution.
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All frozen samples were taken from the freezer and kept at room temperature for 
30 min before analysis, it was then sonicated with cooling and shaking for 5 min 
and immediately analysed after filtration using a 0.45 pm nylon filter saturated with 
30 ml of standard preparation.
These samples include the followings:
Media samples: Those withdrawn (2ml) samples from the TC 199 medium 
surrounding the intestinal sac.
Intestinal (Wash & inside samples): Those taken from inside the intestine and its 
wash after the test. Samples were centrifuged before freezing for 10 min at 4,000 
rpm in a cooled centrifuge.
Syringe wash samples: for the undissolved CA remaining in the syringe, the 
syringe was loaded with 3.5 ml methanol, shacked well after closing its end, to 
completely dissolve CA. The syringe content was then transferred to a 10 ml 
volumetric flask, swirled, sonicated for 10 min with cooling and shaking. Volume 
was completed to 10 ml with ammonium dihydrogen phosphate (23 g/L), followed 
by sonication with cooling for about 5 min.
Equal volumes (20pl) of the standard preparation and each sample preparation 
were separately injected into the chromatograph, the chromatograms were 
recorded and the responses for the major peaks were measured. The 
concentration of cefuroxime (mg/ml) present in each sample was calculated in the 
form of CA and C as mentioned under section 2.9.2.2, equations 2.13 and 2.14, 
respectively.
2.9.3 Validation of the HPLC methods
2.9.3.1 Validation of the HPLC method used for the in situ perfusion
To ensure that the HPLC method mentioned in BP 2000 for CA analyses is also 
suitable and valid for analyses of C, the validation was done from different 
aspects, these included linearity, selectivity and stability.
Linearity
The linearity of the HPLC method was tested on 10 points calibration curve in the 




concentration were prepared and injected three times. Figure 2.9 shows the 
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Figure 2.9: Linearity of C using the BP 2000 HPLC method of CA analyses
The linear regression coefficient of R2 = 0.999993, indicated that the analytical 
method was quantitative.
In situ perfusion media interference with the HPLC analyses of CA and C
The standard solution was prepared as described in the method. A further sample 
was prepared exactly in accordance with the standard preparation, however with 
the exception to the dilution using solution 1 and solution 2 mentioned below. 
Solution 1: obtained by passing 200 ml of the perfusion solution in the rat intestine. 
Solution 2: the perfusion media itself, without passing through the intestine.
After the analyses, the chromatograms revealed that there was no interference of 
any of the solutions 1 and 2 with CA or C analyses.
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Stability of CA in the perfusion media
This test was done to study the effect of the perfusion media on the hydrolysis of 
CA , and to see the effect of the test conditions e.g. heat on the degradation of CA 
to A3-lsomer.
A weight of CAA, equivalent to 20 mg cefuroxime, was taken and transferred to a 
200 ml volumetric flask containing 100ml perfusion media. The solution was 
sonicated for 15 min with cooling to avoid degradation and the volume was then 
made up to 200 ml with the same media. The solution was then filtered through 
0.45pm nylon filter and analysed. The remainder of the solution was kept in a 
water bath adjusted at 37°C. Samples were analysed, at 0 and 2 hrs.
Results of this test indicated that CA degradation occurred with time in the 
perfusion media at 37°C. After 2 hrs, there was a loss of assay at 10% -  15% 
level, related to degradation of CA to C and to A3-lsomer. Thus cooling of the 
solution was necessary during in situ perfusion studies.
Adsorption of CA to the walls of syringes and tubes used for the in situ 
perfusion test
A weight of CA equivalent to 50 mg cefuroxime was taken and transferred to 500 
ml volumetric flask containing 100ml perfusion media.The solution was sonicated 
for 15 min, and the volume was made up with the same media. The solution was 
then filtered using 0.45pm filter and tested for the initial assay. A portion of the 
solution was stored at 2°C -  8°C, and considered as a reference solution.
A volume of the solution (60 ml) was transferred to a syringe, left for 2 hrs soaked 
in ice, and then analysed. Also 6 ml of the solution were passed into a tube 
(Enteplin, disposable infusion set), which was then closed from both sides and 
immersed in ice. Initial and two hours samples were taken and analysed for C and 
CA content.
Another simulation test was conducted where the parameters used for in situ 
perfusion were applied. The only exception was that the intestine was not
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connected to the tubes during this study. Samples were collected through out the 
100 min, and analyses was done for initial and every 30 min samples.
Results of these tests indicated that there was no adsorption of CA to the walls of 
the syringe or the tubes used for the in situ perfusion experiments, but there was a 
loss of CA assay related to its hydrolysis and degradation to C and A3 isomer in the 
perfusion media under the conditions of the test.
2.9.3.2 Validation of the In vitro gut HPLC method 
Lower limit of quantitation
2pg of cefuroxime/ml was taken as the LLOQ for this method. Table 2.2 shows 
LLOQ for C analyses.
Acceptance Criteria Result
The analyte response at the LLOQ > 5 times | 
the response of blank | 5
RSD of analyte peak £ 20% 5.2%
Table 2.2: LLOQ for C analyses using the in vitro gut HPLC method of analyses 
Recovery from tissue media
Recovery of cefuroxime from tissue media was tested in triplicate, by applying the 
method to samples of tissue media having amounts of C working standard added 
at a concentration range of 1 to 80pg/ml. Results were as presented in Table 2.3.
Acceptance Criteria Result
% Recovery from LLOQ = 100 ± 20% 111.1
% Recovery from other preparations = 100 ± 15% 102.95
Table 2.3: HPLC Recovery results of C from the in vitro gut TC 199 tissue media.




Repeatability results for 6 injections are shown in Table 2.4.
C ( 4.983 pg cefuroxime / ml) %RSD
Injection # 1 2 3 4 5 6
Peak area 10193 10545 10197 10541 9993 10228 2.12
R.T (min) 4.142 4.141 4.143 4.141 4.136 4.147 0.09
Table 2.4: Repeatability results of the in vitro gut HPLC method of analyses
Intermediate precision:
Intermediate precision results of the HPLC method at the same concentration 
tested for precision, from analyst to analyst, and from day to day are as shown in 
Table 2.5.
I Acceptance Criteria Result
I Repeatability of injection %RSD < 5 2.12%
Intermediate precision %RSD < 10% From analyst to analyst = 0.40% 
From day to day = 0.40%
Table 2.5: Precision results of the in vitro gut HPLC method of analyses
According to the obtained results, it was concluded that this analytical method was 
precise.
Linearity
The linearity of the HPLC method was tested on 10 points calibration curve in the 
range 0.99 to 79.20 pg cefuroxime/ml. Two solutions of each single concentration 
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Figure 2.10: Linearity of C in the in vitro gut HPLC method of analyses
According to the obtained results, it was concluded that the analytical method is 
linear.
Selectivity
The results of HPLC method selectivity for C and CA from tissue media indicated 
that the tissue media does not interfere with C or CA analyses.
Stability
To determine the stability of C during analyses of in vitro gut samples, a solution of 
C in tissue media (4.983 pg of cefuroxime/ml) was stored for 17 hrs at ambient 
temperature, and for 4 hrs at 37°C ± 1, and then analysed. The test revealed that 
C concentration decreased by 6.0% and 10% when stored dissolved in tissue 
media at ambient temperature for 17 hrs, and at 37°C ± 1 for 4 hrs respectively.
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A typical chromatogram of a standard solution of the in vitro gut HPLC method is 










  SampleName Cef_0.04mg/ml Vial 14 Injection 1 Channel 996 Date Acquired 10/23/03 2:21:48 AM
Figure 2.11: Typical chromatogram for a standard solution of the in vitro gut HPLC 
method of analyses.
2.10 KARL FISHER (WATER CONTENT) DETERMINATION
2.10.1 Introduction
The Karl Fischer titration is a moisture determination method specific for water and 
is suitable for samples with high moisture content (titrimetry) and also for those 
with water contents in the ppm range (coulometry). It was originally developed for 
non aqueous liquids (Harris et al, 1995), but is also suitable for solids if these are 
soluble or if the water they contain can be removed by heating in a stream of gas 
or by extraction.
The Karl Fischer method is used for many substances as a reference method. It is 
a chemical analyses procedure which is based on the oxidation of sulfur dioxide by 
iodine in a methanolic hydroxide solution. In principle, the following chemical 
reaction takes place (Skoog et al 1994):
H20  + l2+ S 02 + CH3OH + 3RN -> [RNH]S04CH3 + 2[RNH]
The titration can be performed volumetrically or coulometrically. In the volumetric 
method a Karl Fischer solution containing iodine is added until the first trace of 
excess iodine is present. The amount of iodine converted is determined from the 
burette volume of the iodine-containing Karl Fischer solution. In the coulometric
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procedure, the iodine participating in the reaction is generated directly in the 
titration cell by electrochemical oxidation of iodide until again a trace of unreacted 
iodine is detected.
2.10.2 Materials and methods
Avolume of 35-40ml methanol were transferred to the titration vessel. Titration with 
the Karl Fischer reagent to the electrometric endpoint was done to consume any 
present moisture in the sample.
An accurately weighed quantity of 100 mg sample to be tested was mixed and 
titrated with Karl Fischer reagent to the electrometric endpoint. Water content of 
the specimen was calculated in mg, as shown in equation 2.15:
Water content = S x F ..................................................  Eq 2.15
Where S is the volume in ml of Karl Fischer reagent consumed in the titration. F is 
the water equivalence factor of the Karl Fischer reagent.
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CHAPTER 3
PHYSICAL PROPERTIES OF CEFUROXIME AXETIL AMORPHOUS 
POWDER (CAA) AND COMPRESSED (CAAc) AND 
CEFUROXIME AXETIL CRYSTALLINE (CAC)
3.1 INTRODUCTION
It has been reported that cefuroxime axetil (CA) exists in an amorphous (CAA) and 
a series of crystalline forms (CAC) (Oszczapowicz et al, 1995; Sansinowska et al, 
1995; Crisp et al, 1985). Sasinowska et al. have reported that CA serum 
concentration after oral administration in rats was dependant on the form as well 
as the particle size of the drug (Sasinowska et al, 1995).
The levels of cefuroxime in the serum 15 min after oral administration of CAA with 
a median particle size of 0.09 mm were found to be significantly greater (£ 63%) 
than administration of particles with a median particle size of 0.4 mm. In addition, 
for the same particle size distribution, cefuroxime serum levels 15 min after 
administration of the amorphous CA were 120% greater than the crystalline form.
Oszczapowicz observed three forms of cefuroxime axetil, named A7, A77 and K, all 
of which were found to be significantly different (Oszczapowicz et al, 1995). Form 
A7 was found to posses the highest solubility values in different media, while form 
A!1 showed a slightly lower solubility in chloroform, methylene chloride, and N,N- 
dimethyl acetamide. The absolute bioavailability values were 25.85% ± 1.53% and 
23.95% ± 0.62% for forms A7 and A77 respectively. When thermal DSC analyses 
was done, it showed an endothermic peak for form A7 between 84°C -  86°C and 
for A77 between 135°C-138°C. The form A7 showed a higher solubility and a better 
bioavailability than form A77, indicating a higher molecular packing in the latter, thus 
a reduced dissolution rate.
Form K showed a melting peak between 179°C-181°C. This form was found to 
have the lowest solubility and absolute bioavailability (19.68%±0.37%) of all. This 
was related to being the crystalline form of the drug which has the lowest solubility 
and bioavailability.
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The in vitro dissolution behaviour of these forms was also compared in the study. 
Forms Ay and A/y were readily suspended in the total volume of gastric fluid and 
.subsequently, dissolved rapidly. The dissolution of form A; was found to be 
slightly greater. In the case of the crystalline form K, both suspension formation 
and dissolution were comparatively slow (Oszczapowicz et al, 1995). However 
data from this thesis show different interpretation of results of analysis for the 
different forms of cefuroxime axetil (CA).
Crisp et al. (1985) had first prepared CA in the substantially pure amorphous form. 
It was found that despite the well known tendency of amorphous materials to have 
inferior chemical stability to the crystalline form, and the known tendency for highly 
pure amorphous material to crystallise , this was not the case with amorphous CA. 
The crystalline form was surprisingly not found to have the best balance of 
properties for commercial use, and contrary to previous experience in the 
cephalosporin field, CA was advantageously used in a highly pure substantially 
amorphous form. Crisp et al. also determined that CA in its pure amorphous form 
had higher bioavailability upon oral administration with respect to the crystalline 
form. Moreover, the amorphous form of CA had adequate chemical stability upon 
storage (Crisp et al, 1985).
Amorphous preparation of CA by Crisp et al. contained less than 5% w/w of 
impurities. Any residual solvent was in concentration of less than 2% w/w. Typical 
impurities which were found to be present were the A3-isomers of CA and its 
corresponding E-isomers. The prepared CA ester was essentially free from the 
crystalline form, i.e. it contained < 5% CAC, and it was in the form of a (1:1) 
mixture of its R and S isomers. Such a mixture was found to have a substantially 
improved solubility as compared with amorphous R isomer or amorphous S isomer 
alone. It was prepared by recovery of CA from a solution under conditions whereby 
the highly pure substantially amorphous form of the product was obtained. 
Techniques that were employed included the rapid removal of solvent Lacquer to 
precipitate the drug. Other satisfactory methods included spray drying, roller 
drying, solvent precipitation and freeze drying (Crisp et al, 1985).
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Following intensive work on the preparation of substantially pure amorphous form 
of CA, Crisp et al. confirmed that spray drying technique was the best method for 
obtaining the pure amorphous form of the drug (Crisp et al, 1989). In this technique 
a suitable organic solvent for dissolving CAC was used (e.g. ketones, alcohols, 
acetonitrile, tetrahydrofuran, esters, chlorinated solvents), or mixtures with other 
solvents (e.g. water) (Crisp et al, 1991). The drying gases tested were inert gases 
such as nitrogen, argon, and carbon dioxide. The gas inlet temperature to the 
spray dryer was chosen according to the solvent used, and was in the temperature 
range of 50°C-140°C. The gas outlet temperature was similarly dependent on the 
solvent and was in the range 45°C-100°C.
The spray dried product had a consistent range of particle sizes, and it had the 
form of hollow microspheres which could conveniently be used for pharmaceutical 
compositions.
It was subsequently reported that the prior art processes for the preparation of 
amorphous form of CA suffered several disadvantages, and were not suitable for 
operation at a large scale (Handa et al, 2002). These disadvantages included the 
requirement of large volumes of solvents for dissolving CA, because of its poor 
solubility in the solvents utilised. This was considered uneconomical on a 
commercial scale because large size reactors were necessary. Furthermore, 
because of the poor solubility of CA, higher temperatures were required. These 
disadvantages made the process operationally tedious and inefficient.
Handa et al. (2002) analysed a method for preparing CAA, which comprised 
dissolving CAC in a solvent such as formic acid, present in an amount just 
sufficient to dissolve the CAC. The resulting CA solution was added to water all at 
once, leading to rapid precipitation (dumping) due to the anti-solvent effect of water 
on CA. The crystallinity of the resulting product was greatly reduced via dumping, 
i.e., the product was highly amorphous by use of the rapid precipitation method. 
Additionally, it had been determined that in order to precipitate an amorphous 
product that contained minimal amount of crystalline material, a specific volume of 
water is required in relationship to the weight of the starting material (CAC).
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Handa et al. (2002) applied the same process for the preparation of the pure CAA 
by dissolving CAC in acetic acid instead of formic acid, including at least 5% v/v 
water. Thus these new methods opened the door for highly efficient methods to 
obtain CAA.
Since CAC was not found to possess the necessary bioavailability characteristics, 
the amorphous CA was registered throughout the world. This remained until 
Zenoni et al. prepared a comparable bioavailable form of CAC. This was achieved 
by treating the crystalline and the amorphous forms with a mixture of water or 
water miscible organic solvent at a temperature between 20°C -  60°C, followed by 
cooling (Zenoni et al, 1997).
More recently, Woo et al. (2000) confirmed what Oszczapowicz et al. published in 
1995, of that CA exists as a crystalline form having a melting point of about 180°C, 
and two other forms of endothermic peaks at about 70°C and 135°C.The same 
was also reported by Guk et al. (2002) who stated that CA can be found as a 
crystalline form which has a melting point at 175°C, and as other two forms having 
endothermic peaks at 80.25°C and 137.7°C, respectively. These different forms 
were obtained due to different preparation parameters and conditions, such as 
cooling rate during crystallisation.
It was noticeable, however, from the published data that the onset temperatures of 
the endothermic peak for amorphous CA are different. Such differences were also 
found in this study, and can be related to dynamic shifts in the Tg temperature at 
different water content levels in the material.
This shifted Tg of CAA has been shown in this study to revert back to its original 
temperature under vacuum drying. This has not been the case with the other 
known amorphous pharmaceutical systems, e.g. Lactose (Mahlin et al, 2003; 
Buckton et al, 1996) which upon exposure to elevated conditions of temperature 
and/or relative humidity undergoes irreversible changes in its physical properties 
(crystallisation). This indicates a superior stability of CA amorphous system, which 
enables it to maintain the state of desirable physical properties even upon 
fluctuation in the storage conditions.
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Woo et al. (2002) previously reported that the water absorbed in CA is judged to be 
bound water which causes physico-chemical changes in the drug, leading to 
shifting in its endothermic peak onset.
The current commercially available CA formulations, Ceftin®, are prepared from the 
highly pure amorphous CA produced by the spray drying method under careful 
processing to avoid the possible conversion to the crystalline form upon storage 
(Somani et al, 2003).
Current BP, USP and Eur. Ph monographs for CA do not specify a requirement for 
the form of the drug. That is, it may be in either amorphous or crystalline forms, but 
both forms should meet the criteria for dissolution when in its tablets form (>60% 
after 15 min and >75% after 45 min).
In this study, both CAA and CAC forms were investigated in order to further 
understand their physical properties. The effect of some processes on these forms 
was also studied, e.g. the effect of compression on CAA. The compressed form of 
CAA was defined as CAAc.
3.2 MATERIALS AND METHODS
Table 3.1 defines the tested amorphous and crystalline preparations of CA .
-— Material 
P a ra m e te i^^^ -^^ CAA CAC
Batch No. CAFAA/003/00 CRCB030005
Assay 81.8% (as cefuroxime) 83.4 (as cefuroxime)
Water Content 0.99% 0.16%
Retesting Date 12/2003 02/2006
Source Orchid Orchid
Table 3.1: Amorphous and crystalline CA materials tested.
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The compressed cefuroxime axetil amorphous (CAAc) was prepared by 
compacting CAA powder into 10 mm biplanner tablets with a hardness range 
between 70-90 N, using a single punch compression machine (Erweka EKO).
Tablets were then crushed through 0.2mm screen. The crushed powder was 
subsequently passed through a set of sieves, and particles passed through the 
63pm sieve were collected. This final step was done to obtain a similar particle 
size distribution for CAAc to CAA and CAC materials used in the study.
Conditioned forms of the amorphous and crystalline materials were prepared upon 
exposure to elevated relative humidity. The particles were exposed to a saturated 
solution of di-sodium hydrogen phosphate dodeca hydrate (Na2HP0 4 .12H20 ) in a 
sealed vessel. The saturated atmosphere had a relative humidity (RH) of 95%, at 
25°C. CAA and CAC were placed in the sealed vessel for 10 days, samples were 
called CAAh and CACh, respectively.
DSC testing and water content analyses of the stored samples were done prior 
and at different time intervals (3 days, 1 week and 10 days) upon exposure to 
95%RH at 25°C. Further, a one week sample of the CAAh powder was taken, 
dried in a vacuum oven for 10 hours, and subsequently analysed. This sample was 
labelled CAAd.
3.2.1 Methods of testing CAA, CAC and CAAc

























































CAA / S S S / S X V V /
CAAh S X X X X X X X X /
CAAd V X X X X X X X X /
CAAc V S S / s X V X / X
CAC •/ S / / ✓ / X X S /
CACh X X X X X X X X </
Table 3.2: Comparative tests for CAA, CAC, CAAc, stored at different conditions, 
v ' : Tests performed *  : Tests not performed
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3.3 RESULTS AND DISCUSSIONS
3.3.1 Particle size distribution
3.3.1.1 Particle size distribution of cefuroxime axetil amorphous (CAA)
The particle size distribution of CAA in the Log-normal form is presented in Figure 
3.1.
Size (urn)
Figure 3.1: Log-normal particle size distribution of CAA 
The geometric mean diameter (median diameter) for CAA tested was 19.5 pm.
The geometric standard deviation (a ) of the particle size distribution was 
















The results above indicated that fine particles of CAA material were used in the 
study. The standard deviation (5) of the CAA particle size distribution indicated a 
log-normal distribution.
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3.3.1.2 Particle size distribution of cefuroxime axetil crystalline (CAC)
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Figure 3.2: Log-normal particle size distribution of CAC
The geometric mean diameter (median diameter) of tested CAC was determined 
to be 3.3 pm. The geometric standard deviation of the particle size distribution was 
calculated according to equations 3.1 and 3.2.
pg = d5°  = 3 ^ m =2.0
d15.78 1.59pm
and
d84.13 6.72pm onag = ---------- = -------- -— =2.0
d50 3.3 pm
Results indicated that the particle size of the CAC material used in the study was 
less than 5pm. This can be related to the fact that manufactures of CAC tend to 
micronize the material, aiming to increase the surface area, thus enhancing the 
dissolution and bioavailability of this form of the drug. The standard deviation (5) of 
the CAC particle size distribution indicated a log-normal distribution.
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3.3.1.3 Particle size distribution of compressed cefuroxime axetil amorphous 
(CAAc)
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The geometric mean diameter (median diameter) of tested CAAc was determined 
to be 21.9pm. The geometric standard deviation of the particle size distribution 
was calculated according to equations 3.1 and 3.2.
The particle size distributions of CAA, CAC and CAAc revealed that CAA and 
CAAc particles tested had similar d50 values, (around 20pm), while the CAC had 
the finest particles (d50 = 3pm). The standard deviation (5) of the CAAc particle 
size distribution indicated a log-normal distribution.
3.3.2 DSC and MTDSC testing
DSC thermograms for CAA, CAAc and CAC are shown in Figures 3.4-a, b, and c, 
respectively.
d50 21.9 pmag = --------- = ------- -— = 2.0
d15.78 10.9pm
and
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Figure 3.4: DSC thermograms of CAA(a), CAC(b) and CAAc(c), at the heating rate 
25°C/min.
The DSC thermogram of CAA material showed an endothermic peak at 85.9°C. 
The CAAc thermogram showed two endothermic peaks, one at 76.0°C and the 
other at 171.1°C. For CAC, two endothermic peaks were also detected at 131.7°C 
and at 186.5°C.
To further elucidate the endothermic peaks in the DSC tested samples, MTDSC 
analyses was also undertaken. The heat flow and the heat capacity (Cp) 
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Figure 3.6: Fleat capacity curve (Cp complex) of CAA, at heating rate 1°C/min, 
amplitude 0.5°C/48 seconds
The MTDSC heat flow thermograms of CAC are presented in Figure 3.7. Figures 
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Figure 3.7: MTDSC heat flow thermograms of CAC, at heating rate 1°C/min, 
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Figure 3.8: MTDSC heat flow thermograms of CAAc, at heating rate 1°C/min, 
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Figure 3.9: Heat capacity curve (Cp complex) of CAAc, at heating rate 1°C/min, 
amplitude 0.5°C/48 seconds.
From the MTDSC results shown above, the endothermic peaks of CAA and CAAc 
at around 80°C were interpreted as the glass transition temperature of the 
amorphous material with a mid point of 74°C, overlapping the relaxation peak.For 
CAA and CAAc, the non-reversing heat flow curves show a relaxation peak which 
was separated from the glass transition temperature using the MTDSC. While for 
CAC, the reversing heat flow curve did not reveal glass transition at any 
temperature. It might indicate, however, a second polymorph of the crystalline form 
of the drug.
When CAC samples from different raw material sources were tested, similar 
results were obtained. This may indicate that manufacturers of the crystalline 
material prepare the CAC as a mixture of two polymorphs, one of which has a 
lower melting temperature at 135°C. This can either be related to the 
manufacturing or crystallisation procedures, or to aimed selection, to possibly 
enhance dissolution and bioavailability.
After compression, the DSC thermogram of CAAc gave rise to a new melting peak 
characteristic of the crystalline form of the drug at 171°C. When the melting 
enthalpy (9.3J/g) of the generated CAC peak was fitted to CAC enthalpy/ 
concentration curve (Figure 3.10), it revealed an approximate content of 15% 
crystalline material in the sample. This suggested that compression may result in 
partial transformation of the pure amorphous CA to the crystalline form. This may 
be related to the heat and pressure generated during compression and crushing of 
CAA. These may have significant plasticization effect on the material, and can





















lower the Tg below the experimental temperature under compression or slugging. 
Thus increasing the entropy of the molecules and enhancing crystallisation. The 
amount of crystallised material would be dependant on how much heat and 
pressure are generated, and on how the drug was distributed in the slugged 
matrix.
This may also be related to the fact that pressure effects on CAA may be 
significant enough to affect its molecular packing, potentially reducing the volume 
and enthalpy, leading to crystallisation in some parts of the slugs where the 
compressive load is at maximum.
An enthalpy/concentration calibration curve was established (using DSC analyses) 
for the determination of crystalline content in CAA material. The calibration curve 
was established for 5mg mixtures containing different concentrations of CAC (1%, 
2%, 4%, 5%, 25%, 50%, 75% and 100%) with CAA material. Melting enthalpy 
values of the crystalline peak where obtained at the different concentrations of 
CAC. Results were as shown in Figure 3.10. Also a calibration curve based on 
relaxation enthalpy values of the different concentrations of CAA in the same 
mixtures was blotted and results were compared to those of the CAC calibration 
curves. It was unexpectedly found that data from both curves were comparable.
For cone 5-100% of CAC
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R2 = 0.999997
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Figure 3.10: Enthalpy/concentration calibration curve of CAA mixtures with CAC
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'Results above indicated that the DSC is a good technique for the detection of 
down to 1% w/w CAC in a mixture with CAA, although not quantitative for 
concentrations below 5% w/w (as the both curves showed loss of linearity below 
this concentration).
It was noticed that the DSC thermograms of different CAA samples show different 
onset values for Tg. This was further studied and found to be related to 
plasticization effect of water on samples having different water content levels.
Figure 3.11 shows the plasticization effect of water on the Tg of CAA. The 
thermograms of CAAh demonstrated that there is a shift in the Tg towards lower 
temperatures upon exposure to humid conditions. This may be related to the 
increasing water content in the amorphous material. The plasticization effect of the 
sorbed water can be summarised by increasing the free volume, reducing the 
viscosity of CAA and increasing its molecular motion. Thus reducing the Tg of the 
amorphous material (Royall et al. 1999; Zografi et al. 1990). The thermogram of 
CAAd indicated that upon vacuum drying the conditioned material loses its water, 
and its Tg reverts back to its original temperature.
These data demonstrated an unusual stability of the amorphous form of CA 
compared to other pharmaceutical amorphous systems, which may undergo 
crystallisation upon short term exposure to humid conditions. Of these, amorphous 
sucrose which crystallises at conditions above 21% relative humidity at 30°C 
(Oksanen et al, 1999). Spray dried amorphous lactose has also been reported to 
recrystallise after 11 hrs of storage at 53% RH at 25°C (Mahlin et al, 2003; 
Buckton et al, 1996). Price et al (2003) also studied the recrystallisation 
transformation of amorphous lactose during moisture uptake at 58%RH and 
75%RH. They suggested that a secondary nucleation and growth process occurs 
at these humid conditions, and that primary nucleation requires an elevated 
relative humidity (94%RH). Other reported examples of unstable amorphous 
systems include the crystallisation of amorphous indomethacin and phenobarbital 




























Figure 3.11: DSC thermograms of CAAd and CAAh after storage under 95%RH humidity 
for different time intervals, at the heating flow 25°C/min.
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The stability of CAA is presented by maintaining the Tg value of the material well 
above that of the experimental conditions, even after extended exposure (10 days) 
to elevated relative humidity conditions (95%RH, 25°C). Under these conditions, 
the maximum water uptake by the material was 1.3%, associated with a 15°C 
reduction in Tg value.
Thus, the potential crystallisation of CAA would be difficult to induce upon 
exposure to humidity under the normal experimental and storage conditions (15°C- 
30°C). This is most probably related to the low water affinity of CAA material which 
is non-hygroscopic. Absorbed water can not, therefore, form a saturated solution at 
CAA surface, consequently the plasticization effect of water on it will be very 
limited.
When water was withdrawn from CAA, its Tg value increased again to its original 
value. This, further, supports the physico-chemical stability of the material under 
fluctuations in storage conditions.
In conclusion, exposure of CAA to conditions of elevated relative humidity were not 
significant to induce its crystallisation. A case which is rare to find with other 
amorphous materials that crystallise under lower humidity conditions than the 
95%RH. The latter severely limited the use of amorphous pharmaceutical dosage 
forms in the pharmaceutical industry.
Thermograms of crystalline CA upon exposure to elevated relative humidity 
showed no shift in the melting peaks as demonstrated in Figure 3.12. This 
highlighted the insignificant plasticization effect of water on crystalline materials, 
































131.98 °C . 183.36°C
20 40 60 80 100 120 140 160 180 200 220 240 260
Temp (°C)
Figure 3.12: DSC thermogram of CACh after storage for one week at 95%RH 
humidity, at the heating rate 25°C/min.
3.3.3 Water content determination (Karl Fisher)
Table 3.3 shows the water content, Tg, and melting temperatures (Tm) of CAAh and 
CACh after different storage times under 95%RH. It also shows the results for the 
dried CAAd sample.
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No. Storage Period Storage Condition Tg or Tm WaterContent
1. CAA zero time Ambient 83.99°C (Tg) 0.99%
2. CAAh 3 days 95%RH,25°C 78.18°C (Tg) 1.80%
3. CAAh 1 week 95%RH,25°C 73.04°C (Tg) 2.10%
4. CAAh 10 days 95%RH,25°C 69.01 °C (Tg) 2.30%
5. CAAd Dried under vacuum 84.93°C (Tg) 0.70%
6. CAC zero time Ambient 131.98°C (Tm) 183.50°C (Tm) 0.16%
7. CACh 1 week 95%RH,25°C 131.98°C (Tm) 183.36°C (Tm) 0.24%
Table 3.3: Results of analyses of CAAh and CAAd at different storage conditions
Results above indicated that the water content increased in CAA upon storage for 
10 days at humid conditions (95%RH), until it reached a maximum at 2.3% (from 
0.9%). Results also indicated that higher water content led to a shift in the Tg 
towards lower temperatures. The highest shift observed in the Tg was 15°C.
For CAC, the water content started initially low (0.16%). After one week of storage 
at the humid conditions, water content increased only to 0.24%.
Upon vacuum drying of CAA exposed to humidity (CAAh, one week sample), the 
loss in water was associated with a shift in the Tg to 84°C.
3.3.4 X-Ray powder diffraction (X-RPD)
Figures 3.13a, b and c, show the XRPD diffractograms of CAA, CAC, and CAAc, 
respectively. The broad diffuse peaks in Figure 3.13a clearly indicated the lack of 
resolved reflections, and the absence of any significant crystalline long-range order 
in CAA. In contrast, the XRPD of CAC in Figure 3.13b shows characteristic sharp 
diffraction peaks associated with a highly crystalline material.
The diffractogram of CAAc (the partially crystalline material) showed an apparent 
absence in crystallinity within the material, as demonstrated by the presence of a 
broad halo which lacked the resolved reflections associated with the long-range 
order.
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This suggested that the XRPD technique was not sensitive enough for the 
detection of crystalline material in a nominally amorphous drug at 15% 
concentration. While XRPD technique was previously reported to be a sensitive 
technique for the detection of amorphous material in a crystalline drug at a lower 
concentration of 5%-10% (Gerhardt et al, 1994), the converse was not observable.
On the contrary, the DSC technique utilised for testing the samples as mentioned 
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Figure 3.13: X-Ray powder diffraction for CAA(a), CAC(b), CAAc(c).
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3.3.5 Dynamic vapour sorption (DVS)
The moisture sorption and desorption isotherms of CAA, CAC, and CAAc at 25 ± 
0.5°C are shown in Figures 3.14, 3.15, and 3.16, respectively. Figure 3.14 
indicated that CAA adsorbed water slowly up to 2.0 -  2.5 %w/w at 90%RH. This 
indicated a limited water affinity of CAA, related to its low hygroscopicity. Thus, it 
would be difficult to plasticize CAA under the applied humid conditions, and it 
showed resistance to crystallisation even after exposure to high relative humidity 
conditions.
This behaviour is significantly different from other pharmaceutical amorphous 
materials. Spray dried Lactose which was found to increase its moisture uptake by 
11% w/w at 50%RH, 25°C (Price et al, 2004). Increasing the partial water vapor 
pressure to > 50%RH led to a dramatic weight loss, associated with the expulsion 
of water during the recrystallisation process. This behaviour was not observed for 
CAA at 25°C even at 90%RH, indicating a distinguished stability of the amorphous 
CA compared to conventional pharmaceutical ingredients.
The desorption isotherm indicated that CAA can readily displace the adsorbed 
moisture, as indicated with the minimal hystersis in the sorption/desorption curves.
The sorption isotherm of CAC at 25°C is shown in Figure 3.15. The water uptake is 
considered negligible as humidity increases to 50%RH. A slight water uptake of 
about 0.2% occurs at 60%RH, followed by a further 1.5% increase in water content 
between 70 -  90 %RH. The maximum water uptake achieved was 2.0%, a similar 
value to that obtained with the CAA material, indicating a limited affinity of both 
CAA and CAC forms to water uptake. The absorbed water was easily expelled in 
the desorption isotherm of CAC.
Figure 3.16 showed a similar sorption and desorption isotherms of CAAc to CAA, 
suggesting that this technique, which is sensitive to the presence of amorphous 
material, is not sensitive in detecting small quantities of crystalline content in a 
predominantly amorphous system. It was previously reported that DVS technique 

















Cycle 1 Sorp-*- Cycle 1 D e s o r p C y c l e  2 Sorp-*- Cycle 2 Desorp
20 30 40 50 60 1000 10 70 80 90
Target RH (%)









Cycle 1 Sorp-*- Cycle 1 Desorp*- Cycle 2 Sorp*-Cycle 2 Desorp
- 0 . &0 10 20 30 40 5 60 70 80 9 100
Target RH (%)









Cycle 1 Sorp—  Cycle 1 Desorp—  Cycle 2 Sorp—  Cycle 2 Desorp
-0.5*0 10 20 50 60 70 80 90 10030 40
Target RH (%)
Figure 3.16: Dynamic vapour sorption/desorption isotherms of CAAc
3.3.6 intrinsic dissolution
3.3.6.1 Intrinsic dissolution of CAA
The CA cumulative amount released from CAA disks at different time intervals are 
shown in Table 3.4 and Figure 3.17. The area of exposure of the disk to dissolution 
media, and the intrinsic dissolution rate of CAA were calculated using equations
3.3 and 3.4 respectively.
Area of exposure of CAA disks = (r2) n .................................... Eq. 3.3
= (0.4)2ji = 0.5027 cm2








Table 3.4: Intrinsic dissolution of CA from CAA disks, n=6.
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. . . . . .  . .. . x^ aa Cumulative amount released (mg/min) _ _ .Intrinsic dissolution rate of CAA = ---------------------------------------——-----   .... Eq. 3.4
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Figure 3.17: Intrinsic dissolution profile of CA from CAA, n=6.
The above release profile of CAA indicates a linear zero order release pattern. The 
lag time (1 min) is related to the compression of the material into a disc, leading to 
delay in the release onset.
3.3.6.2 Intrinsic dissolution of CAC
Table 3.5 and Figure 3.18 show the cumulative amount release of CA from CAC at 
various time intervals. The area of exposure of CAC disks was calculated as:
(r2) k = (0.4) 2tc = 0.5027 cm2
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Table 3.5: Intrinsic dissolution of CA from CAC disks, n=6.
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Figure 3.18: Intrinsic dissolution profiles of CAA and CAC disks, n=6.
Figure 3.18 shows the comparative intrinsic dissolution profiles for CAA and CAC. 
It demonstrated that during the first 15 minutes CAC showed a higher amount 
released than the CAA, for an equivalent area of exposure. This may be related to 
smaller particle size of CAC (d5o=3.3pm), compared to CAA (d50=20pm), leading to 
faster and higher initial dissolution results. This may also be due to the fact that 
compressibility of the amorphous materials is higher than that of the crystalline 
(Berggren et al, 2004), leading to a higher CAA disk hardness, thus lower initial
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dissolution results. This remains the case until the solubility of CAC reaches a 
plateau (solubility limit), after which saturation occurred and CAC crystallized out in 
the media leading to the slight noticed decrease in the dissolution results .
After the first 20 minutes, the amount dissolved from CAA became significantly 
higher with time compared to that from CAC. After 45 minutes, the cumulative 
amount dissolved from CAA was around 3 times higher than that from CAC.
3.3.7 Dissolution using apparatus II
Intrinsic dissolution was considered not suitable for testing CAAc, as the material 
was compressed, and crushed, i.e. it underwent processing. Dissolution using the 
BP 2003 method was seen the most appropriate to measure the dissolution rate of 
CAAc. Results were compared to the official compendial (BP & USP) specified 
limits for release of CA from tablets.
Table 3.6 and Figure 3.19 show the results of dissolution of CAAc granules tested 
according to BP 2003.
Time (min) % Release of CAAverage ±SD
1 5 35.89 1.99I 10 48.72 2.94
15 54.82 2.01I 20 59.50 2.64
30 65.32 3.29
| 45 70.29 2.86






Figure 3.19: Dissolution profile of CAAc using BP 2003 method, n=6.
It can be shown from the above profile that the dissolution results of CAAc (55% 
after 15 min) is lower than that requested by the official compendia (> 60%).
3.3.8 In situ perfusion of CAA
Only CAA was tested for in situ perfusion as the material needed to be solubilised 
in the in situ perfusion medium before being loaded in the intestine. In this case, 
the issue of concern is the CA absorption rate across the rat intestinal membrane 
after being dissolved, and not the rate of dissolution and absorption of its different 
forms.
The concentration of cefuroxime remaining in the in situ perfusion media was 
corrected to volume for each time point, and presented in Table 3.7 and Figure 
3.20.
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Concentration of CA (mg/ml)
Time (min) Rat 1 Rat 2 Rat 3 Av. SD
0 0.084 0.094 0.084
10 0.072147465 0.07316129 0.056709677 0.0673395 0.00922
20 0.061640553 0.081774194 0.077640553 0.0736851 0.010634
30 0.086588645 0.112626728 0.076313364 0.0918402 0.018719
40 0.074661751 0.066176115 0.067261106 0.076106 0.009508
50 0.080875576 0.080552995 0.070967742 0.0774654 0.005629
60 0.084193548 0.096239631 0.064700461 0.0817112 0.015915
70 0.073824885 0.081290323 0.069262673 0.0747926 0.006072
80 0.041474654 0.081387097 0.061124424 0.0613287 0.019957
90 0.041474654 0.067741935 0.076497696 0.0619048 0.018227
100 0.069308756 0.068018433 0.0686836 0.000812
Table 3.7: CA concentration (mg/ml), remained in the media after in situ
perfusion test.
The concentration values in the table above includes the concentration of CA 
remaining in the media, plus the concentration of C resulted from the hydrolysis of 
CA by the intestinal enzymes, and the concentration of A3- Isomers generated from 
the degradation. Both were converted by calculation to CA, and the sum 
concentration had been corrected according to the volume collected at each time 
point. The HPLC chromatograms for CA in situ perfusion at zero time and after 70 
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Figure 3.20: CA concentration (mg/ml), remained in the media (taken out) after 
in situ perfusion test.
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Figure 3.21: In situ perfusion HPLC chromatograms of CAA at zero and 70 
minutes.
167
The bioavailabilty F was then determined as ( 1 -  C out/C jn) versus time. This is 
shown in Table 3.8.
F value of CA
Time (min) Rat 1 Rat 2 Rat 3 Av. SD
0 0 0 0 0 0
10 0.198361495 0.238696251 0.340585146 0.2592143 0.073298
20 0.315104967 0.149071867 0.097202872 0.1871266 0.113826
30 0.837992832 -0.17197428 0.112635302 -0.0071154 0.147569
40 0.168202765 0.103276637 0.217661558 0.163047 0.057366
50 0.101382488 0.161779444 0.174793698 0.1459852 0.039171
60 0.064516129 -0.00145298 0.24766906 0.1035774 0.129073
70 0.179723502 0.154106945 0.194620084 0.1761502 0.020492
80 0.539170507 0.15309993 0.289250884 0.3271738 0.195809
90 0.539170507 0.295089121 0.110491909 0.3149172 0.215026
100 0.27878506 0.209087986 0.2439365 0.049283
Table 3.8: In situ perfusion bioavailability results of CA.
Peff values for CA were calculated at each time point according to equation 3.5, 
Fagerholm, (1996).
- Q  In
Cout
Peff =
2 tt r I
.Eq. 3.5
Q = Flow Rate, 0.22 ml/min = 0.00362 ml/sec 
r = 0.19 cm
I = 13.5 cm for Rat 1 & 15 cm for Rat 2 and Rat 3
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Average of the three readings at each point was taken. The results obtained are 
tabulated in Table 3.9.
Time (min) Petr (cm/sec) P eff ( Av.)Rat 1 Rat 2 Rat 3
0
10 4.9642E-05 5.51099E-05 8.41436E-05 6.297E-05
20 8.498E-05 3.26201 E-05 2.08834E-05 4.609E-05
30 8.69663E-06 -3.2067E-05 2.41475E-05 2.591 E-07
40 4.13501 E-05 2.20275E-05 4.96024E-05 3.766E-05
50 2.40013E-05 3.56606E-05 3.88226E-05 3.283E-05
60 1.49739E-05 -2.9339E-07 5.75057E-05 2.406E-05
70 4.44816E-05 3.38194E-05 4.37369E-06 4.068E-05
80 0.000173946 3.3579E-05 6.89949E-05 9.217E-05
90 0.000173946 7.06616E-06 2.366E-05 8.942E-05
100 6.60411 E-05 4.73999E-05 5.672E-05
Table 3.9: Pe/r values for CA in the in situ perfusion test
The results of Pe/rshow steady state constant values between 40-70 minutes, thus 
only average of these values were taken. The values for 10 and 30 minutes were 
excluded due to erratic absorption noticed at the beginning. The end values from 
80-100 minutes were also excluded due to water absorption from the small 
intestine leading to differences in drug concentration.
The average of Peff ± SD was calculated to be (3.381 E-5 ± 7.257E-6 cm/sec).
The first order absorption rate constant (Kabs) and the half life (IV 2) were then 
calculated according to equations 3.6 and 3.7, respectively (Fagerholm, 1996).
Ka£»s —
2 Pe Eq. 3.6
T 0 . 5 -
Ln2
K a b s
Eq. 3.7
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The Kabs value obtained was 1.281 hr'1, with a half life of 32.46 min in rats. The 
Peft.rat of CA was correlated to its human effective permeability (Petf.man) according 
to equation 3.8 (Lennerans, 1998).
Peff.man= 3.6X Peff + 0.03 X 10'4 ...............................Eq. 3.8
The effective permeability in man was determined to be 12.17E-5 cm/sec. The first 
order absorption rate constant (Kabs) was then calculated to be 
4.612hr'\ with a half life of 83.035 min in human.
It was determined that the t0.5 absorption of CA in the jujenal membrane of the rat 
is around 32.5 minute, while in human (by correlation) it could be approximated to 
83.0 min. This can be considered an adequate absorption rate for an antibiotic 
drug. A recent finding by Sanjuan et al (2000), indicated a similar Peff value for CA 
in rat intestine, with a value of 3.1 E-5 cm/sec.
3.3.9 In vitro gut absorption
3.3.9.1 In vitro gut absorption of CAA
Results of in vitro gut percentage release of C from CAA to media are shown in 
Table 3.10 and Figure 3.22.
^ ^ \ T i m e  (min) 
Trial 15 30 45 60 75 90 105 120
Average (%) 4.22 7.97 12.76 17.37 21.48 25.37 30.07 34.54
SD 2.41 3.54 4.88 5.14 6.09 6.88 5.81 6.02
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Figure 3.22: In vitro gut release of C from CAA to the media, n=3.
The above data shows a linear zero order release kinetics of C from CAA, with a 
34% (i.e. 9 mg) transported across the rat intestine after 120 min. This indicated 
that around 4 times the dose needed for rat was absorbed. Thus the bioavailability 
of the amorphous form of CA was adequate.
The percentage recovery was also calculated by determining the amount of 
efuroxime (as C and CA) released to the media at the end of the test, remained 




















C CA C DegradedA3 CA C Total Initial
1 10.00 0.00 3.10 0.00 0.00 0.04 13.10 16.8 78.0
2 8.50 0.00 5.10 0.00 0.00 0.07 13.60 16.8 81.0
3 7.30 0.00 6.10 0.00 0.00 0.06 13.40 20.5 65.4
Table 3.11: Recovery (%) of cefuroxime from the in vitro gut test of CAA
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From the above, it was shown that the recovery of C after testing was in the range 
of 65% - 81%, which indicated that some amounts of the drug remained on the 
membrane brush after the experiment, which could not be recovered.
It was also shown that 40% of CA was hydrolysed to C in the intestine, a matter 
which reduced the percentage drug absorbed. This was in agreement with 
previously published work by Mosher et al. (1991) that the intestinal hydrolysis of 
CA to C lead to an incomplete and erratic absorption of the drug, resulting in the 
wide absorption variations that may occur.
3.3.9.2 In vitro gut absorption of CAC
Table 3.12 and Figure 3.23, show the results of the in vitro gut release of C from 
CAC to the media. The release rate of C from CAA is also shown for comparison.
^ ^ ^ T im e  (min) 
Trial 15 30 45 60 75 90 105 120
Average (%) 0.60 1.69 3.34 5.53 7.90 10.18 12.56 15.10 |
SD 0.20 0.12 0.15 0.47 0.89 1.06 1.75 139 I
Table 3.12: In vitro gut percentage C released from CAC to the media, n = 3.
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Figure 3.23: In vitro gut release of C from CAC to the media, n=3.
y = 0.2857X 
R2 = 0.9994
y = 0.1129x 
R2 = 0.9499
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The results above indicated that CAC has a linear zero order release kinetics. The 
rate of C release (K) from CAA, however, was found to be over two folds higher 
than that from CAC (K= 0.286 and 0.113, respectively). This confirmed the 
significantly higher absorption rate of CAA than CAC, as reported in previous 
related studies (Somani et al, 2001, 2003; Guk et al, 2002; Crisp et al, 1991; 
Zenoni et al, 1997; James et al, 1989).
3.3.9.3 In vitro gut absorption of CAAc
Results of in vitro gut percentage release of C from CAAc to the media are shown 
in Table 3.13 and Figure 3.24. The release rate of CAA is also shown for 
comparison.
^ - ^ T im e  (min) 
Trial 15 30 45 60 75 90 105 120
Average (%) 0.94 3.17 5.93 9.50 13.11 16.01 19.71 22.49
SD 3.16 2.14 3.60 4.23 5.25 4.87 2.57 3.33
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Figure 3.24: In vitro gut release of C from CAAc to the media, n=3.
y = 0.2857X 
R2 = 0.9994
y = 0.19 9 x -1.8464 
R2 =0.9875
173
The above results indicated a zero order release for C from CAAc, with a lag time 
for the first minutes, related to the time needed for granules to disintegrate before 
dissolution. There was a noticeable decline in the absorption rate of C from CAAc 
compared to that from CAA related to partial transformation of CAA to CAC upon 
compression, as the DSC thermograms revealed (section 3.3.2). Thus, 
compression resulted in a decrease in the release rate (K) of CAA across the rat 
intestines by 30% from (0.288 to 0.199).
Statistical two-way ANOVA of the two materials CAA and CAC showed that they 
were significantly different (P<0.05). The same statistical evaluation was applied to 
determine if CAA is different from CAAc, and the two release rates were found also 
significantly different (P < 0.05).
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3.4 CONCLUSIONS
Results of tests conducted on CAA and CAC indicated differences in their physical 
properties. The amorphous form, which has a Tg at a mid point temperature of 
74°C showed a significantly higher dissolution rate and bioavailability than CAC. 
The latter showed two distinct DSC melting peaks at about 135°C and 180°C, 
representing two polymorphs of the crystalline drug. This indicated that the 
commercial form of CAC is a mixture of two polymorphs.
Upon compression, CAA showed a degree of instability presented by a partial 
transformation of the pure CAA to CAC (at 15% w/w). Thus, DSC testing of CAAc 
showed a melting peak at around 180°C characteristic of the crystalline form. The 
formation of the crystalline material may be a function of the heat and pressure 
generating during compression.
X-ray powder diffraction testing of both the pure and the partially crystallised CAA 
showed no evidence of crystallinity, indicating that this technique is not adequate in 
detecting relatively low percentages of crystalline content of CAC (up to 15% w/w) 
upon compression of the amorphous (CAAc) material.
The vapor sorption isotherms of CAA showed a limited (2%) water uptake at high 
relative humidity (90%) at 25°C, with no evidence of crystallisation, indicating a 
very stable amorphous drug. Furthermore, the water uptake of CAA at 90%RH was 
close to that of CAC. The desorption isotherms of both forms indicated that the 
sorption and desorption of condensed water was reversible.
The similar sorption isotherms of CAAc to CAA indicated that the DVS technique 
was not sensitive in detecting small levels of crystalline content in the amorphous 
drug.
The only technique which was highly efficient in detecting small levels of crystalline 
CAC material in the CAAc sample was the DSC. Furthermore, the enthalpy/ 
concentration calibration curves indicated the possibility of detecting as low as 1% 
w/w CAC in the amorphous material.
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The intestinal absorption studies indicated that the absorption rate of the crystalline 
(CAC) drug was the lowest, despite being introduced in the study as the finest 
particles (d50 = 3pm). This suggested that the form of the drug (i.e. crystalline or 
amorphous) was more determinant to the rate of CA absorption than its particle 
size. The compression effect on CAA was demonstrated by lower in vitro gut 
absorption rate of CAAc (by 30%) compared to that of CAA.
The experimentally determined Peff value of CA indicated sufficient bioavailability of 
the drug, regardless of the rapid and extensive hydrolysis of CA in the rat intestine 
and under the test conditions.
The Tg onset of CAA material was found to be affected by the presence of water, 
which has a plasticization effect on the material. This was indicated by the 
reduction in the Tg value of CAA to an extent related to water uptake upon 
exposure to high humidity condition. However, the limited uptake of moisture 
(1.3%) upon exposure to 95%RH, remained insufficient to induce crystallisation 
within the amorphous drug. Furthermore, the Tg value of CAA reverted back to its 
original value upon vacuum drying, indicating that CAA material can withstand 
fluctuations in storage conditions. This demonstrated a stable amorphous drug, a 
case which has rarely been seen in other amorphous pharmaceutical systems.
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CHAPTER 4
EFFECT OF SOME EXCIPIENTS ON THE PHYSICAL PROPERTIES 
OF CEFUROXIME AXETIL CRYSTALLINE (CAC) AND 
CEFUROXIME AXETIL AMORPHOUS (CAA) AS POWDER BLENDS
AND COMPRESSED MIXTURES
4.1 INTRODUCTION
Only limited studies had been undertaken on mixing, formulation properties and 
the possibility of enhancing stability, solubility, and bioavailability of CA with the 
introduction of excipients. Of these, the use of citric acid sodium salt in a tablet 
formulation containing CA, microcrystalline cellulose, SLS, croscarmellose sodium 
and calcium carbonate (Somani et al, 2001). The addition of sodium salt of citric 
acid was undertaken to inhibit the tendency of CAA to form a gel that prolonged 
the disintegration time and retards the dissolution of the tablet formulation. The 
dissolution behaviour of the formulated tablets was satisfactory (77% after 45 min), 
and the product was bioequivalent to the commercial Ceftin® preparation, 
containing pure CAA.
Crisp et al. (1991) described compositions for oral administration whereby 
enhanced absorption of CA via the GIT was achieved. These pharmaceutical 
compositions took the form of tablets or capsules prepared by conventional 
processes with pharmaceutically acceptable excipients such as binding agents 
(e.g. PVP, or HPMC), fillers (e.g. starch, lactose, microcrystalline cellulose or 
calcium phosphates), disintegrants (e.g. potato starch, or sodium starch glycolate), 
wetting agents (e.g. SLS), and lubricants (e.g. Mg-stearate, hydrogenated 
vegetable oils, talc, silica or PEG).
In another study, a solid dispersion of CA was prepared by dissolving CA and a 
surfactant (e.g. Tween®, Cremophor®, Myrj®, Poloxemer®, Migloyol®, Labrafil®, 
Imvitor®, and Span®) in an organic solvent (e.g. acohol, acetonitril, THF, 
dichloromethane, and chloroform), followed by suspending a water insoluble 
inorganic carrier (e.g. silicon dioxide, hydrotalcite, aluminum magnesium silicate,
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aluminium hydroxide, titanium dioxide and talc) in the resulting solution and drying 
the resulting suspension to remove the organic solvents (Woo et al, 2000).
The solid dispersant showed an improved bioavailability and increased the stability 
of CA. The dispersant was used for the preparation of tablets containing 
microcrystalline cellulose, cross-linked povidone and Mg-stearate, tablets were 
further coated with a regular film coat. The dissolution of these tablets was 
comparable to those of the control drug (Zinnat® tablets)(> 90% after 45 minutes). 
This high dissolution rate of these tablets can be related to the rapid rupturing of 
the film coating in the GIT fluids, after which the core disintegrates quickly and 
CAA becomes rapidly exposed to the absorption media (Deutsch et al, 1990-a,b). 
The coat composition was made up to HPMC 5 or 6, propylene glycol, methyl 
hydroxy benzoate and propyl hydroxy benzoate.
Somani et al. (2003) developed a method for preparing CAA from an admixture of 
CAC with one or more pharmaceutically accepted excipients (e.g. NaCI, CaC03 , 
Lactose, Starch, Microcrystalline cellulose, Colloidal Silica, Talc, and SLS). The 
mixture was then subjected to a milling action. Upon milling pure CAA was 
obtained, which contained less than 5% CAC.
In another study, a solid dispersion technique was used to obtain and stabilise the 
amorphous form of the drug (Guk et al, 2002). Upon dissolving CAC in a mixture of 
acetone, methanol and methylene chloride at ambient temperature, PVP K-30, 
HPMC and PEG were added each individually to the solution while stirring. The 
solution was sprayed into a vessel with supercritical CO2 (100 bar, 45°C) which 
acted as anti solvent. The solid dispersion containing CAA showed similar solubility 
to that of CAA in the reference product Zinnat® tablets.
Sherman et al. (2000) published a method for stabilisation of CA by forming an 
admixture of CA with zinc chloride in a 0.1 -  4% concentration. The zinc salt was 
added to CAA co-preciptate with a water soluble diluent (e.g. sorbitol). Accelerated 
stability testing on the prepared tablets from the admixture (60°C for 7 days) 
revealed a low increase in impurities, indicating good stability.
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As discussed in chapter 3, compression of CAA resulted in reduction in its 
dissolution and intestinal absorption rates, due to its partial crystallisation.
In this chapter, mixtures of CAA were prepared with some excipients with and 
without compression, for the objective of characterising their effect on enhancing 
the dissolution and bioavailability of CA.
A powder blend and a compressed mixture of CAA with all excipients was also 
prepared to determine their possible synergistic effect. The same study was 
repeated with CAC to determine whether these excipients have any significant 
effect on the solubility and intestinal permeability of the crystalline form of the drug.
4.2 MATERIALS AND METHODS
Table 4.1 summarises materials used in this study.
No. Material Batch No. Assay WaterContent Source
Retesting
Date
1. Cefuroxime axetil amorphous (CAA) CAFAA/003/00 81.8% 0.99% Orchid 12/2003
2. Cefuroxime axetil crystalline (CAC) CRCB030005 83.4% 0.16% Orchid 02/2006
3. Crosscarmellose sodium (Ac-Di-Sol) T506C — 2.2% FMC 02/2000
4. Pregelatinizedstarch IN 502729 — 8.6% Colorcon 03/2003
5. Colloidal silicon dioxide (Aerosil 200) C2711011 — 0.1% Degussa 01/2003
6. Sodium lauryl 
sulphate (SLS)
00015026 — 0.87% Hankel 02/2002
I
Table 4.1 Materials used in the mixtures prepared with CAA and CAC.
4.2.1 Preparation of Mixtures
4.2.1.1 Powder blends preparation
Mixtures of 20 gm weight were prepared for each of the following excipients with 
CAA at the following concentrations: Ac-Di-Sol at 15% and 50%, starch 1500 at 
30% and 50%, SLS at 15% and 50%, and Aerosil 200 at 3% and 50%.
The mixtures were prepared by accurately weighing each material at the quantities 
needed using a calibrated Mettler balance. Materials for each mixture were then 
transferred to a beaker of a suitable size and mixed using a spatula for 5 minutes.
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4.2.1.2 Compressed mixtures preparation
From each of the prepared powder blends mentioned under section 4.2.1.1, 10 gm 
were taken and compressed into tablets with a hardness of 70-90N using an 
“Erweka EKO” single punch machine. Tablets were crushed into granules using an 
“Erweka” crusher, and then passed through a 0.2 mm sieve.
In order to exclude differences in particle size distribution, compressed granules of 
each mixture were sieved through a set of sieves ranging 50-200pm. Only 
granules at the size range of 90-100pm were collected, analysed for homogeneity, 
and tested as described under section 4.2.3 below.
4.2.2 Powder blends and compressed mixtures prepared
4.2.2.1 Mixtures of CAA with Ac-Di-Sol
Croscarmellose sodium (Ac-Di-Sol), a cross linked polymer of carboxymethyl- 
cellulose sodium, is a non crystalline fibrous material of high molecular weight of 
90 K -700 K. It is most commonly used in oral pharmaceutical formulations as a 
disintegrant for capsules, tablets and granules (Botzolakis, 1988; Gorman et al. 
1982). It is generally regarded as an essentially nontoxic and nonirritant material.
In tablet formulations, croscarmellose sodium may be used in both direct 
compression and wet granulation processes. When used in wet granulation the 
croscarmellose sodium is best added both intra and extra-granular, so that the 
swelling ability of the disintegrant is best utilised (Khattab et al, 1993).
Two ratios of CAA powder mixtures with Ac-Di-Sol were prepared, the 50:50 
(Mixture 1), and the 85:15 (Mixture 2). The compressed granules were only 
prepared from mixture 2.
4.2.2.2 Mixtures of CAA with pregelatinized starch 1500
Pregelatinized Starch 1500 performs key functions in direct compression 
formulations as a binder, disintegrant and a self-lubricant (Shangraw et al, 1981). It 
also promotes formulation flexibility by complementing and enhancing other 
excipients. Starch is a semi crystalline material, it loses its crystalline properties 
when pregelatinized.
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Powder mixtures of CAA with pregelatinized starch 1500 were prepared in 50:50 
ratio (Mixture 3), and 70:30 ratio (Mixture 4). The compressed granules were only 
prepared from mixture 4.
4.2.2.3 Mixtures of CAA with Aerosil 200
Colloidal silicon dioxide is an amorphous material with a large specific surface 
area. It is widely used in pharmaceuticals, cosmetics and food products to give it 
the desirable flow characteristics which are exploited to improve the flow properties 
of dry powders in a number of processes (Lerk, 1977).
Colloidal silicon dioxide is also used to stabilise emulsions and as a thixotropic, 
thickening, and suspending agent in gels and semisolid preparations.
Powder mixtures of CAA with Aerosil 200 were prepared in 50 : 50 ratio (mixture 
5), and 97 : 3 ratio (mixture 6). The compressed granules were prepared from 
mixture 6 only.
4.2.2.4 Mixtures of CAA with SLS
Sodium lauryl sulfate is an anionic surfactant. It is a crystalline material having a 
molecular weight at 288.38. It is employed in a wide range of non parenteral 
pharmaceutical formulations and cosmetics as a detergent and wetting agent 
which is effective in both alkaline and acidic conditions (Wang et al, 1990).
Powder mixtures of CAA with SLS were prepared in 50 : 50 ratio (Mixture 7), and 
85 : 15 ratio (Mixture 8). The compressed granules were prepared from mixture 8 
only.
4.2.2.5 Blends of CAA and CAC with Ac-Di-Sol, Starch 1500 and Aerosil 200
A powder blend composed of the followings was prepared with 600 gm of each of 
CAA and CAC:
Ac-Di-Sol : 100.0 gm
Starch 1500 : 180.0 gm
Aerosil 200 : 20.0 gm
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CAA or CAC, Starch 1500 and Aerosil 200 were mixed using the “Niro PMA” high 
sheer mixer of a 10L container for 2 minutes. Ac-Di-Sol was then added and mixed 
with the rest of the blend at low speed for 1 minute.
The compressed mixture was prepared from the CAA mixture with excipients. The 
obtained granules were called cefuroxime axetil direct compression granules 
(CADC). A compressed mixture of CAC with excipients was not prepared, as the 
dissolution results of its powder blend indicated insignificant role of the excipients 
on this form of the drug.
4.2.3 Mixtures testing
4.2.3.1 HPLC method for mixtures analyses
Mixtures were tested for homogeneity of CA distribution by analyses of 5 different 
samples from each. The test was undertaken on powder quantities equivalent to 
the weight needed for sample preparation according to the HPLC method 
mentioned in chapter 2, section 2.9.2.1.
4.2.3.2 DSC testing of the mixtures
To study the physical and chemical compatibility of CA with each of the tested 
excipients, DSC testing on 1 : 1 CAA mixtures with excipients was performed 
according to the method described in chapter 2, section 2.1.2. Each excipient was 
also tested alone and results were compared with those of related mixtures.
4.2.3.3 MTDSC testing of the mixtures
MTDSC testing using the method described in chapter 2, section 2.2.2, was 
applied for CAA and CAC mixtures with all excipients chosen. This included the 
compressed mixture (CADC).
4.2.3.4 Dissolution testing of the mixtures
Dissolution rate of CA from each mixture was tested using BP 2003 method 
described in chapter 2, section 2.7.2.2.
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4.2.3.5 In vitro gut absorption testing of the mixtures
In vitro gut absorption of CA from each mixture was tested as described in chapter 
2, section 2.8.2.2.
4.3 RESULTS AND DISCUSSIONS
4.3.1 Mixtures of CAA with Ac-Di-Sol
4.3.1.1 Homogeneity measurements
The homogeneity results of CA in mixture 1 (50:50, CAA : Ac-Di-Sol), and mixture 
2 (85:15, CAA : Ac-Di-Sol) were 47.0 -  54.0 mg% and 80.0 -  89.0 mg% CA, 
respectively. Results of compressed mixture 2 were 78.0 -  92.0 mg% CA. The 
obtained results indicated good blend homogeneity (± 10%).
4.3.1.2 DSC measurements
The DSC thermogram of mixture 1 showed two endothermic peaks, one at 84.3°C 
representing the Tg of CAA overlapping the relaxation peak, and another wide 
peak for Ac-Di-Sol at 131.8°C. DSC thermogram of Ac-Di-Sol alone showed one 
wide endothermic peak at 130.3°C.
These measurements indicated that Ac-Di-Sol is physically and chemically 
compatible with CA upon mixing, and that there is no apparent effect of Ac-Di-Sol 
on the Tg value of CAA upon mixing.
4.3.1.3 Dissolution testing
The results of CA release from mixtures of CAA with Ac-Di-Sol are shown in Table
4.2 and Figure 4.1.
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Time
Average %C release (±SD)
Powder blends Compressed
Mixture 1 Mixture 2 Mixture 2
5 67.2 ±3.0 83.5 ± 1.3 93.1 ±6.0
10 78.5 ± 5.9 99.8 ±0.8 107.2 ±0.3
15 81.0 ±7.2 98.8 ± 2.0 103.3 ±0.4
20 85.9 ±2.5 100.6 ± 1.6 103.0 ±0.6
30 88.0 ±2.0 100.9 ± 1.6 103.6 ±0.6
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Figure 4.1: Dissolution CA% release from CAA mixtures with Ac-Di-Sol, n=6.
As shown above, the dissolution results of CA from all mixtures with Ac-Di-Sol 
were compliant with BP and USP current specifications for the dissolution of CA 
tablets (> 60% after 15 min and > 75% after 45 min).
The dissolution rate of CA was higher from mixture 2 than that from mixture 1. This 
is related to the fact that mixture 1 contained 50% (by weight) insoluble Ac-Di-Sol 
material, which settled at the bottom of the dissolution vessel, thus, trapping and 
retarding the complete release of CA. This was not observed with mixture 2 which
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contained 15% Ac-Di-Sol only. This last concentration led to a fast and efficient 
dispersion and dissolution of CAA particles in the dissolution media.
Results also indicated that the rate of dissolution of CA from compressed mixture 2 
was significantly higher than that from CAAc, as shown in chapter 3, section 3.3.7. 
This indicated that compression had no detrimental effect on the release of CAA 
when in the form of a mixture with Ac-Di-Sol.
Also, the release rates of CAA from mixture 2 and compressed mixture 2 were 
both high, with a slight increase observed with the latter. This may be related to 
the micro-environment that Ac-Di-Sol could provide to CAA material upon 
compression, which led to a better enhancement in CAA dissolution rate compared 
to being in the form of a blend that is immediately dispersed when loaded into the 
media.
4.3.1.4 in vitro gut absorption test
The in vitro gut results of C release from compressed and uncompressed mixture 
2 are presented in Table 4.3 and Figure 4.2.
Time Average %C release (± SD)
(min) Mixture 2 Compressed mixture 2
15 2.02 ± 2.50 5.45 ± 1.30
30 5.32 ±5.10 7.31 ± 3.33
45 9.92 ± 4.30 12.65 ±2.87
60 15.77 ±2.75 19.47 ±3.66
75 21.74 ±3.37 24.78 ± 5.80
90 26.75 ± 4.82 30.47 ± 6.20
105 33.36 ± 5.00 34.33 ± 7.50
120 38.04 ± 3.00 41.08 ±7.20
Table 4.3: In vitro gut C% release from CAA mixtures with Ac-Di-Sol, n=3.
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Figure 4.2: In vitro gut release of C from compressed and uncompressed CAA 
mixtures with Ac-Di-Sol, n=3.
The above figure shows a linear zero order in vitro gut release of C from mixture 2, 
the rate of which was found similar to that from CAA alone. This indicated that Ac- 
Di-Sol in the ratio used in mixture 2 retained the intestinal absorption rate of CAA. 
A linear zero order release rate of C was also observed for the compressed 
mixture 2, which was close to that of the uncompressed mixture.
The reduction in intestinal absorption rate of CAA upon compression, related to 
partial crystallisation of CAA (chapter 3), was not noticed with the compressed 
mixture 2. This may be related to the inhibition of crystallisation by the introduction 
of Ac-Di-Sol within the compressed CAA granules. Thus, compression of CAA in 
the presence of AC-Di-Sol maintained its original absorption rate, unlike 
compression of CAA alone, which significantly reduced its rate of absorption.
The above may be related to mixing of CAA with the highly fibrous non crystalline 
material (Ac-Di-Sol), which might have diluted the effect of heat and pressure 
generation upon compression. This was aided by the fact that Ac-Di-Sol is a 
relatively poorly compressible material compared to other polymers such as PVP,
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(Gissinger, 1980). It may also be considered the hydrogen bonding between CA 
and Ac-Di-Sol polymer, which might have reduced the molecular mobility of CAA in 
the mixture, thus linking its local motions to that of the polymer and preventing 
crystallisation. Thus Ac-Di-Sol stabilised the amorphous form of the drug and 
inhibited its crystallisation during compression.
The lag time noticed in Figure 4.2 for compressed mixture 2 release curve is 
related to time needed for the compressed granules to disintegrate, and the 
powder to be dispersed in the media before absorption started.
Statistical analyses (two way Anova) was applied to determine similarity of the in 
vitro gut release rates of C from mixture 2 and from CAA. Data obtained indicated 
that these two were not significantly different (P>0.05), but both were significantly 
different from that of the compressed CAA alone (CAAc), (p<0.05).
4.3.2 Mixtures of CAA with pregelatinized starch 1500
4.3.2.1 Homogeneity measurements
Homogeneity results of CA in mixture 3 (50:50, CAA : Starch1500) were 45.0mg -  
51.0mg% CA, for mixture 4 (70:30, CAA : Starch1500) and compressed mixture 4 
results were 67.3mg -  72.5mg%, and 63.5mg -  71.5mg % CA, respectively.This 
indicated good blend homogeneity (± 10%).
4.3.2.2 DSC measurements
The DSC thermogram of mixture 3 had an endothermic peak at 83.0°C 
representing the Tg of CAA overlapping the relaxation peak, and a wide 
endothermic peak for Starch 1500 centred at 141.1°C. Testing of Starch 1500 
alone showed one wide endothermic peak at 142.7°C. Thus, the DSC results 
indicated that starch 1500 was chemically and physically compatible with CA, and 
that there was no effect of Starch 1500 on the Tg value of CAA.
4.3.2.3 Dissolution testing
The results of CA release from its mixtures with starch 1500 are shown in Table







Average % CA re lease (± SD)
Time Powder blends Compressed
Mixture 3 Mixture 4 Mixture 4
5 57.70 ± 14.76 68.0 ±3.1 86.39 ±9.17
10 69.26 ±15.39 79.7 ±2.9 105.58 ±0.96
15 70.00 ±10.16 85.0 ±2.0 102.26 ±1.22
20 68.93 ± 8.69 85.2 ±2.2 99.29 ± 2.69
30 68.91 ± 10.14 83.7 ±1.1 100.72 ±0.89
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Figure 4.3: Dissolution CA% release from CAA mixtures with Starch 1500, n=6.
The above data show that the dissolution rate of CA from mixture 4 was in 
compliance with BP and USP current specifications for dissolution of tablets, 
(> 60% after 15 minutes). It was also shown that the dissolution rate of CA in 
mixture 4 was higher than that in mixture 3. This can be related to the fact that 
mixture 3 contained 50% (by weight) insoluble material (Starch 1500) which settled 
at the bottom of the dissolution vessel, trapping and retarding the complete release 
of CAA. This case was not found with the 30% Starch 1500 content in mixture 4.
It was also evident that in compressed mixture 4 the rate of dissolution of CA was
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higher than that from the uncompressed mixture. This may be related to the 
compaction of the mixture which brought the disintegrent (Starch 1500) particles in 
close proximity to the CAA particles, thus potentially providing it a faster dispersion 
and a higher surface area of exposure in the dissolution media.
4.3.2.4 In vitro gut absorption
The in vitro gut results of C release from compressed and uncompressed mixture 4 
are presented in Table 4.5 and Figure 4.4.
Time
(min)
Average %CA release (± SD)
Mixture 4 Compressed Mixture 4
15 5.34 ± 1.58 2.52 ±0.50
30 8.98 ± 2.74 4.03 ± 1.47
45 14.40 ±3.78 8.78 ±2.00
60 20.61 ± 5.60 13.97 ±3.35
75 27.10 ±2.93 20.15 ±4.20
90 31.08 ±4.72 26.03 ± 5.67
105 34.73 ± 5.08 31.49 ±6.33
120 37.34 ± 2.30 37.25 ± 5.27
Table 4.5: In vitro gut C% release from CAA mixtures with Starch 1500, n=3.
45
y = 0.331 x
F? = 0.9902
y = 0.3236x - 3.3942 
0.9775










Av. mixture 4 





0 10 20 30 40 50 60 70 80 90 100 110 120
Time (min)
Figure 4.4: In vitro gut release of C from compressed and uncompressed CAA 
mixtures with Starch 1500, n=3.
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The figure above shows a linear zero order in vitro gut release rate of C from 
mixture 4, which was found close to that from CAA alone. Thus, the introduction of 
starch 1500 in mixture 4, at the 30% ratio, retained the intestinal absorption rate of 
CAA.The few minutes lag time seen in Figure 4.4 for compressed mixture 4 is 
related to time needed for the compressed granules to disintegrate and disperse in 
the media before absorption started.
It was also clear that the absorption rate of CA from compressed mixture 4 was 
similar to that uncompressed. This indicated that compression of CAA in the 
presence of starch 1500 maintained its original absorption rate, which was different 
from what was noticed with compression of CAA alone, where absorption rate was 
reduced significantly. The reduction in dissolution rate of CAA after compression 
was referred to partial transformation of CAA to the crystalline form. Starch 1500 
was found to minimize such an effect, thus it stabilised CAA and inhibited its 
crystallisation upon compression.
On the other hand, the possible hydrogen bonding formation between CAA and 
this polymer might have hindered its molecular mobility, and prevented 
crystallisation. It was also reported that the compressability of Starch 1500 was 
less than that in other polymers (as PVP) (Gissinger, 1980). Thus, less pressure 
and heat would be generated in the slugs, hence reducing the plasticization and 
possible crystallisation of the amorphous drug.
Statistical analyses (two way Anova) was applied to determine similarity of the in 
vitro gut release rates of C from mixture 4 and from CAA. Data obtained indicated 
that these two were not significantly different (P>0.05), but both were significantly 
different from that of the compressed CAA alone (CAAc), (p<0.05).
4.3.3 Mixture of CAA with Aerosil 200
4.3.3.1 Homogeneity results
The homogeneity results of CA in mixture 5 (50:50, CAA : Aerosil 200) and mixture 
6 (97:3, CAA : Aerosil200) were 46.0mg -  53.0mg%, and 92.0mg -  99.0mg%CA, 
respectively. For compressed mixture 6, results were 93.0mg -  103.0mg% CA. 
This indicated good distribution of CA in all mixtures tested (± 10%).
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4.3.3.2 DSC measurements
The DSC thermogram of mixture 5 indicated physical and chemical compatibility of 
Aerosil 200 with CA. The endothermic peak characteristic of CAA Tg overlapping a 
relaxation peak at 82.8°C was detected, together with a Tg for Aerosil at 302.0°C. 
Testing Aerosil 200 alone indicated a Tg at 303.3°C.
4.3.3.3 Dissolution testing
The results of CA release from its mixtures with Aerosil 200 are shown in Table 4.6 
and Figure 4.5.
Time
Average %CA release (± SDL_
Powder blends Compressed
Mixture 5 Mixture 6 Mixture 6
5 31.8 ±6.5 70.1 ±0.3 75.98 ± 11.88
10 49.3 ±9.4 91.0 ±3.4 99.30 ±2.13
15 69.3 ±8.4 91.5 ±3.9 98.43 ±4.05
20 78.3 ±2.8 91.2 ±0.9 99.49 ± 1.61
30 88.8 ±2.0 91.0 ±2.5 99.59 ± 0.76
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Figure 4.5: Dissolution CA% release from CAA mixtures with Aerosil 200, n=6.
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The results above show that the dissolution rate of CA in mixture 6 was slightly 
enhanced with regards to mixture 5. This may be related to the high surface area 
of the water insoluble mesh formed by Aerosil around CAA particles at the 50:50 
ratio in mixtures, which minimized CA contact with the dissolution media. A 3% 
concentration of Aerosil 200 in mixture 6 did not, however, show such an effect.
The slight decrease in CA% dissolved from uncompressed mixture 6 compared to 
the compressed at different time points can be possibly related to the observed 
creaming of CAA particles on the surface of the dissolution media. This may be 
due to the fluffy and light particles of Aerosil 200, which creamed some of the 
smaller CAA particles to the surface of the media during testing. A case that was 
not noticed upon compression of the mixture.
4.3.3.4 In vitro gut absorption
The results of in vitro gut C release from compressed and uncompressed mixture 6 
are presented in Table 4.7 and Figure 4.6.
Time
(min)
Average %<3 Release ± SD
Mixture 6 Compressed Mixture 6
15 2.66 ± 0.22 3.82 ± 0.80
30 7.50 ±1.87 5.58 ±1.53
45 13.01 ±3.59 10.14 ±2.76
60 18.83 ±5.87 15.21 ±3.31
75 23.46 ± 4.44 19.96 ±4.85
90 28.75 ± 5.55 24.42 ± 5.66
105 33.25 ± 3.73 29.39 ± 6.30
120 37.04 ± 4.93 33.74 ±6.10
Table 4.7: In vitro gut C release from CAA mixtures with Aerosil 200, n=3.
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Figure 4.6: In vitro gut release of C from compressed and uncompressed CAA 
mixtures with Aerosil 200, n=3.
The C release profiles from CAA mixtures with Aerosil, shown in Figure 4.6, 
reflected linear zero order release rates. The few minutes lag time noticed with 
compressed mixture 6 may be related to time needed for the granules to 
disintegrate and disperse in the media before absorption started.
The in vitro results indicated that Aerosil 200 in the ratio applied in mixture 6 
maintained the intestinal absorption rate of CA from CAA. It was also noticed that 
compression didn’t reduce the absorption rate of CA from compressed mixture 6, 
as it did with CAA alone. This, once again, indicated that Aerosil 200 prevented the 
transformation of CAA to CAC. Thus, although it did not form an ideal mixture with 
CAA as each material retained its Tg value upon mixing, Aerosil 200, by having a 
higher Tg value (300°C), tended to stabilise CAA and to prevent its crystallisation, 
thus it maintained its original absorption rate.
Such stabilisation mechanism of small amorphous drugs by materials having 
higher Tg values was previously reported by Craig et al.(1999-a).
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On the other hand, because of the high surface area of Aerosil 200, it efficiently 
covered CAA particles in the mix, this might have an aid in relieving the effect of 
compression on the amorphous drug.
Another reason for Aerosil being enhancing the dissolution and maintaining the 
absorption rate of CAA may be related to the fact that silicon dioxide can act as a 
micro-environmental pH adjustor around CA, and as an anti-gelling agent for the 
drug (James et al, 1989). It was confirmed in the lab that at pH > 5.5 
decomposition rate of CA increased. When CA was mixed with silicon dioxide to 
prepare solid formulation for oral administration, the micro-environment around CA 
was maintained with an acidic state between 3.5 and 5.5, which increased its 
stability.
Thus, despite the relatively small amount of Aerosil 200 mixed with CAA, it had 
evenly distributed between the particles due to its large surface area. Thereby the 
attractive forces between CAA particles was reduced, and its gelation was 
subsequently prevented. Consequently good dissolution and absorption rates of 
the drug were maintained.
Statistical analyses (two way Anova) was applied to determine similarity of the in 
vitro gut release rates of C from mixture 6 and from CAA. Data obtained indicated 
that these two were not significantly different (P>0.05), but both were significantly 
different from that of the compressed CAA alone (CAAc), (p<0.05).
4.3.4 Mixtures of CAA with SLS
4.3.4.1 Homogeneity measurements
The homogeneity results of CA in mixtures 7 (50:50, CAA : SLS) and 8 (85:15, 
CAA : SLS) were 48.0mg -  55.0mg% and 79.5mg -  91.0mg% CA, respectively. 
The compressed mixture 8 results were 81.0mg -  92.0mg% CA. This indicated 
good distribution of CA in all mixtures tested (± 10%).
4.3.4.2 DSC measurements
The DSC thermogram of mixture 7 revealed 3 endothermic peaks, one for the Tg of 
CAA overlapping a relaxation peak at 82.0°C, and the others for SLS at 113.5°C
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and 195.3°C. The DSC thermogram of SLS alone showed its characteristic two 
endothermic peaks at 115.1 °C and 196.2°C.
4.3.4.3 Dissolution testing
The results of CA release from its mixtures with SLS are shown in Table 4.7 and 
Figure 4.7.
Time
Average %CA release (± SD)
Powder blends Compressed
Mixture 7 Mixture 8 Mixture 8
5 10.0 ±7.0 16.5 ±9.3 27.17 ±10.53
10 18.0 ±5.0 24.1 ±8.6 34.66 ± 8.86
15 23.0 ±4.0 28.6 ±7.1 38.80 ±7.18
20 28.0 ±3.0 32.1 ±5.6 41.54 ±7.85
30 30.0 ±6.0 36.6 ± 4.5 46.58 ± 7.76
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Figure 4.7: Dissolution CA% release from CAA mixtures with SLS, n=6.
The results above indicated that SLS did not significantly enhance the dissolution 
rate of CAA when compared to other excipients. The % release of CA from both 
mixtures 7 and 8 were similar, with a slight increase noticed with compressed
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mixture 8 at each time point. The reason for having such low dissolution results, 
despite of SLS being a wetting agent, may be related to the basicity of SLS 
compared to other tested excipients. The increased pH of the solution (by SLS) 
around CAA to 6.3 caused its gelation and limited its dissolution enhancement. 
Hence, dissolution results of CAA as a mixture with SLS were all below the stated 
pharmacopeial limits (> 60% after 15 minutes), and much lower than what was 
obtained from mixtures with other tested excipients.
4.3.4.4 In vitro gut release testing
The results of the in vitro gut C release from compressed and uncompressed 
mixture 8 are presented in Table 4.9 and Figure 4.8.
Time Average % (3 release (± SD)
(min) Mixture 8 Compressed Mixture 8
15 1.10 ± 0.25 1.49 ±0.23
30 3.03 ± 1.30 1.68 ±0.56
45 6.10 ±2.65 3.39 ±1.00
60 10.48 ±4.57 5.67 ±0.90
75 14.12 ±4.53 7.89 ±2.10
90 17.73 ±5.77 10.48 ±3.03
105 21.49 ±6.85 13.41 ±3.00
120 25.21 ±7.00 15.84 ±2.87
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Figure 4.8: In vitro gut release of C from CAA mixtures with SLS, n=3.
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Figure 4.8 shows the zero order linear release rate of C from CAA mixtures with 
SLS. The few minutes lag time for the compressed mixture can be related to time 
needed for granules to completely disintegrate and disperse in the media before 
absorption started.
The results above showed that despite of SLS being a wetting agent, it led to a 
significant reduction in the absorption rate of CAA (by 35%). The CA absorption 
rate from SLS mixtures was found to be significantly lower than those previously 
obtained with other mixtures (namely mixtures 2, 4 and 6). This may be due to the 
fact that SLS is a basic material which induced gelation of CAA, thus reduced CAA 
absorption rate significantly.
Statistical analyses (two way Anova) was applied to determine similarity of the in 
vitro gut release rates of C from mixture 8 and from CAA. Data obtained indicated 
that these two were significantly different (P<0.05).
4.3.5 In vitro absorption results summary Table
Table 4.10 summarises the C release rates (K) from all mixtures studied. It shows 
that the release rate of CAA was maintained when mixed at the chosen ratios with 
Ac-Di-Sol, Starch 1500, and Aerosil 200.
Compressed mixtures also showed similar release rates to that of CAA, with no 
significant difference (P > 0.05). This indicated that the effect of compression on 
CAA was limited when mixed with any of these excipients.Thus, they minimized 
the effect of pressure and heat generated during compression, potentially 
preventing the partial crystallisation of CAA upon compression.
SLS showed the lowest K value because of its basic properties that increased the 
environmental pH around CAA, and led to gelation of the material in the media, 
thus, significantly reduced the absorption rate.
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Material % CAA Content C Release rate (K value)Compressed Uncompressed
CAA 100% 0.20 0.29
CAA + Ac-Di-Sol (Mixture 2) 85% 0.34 0.30
CAA + Starch 1500 (Mixture 4) 70% 0.32 0.33
CAA + Aerosil 200 (Mixture 6) 97% 0.29 0.31
CAA + SLS (Mixture 8) 85% 0.13 0.19
Table 4.10: In vitro gut release rates (K) of C from all mixtures tested
4.3.6 Mixtures of CAA, CAC with all tested excipients
It was shown above, the enhancement effect of Ac-Di-Sol, Aerosil 200 and Starch 
1500 on the dissolution rate of CAA upon compression. The additive enhancement 
effect of these excipients (together) on dissolution and bioavailability of CA from 
both CAC as a powder blend, and CAA as a powder blend and compressed 
mixture (CADC) was studied as described below.
4.3.6.1 Homogeneity measurements
The homogeneity results of CA content in the powder blends of all the above 
mentioned excipients , with CAC were 61.5 -  67.0 mg %CA, with CAA were 
62.0mg -  68.5mg%, and in CADC 67.8mg -  72.5mg %CA .respectively. This 
indicated good homogeneity (± 10%).
4.3.6.2 DSC measurements
The DSC thermograms of CAA and CAC powder blends showed no significant 
change compared to those obtained with each form tested alone (as shown in 
chapter 3, section 3.3.2).
DSC and MTDSC thermograms of CADC shown in Figures 4.9, 4.10 and 4.11 
below revealed a Tg for CAA at about 74°C overlapping a relaxation peak. No 
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Figure 4.9: DSC thermograms of CADC compared to CAAc, at heating rate 
25°C/min.
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Figure 4.10: MTDSC heat flow thermograms of CADC, at heating rate 1°C/min, 
amplitude 0.5°C / 48 second
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Figure 4.11: Cp complex of CADC, at heating rate 1°C/min, amplitude 0.5°C/48 
seconds.
The above DSC thermograms indicated that the crystalline form of CA was not 
generated upon compression of CAA in a mixture with the excipients (Ac-Di-Sol, 
Starch 1500, Aerosil 200).
This stabilisation may be related to the fact that the relatively small drug molecule 
of CAA dispersed in the polymers (Ac-Di-Sol and Starch 1500) physically 
interacted by hydrogen bonding, thus had its molecular motions coupled with those 
of the polymers, leading to prevention of crystallisation. Also, Aerosil 200 was 
found to stabilise CAA due to its high Tg value.
To better understand the effect of the chosen excipients on stabilisation of CAA, a 
DSC test was done for each of the CAA, compressed CAA (CAAc) and 
compressed mixture of CAA with the chosen excipients (CADC). A heating - 
cooling -  heating cycle was applied for each form at 10°C/min rate, for the range 
30°C - 100°C. In this case hermetically sealed lids were used to keep water inside, 
and to get a better estimation of the stability of the material as is. Relaxation 
curves were obtained from the difference between the first and second heating 
curves of each run. Results obtained for CAA, CAAc and CADC are as shown in 
the below 4.12, 4.13 and 4.14 Figures, respectively.
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Figure 4.12: DSC thermograms of CAA, heating -  cooling -  heating cycle, at rate of 
10°C/min.
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Figure 4.14: DSC thermograms of CADC, heating -  cooling -  heating cycle, at rate 
of 10°C/min.
The results above showed the thermal history effect (Relaxation), presented in the 
first heating run in all tested samples. This effect was not seen in the second 
heating run as relaxation did not occur in the samples upon ramping up to 100°C. 
The thermograms also indicated that the Tg value for CADC is lower than that for 
CAA (by 6°C). This may be related to the effect of higher water content in the 
former (2.5%) compared to that of the latter (0.9%). The higher water content in 
CADC caused plasticization and reduction of Tg of the amorphous material to 
60°C.
On the other hand, the Tg of CADC in the second heating run was higher by 2°C 
than that of CAAc. This is despite of CADC having a higher water content than that 
in CAAc by 1.5%. The Tg of CAAc was also found to be lower by 8°C than that of 
the pure amorphous, which indicated that the compressed material (CAAc) was 
less stable than the pure CAA and also was less stable than CADC.
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This, while compression would lower the stability of CAA (reduces its Tg), the 
presence of the formulation excipients limited such an effect and provided 
stabilisation for CAA against compression generated heat and pressure.
Similar suggested stabilisation effect of some polymers on amorphous drugs were 
found in the literature. Examples include, stabilisation of amorphous sucrose 
(Zografi et al. 1999; Shamblin et al. 1996, 1998) and amorphous indomethacin with 
polyvinylpyrolidone PVP (Yoshioka et al. 1994, 1995; Zografi et al. 1999), and 
stabilisation of amorphous acetaminophen using PVP, and polyacrylic acid 
(Miyazaki et al, 2004). These were in the form of solid dispersions and not as 
physical mixtures.
The difference observed in this study was that stabilisation of CAA under process 
conditions was achieved by only physical mixing (i.e. solid dispersion was not 
needed) with the chosen excipients. This may be related to the fact that CAA is a 
highly stable amorphous material.
4.3.6.3 Dissolution testing
The percentage release of CA from the compressed CAA mixture with excipients 
(CADC) and from CAA, CAC blends with the excipients are presented in Table 
4.11 and Figure 4.15.
Time
Average %CA release (±SD)
Blended mixtures Compressed mixture
CAA CAC CADC
5 72.0 ± 5.0 9.72 ± 1.31 78.0 ± 8.00
10 81.0 ±4.0 18.51 ±3.20 92.0 ± 4.00
15 89.0 ± 5.0 25.27 ± 2.93 98.0 ± 4.00
20 98.0 ± 2.0 30.35 ±2.18 101.0 ± 1.50
30 101.0 ±3.0 33.12 ±0.98 100.0 ±2.30





~*“ Av. CAA mixture with excipients 
“■“ Av. CAC mixture with excipients 
~*~Av. compressed CADC
0 5 10 15 20 25 30 35
Time (min)
Figure 4.15: Dissolution %CA release from CADC, CAA and CAC mixtures with the 
three excipients, n=6.
The dissolution profile of CAA with the addition of the excipients together (Ac-Di- 
Sol, starch 1500 and Aerosil 200) was similar to those obtained from mixtures of 
CAA with each excipient individually (as shown in sections 4.3.1.3, 4.3.2.3 and 
4.3.3.3). Thus, the excipients either added singular or together enhanced the 
dissolution rate of CAA to the same degree.
Upon compression, CADC granules showed similar dissolution profile to that of 
CAA powder blend with the excipients, with a slight higher rate for the former. This 
may be due to the micro-environment these excipients provided to CAA when in its 
close proximity, thus, providing better enhancement of dissolution than if being 
purely mixed.
It was also observed that the dissolution results of CA from CAC mixture with 
excipients were lower than that from the CAAs’. Indicating that the studied 
excipients did not have the same dissolution enhancement effect as is the case 
with CAA.
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Thus, these excipients could stabilise the amorphous CA and maintained its 
physical properties, but couldnot enhance the solubility of the crystalline form.
4.3.6.4 In vitro gut absorption
The in vitro gut absorption results of CADC and CAA, CAC mixtures with 
excipients are shown in Table 4.12 and Figure 4.16.
Time
(min)
Average % release of C ± SD
Mixtures of all excipients with CADCCAA CAC
15 1.97 ±1.22 2.29 ±0.30 3.06 ± 1.41
30 4.98 ±2.97 1.87 ±0.25 6.30 ±2.45
45 9.06 ± 3.45 3.41 ±0.75 10.64 ±2.41
60 14.95 ±3.13 5.60 ±1.30 15.78 ±3.15
75 20.76 ± 4.25 8.01 ±2.50 19.82 ±3.73
90 26.48 ± 5.25 10.60 ±3.40 25.38 ± 5.35
105 31.52 ±6.78 13.08 ± 1.73 30.89 ± 7.50
120 35.47 ± 3.52 16.36 ±2.42 34.63 ± 8.45
Table 4.12: In vitro gut release of C from CADC, CAA and CAC mixtures with the
three excipients, n=3.
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Figure 4.16: In vitro gut release of C from CADC, CAA and CAC mixtures with the 
three excipients, n=3.
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It is shown in Figure 4.16 that the studied excipients maintained similar absorption 
rate to that of CAA, but they had no enhancement effect on CAC.
It was also observed that CADC showed similar absorption rate to that of CAA, 
which confirmed that the excipients restored the original absorption rate of CAA 
upon compression.
The absorption rate of C from CAC mixture with excipients was significantly lower 
(by 60%) than that from the CAAs', but similar to that from CAC alone. This 
indicated that these excipients were not able to enhance the solubility or 
bioavalability of the crystalline form of the drug.
Statistical analyses (two way Anova) was applied to determine similarity of the in 
vitro gut release rates of C from the compressed CAA mixture with excipients 
(CADC) and from CAA. Data obtained indicated that these two were not 
significantly different (P>0.05), but both were significantly different from that of the 
compressed CAA (CAAc), (p<0.05).
4.4 CONCLUSIONS:
From the DSC studies, it was clear that the thermal behavior of CAA was not 
affected by the presence of any of the studied excipients, indicating their physical 
and chemical compatibility with it. From the dissolution studies, it was shown that 
the optimum ratios for the studied mixtures with CAA were 15%w/w Ac-Di-Sol, 
30%w/w Starch 1500, and 3%w/w Aerosil 200.
Compared to dissolution results of CAA alone, CAA mixed with the excipients 
either singular or together indicated good dissolution profiles (> ± 90% after 45 
minutes). This indicated that the introduction of the excipients enhanced the 
dissolution rate of CAA by providing it a higher contact surface area with the 
dissolution media. When these mixtures were compressed, slightly higher 
dissolution results were obtained.
The prepared CAC mixture with the same excipients showed low dissolution rate, 
characteristic of the low solubility of the crystalline form of the drug. Thus,
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dissolution of CAC could not be enhanced by the presence of the formulation 
excipients.
In vitro gut studies showed similar intestinal absorption profiles for CAA and CAA 
mixtures with excipients, which indicated that they maintained its absorption rate. 
Upon compression, CAA was shown to undergo partial transformation to CAC 
(Chapter 3). This may be related to compression generated heat and pressure 
which caused plasticization and partial crystallisation of CAA. However, mixing of 
CAA with a variety of formulation excipients (e.g. Ac-Di-Sol, Starch 1500, and 
Aerosil 200) prevented crystallisation and, further, stabilised the amorphous form 
the drug.
Stabilisation achieved by these excipients may be related to hydrogen bonding 
with CAA which reduced its molecular mobility. It may also be related to the high 
molecular weight of the polymers, and the high Tg (300°C) of Aerosil 200, both 
factors reduced the effect of temperature and pressure on the compressed 
material, thus inhibited CAA crystallisation potential.
The introduction of the wetting agent SLS with CAA did not, however, enhance the 
dissolution rate to the same extent as obtained with other excipients. Similarly the 
in vitro gut absorption results showed that the absorption rate of CAA was reduced 
when mixed and/or compressed with SLS. This may be related to the fact of SLS 
being a basic material, thus, its dispersion with CAA gave rise to an increase in the 
pH to 6.3.This induced the gelation of CAA, and reduced the extent of the material 
availability at the absorption site.
The in vitro gut absorption results of CAC mixed with the same excipients were 
confirmatory to the dissolution results, and showed a similar profile to that of CAC 
alone. This indicated that the selected excipients could only stabilise the 




EFFECT OF WAX COATING ON CEFUROXIME AXETIL 
AMORPHOUS (CAA) AND CEFUROXIME AXETIL COMPRESSED 
MIXTURE WITH EXCIPIENTS (CADC)
5.1 INTRODUCTION
In previous chapters, it was shown the effect of compression on the release and 
intestinal permeability of CAA, both in the absence and the presence of excipients.
In this chapter, the effect of another important process factor is described, which is 
the wax coating of CA. It is considered an important factor because in the 
marketed oral suspension, CA particles are processed with integral lipid coatings in 
the form of granules to mask the very bitter taste of CA (James et al, 1989). The 
aim of the lipid coating is to avoid release of the drug into the liquid suspension or 
in the mouth. The coat which has a limited permeability to water is readily 
dispersed or dissolved in the gastro-intestinal fluid.
The melting point of the lipid used is sufficiently high to prevent melting of the 
coated particles in the mouth and release of the bitter tasting active ingredient. In 
order to prevent melting of the active ingredient and/or its chemical degradation 
during the coating process, the lipid or mixture of lipids used have a melting point 
between 40°C and 70°C.
James et al. (1989) reported that wax coating of CAA can be achieved by using 
suitable lipids (e.g fatty acids , monohydric alcohols, fixed oils, fats, waxes, sterols, 
phospholipids and glycolipids). The most common lipids include the high molecular 
weight (C10-30) straight chain saturated or unsaturated aliphatic acid, such as 
stearic acid or palmitic acid (as in Zinnat® commercial preparation). The triglyceride 
tested was a glyceryl ester of a high molecular weight (C10-30) aliphatic acid, such 
as glyceryl trilaurate or glyceryl trimyristate. The partially hydrogenated vegetable 
oil tested was cottonseed oil or soyabean oil. While the wax was beeswax or 
carnauba wax, and the high molecular weight (C10-30) straight chain aliphatic 
alcohol was stearyl alcohol or cetyl alcohol, or a mixture thereof.
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Of the above, the lipid of choice in providing the best bioavailability and physical 
properties, and which was particularly compatible with CA was stearic acid in an 
admixture with palmitic acid in a 1:1 ratio by weight (James et al, 1989).
James et al. described that CA can be first under-coated with a substance of good 
coating properties.This undercoating serves to protect CA from chemical 
interactions with the lipid coat. The undercoat is preferably a water soluble and a 
film forming agent that can be applied from aqueous or non-aqueous systems (e.g 
polysaccharides such as maltodextrin, alkylcellulose such as methyl or ethyl 
cellulose, hydroxyalkylcellulose, polyvinylpyrrolidone and polymers based on 
methacrylic acid).
Wax coated CA particles with an undercoat contained from 5 to 15% by weight of 
CA. If no undercoating was employed the lipid coated particles contained 
approximately 10 to 30% by weight of CA. Particles provided with an integral lipid 
coating to mask the bitter taste of the CA had a diameter of less than 250pm.
The size of the coated particles was found to be an important factor with respect to 
the bioavailability of CA and the acceptability of its products for oral administration. 
Particle sizes in excess of 250pm mean diameter by volume gave an undesirable 
gritty taste, so the mean diameter by volume was maintained below 100pm. The 
coated particles were prepared by atomizing a dispersion of particulate CA in a 
molten lipid and cooling the coated particles thereby. For Zinnat® wax coated 
particles, the dispersion is prepared by adding CAA powder to the molten lipid of 
stearic acid and palmitic acid in the ratio of about 1:1 w/w. The molten dispersion is 
then atomized to give particles of lipid coated CA upon cooling.
Techniques used to coat CA particles have included the use of conventional 
atomizers such as rotary atomizers, pressure nozzles, pneumatic nozzles and 
sonic nozzles. The atomizing gas supplied to the nozzle was air or an inert gas 
such as dry nitrogen. During the coating process, the temperature at which the 
molten dispersion was maintained was in the range of 10° to 20°C above the 
melting point of the lipid or mixture of lipids used. This is in order to provide a 
dispersion having the desired viscosity for atomization. The atomizing pressure 
was controlled in order to produce coated particles of the preferred size. The
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coated particles were solidified and collected by applying a stream of cool air or dry 
nitrogen to the spray chamber, at a temperature of 5°C-20°C, until cooling and 
solidification of the particles were completed. The undercoat was applied to CA 
using conventional coating techniques, e.g. spray coating using a coater or a spray 
drier, or coating with a rotary granulator (James et al, 1989).
It has been reported that even after wax coating, CA continues to have bitter taste 
which is long lasting and cannot be adequately masked by the addition of 
sweeteners and flavors to the granules (Kremminger, 2003).
It has also been reported (Physicain Disk Reference 2000) that oral suspension of 
CA is not bioequivalent to CA tablets when tested on healthy adults. The tablets 
and powder for oral suspension formulation cannot be substituted on a milligram 
per milligram basis .The area under the curve for the suspension averaged 91% of 
that for the tablets. Therefore, the safety and effectiveness of both tablets and oral 
suspension formulations have to be established in separate clinical trials.
Reo et al. (1999) reported another method of masking the taste of the drug in 
particulate form, which was based on mixing CA with a lipid at a temperature below 
that where significant drug degradation occurs. This was done by addition of an 
emulsifier having a hydrophilic—lipophillic balance value (HLB) of 10 -  18, in the 
presence of 5-25% by weight of the wax/emulsifier coating. Emulsifiers tested 
included polyglycerol esters, polysorbates, mono and diglycerides of fatty acids, 
propylene glycol esters, sucrose fatty acids esters, propylene glycol esters, and 
polyoxethylene derivatives of sorbitan fatty acids esters. The waxes tested were 
carnauba wax, beeswax, lanolin, bay berry, sugar cane, candelilla wax, 
microcrystalline waxes, petrolatum wax, carbowax, rice bran wax, paraffin wax and 
mixtures thereof. The wax was presented in an amount of 80 -  90 % of the 
coating. The coating provided rapid dissolution and enhanced long term stability of 
CA.
Sanz et al. (2003) provided a composition comprising CA in particulate form with 
integral coatings of lipid or mixture of lipids, similar to what James et al. (1989) 
proposed. He applied a sweetener system (e.g. Saccharin, sodium saccharin,
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sodium cyclamate, acesulfame potassium, thaimatin, neohesperidin 
dihydrochalcone, ammonium glycyrrhizinate and aspartame) at a concentration of 
0.3-5% by weight. It further contained a texture modifier, and any thickener or 
binding agent which may optionally form a part of the composition.
The introduction of the texture modifier was to improve the mouth feel reducing the 
gritty texture and to enhance easy swallowing. These modifiers included povidone 
K30, sodium carboxy methyl cellulose, hydroxyethyl cellulose, hydroxypropyl 
cellulose, guar gum, or xanthen gum.
Mukherji et al. (2003), masked the very bitter taste of CA by coating the active 
particles in two enteric coating polymers, comprising a methacrylic acid copolymer, 
and a phthalate polymer added into the matrix to enhance the release of the drug 
from the methacylic acid coat. A 1:1 ratio of methacrylic acid copolymer to 
phthalate polymer was optimal for the taste masking effect. The total polymer to 
drug ratio was at least 1:4. It was shown that the obtained coat composition 
effectively masked the taste of the drug without compromising the dissolution rate.
The CA methacrylic acid copolymer and the phthalate polymer were dissolved in a 
suitable organic solvent. This was followed by the recovery of the matrix from the 
solution obtained by conventional methods, which included vacuum evaporation, 
tray drying, spray drying, and drum or belt film drying. Spray drying was the 
preferred method for solvent removal, because it kept the drug in a finely dispersed 
state within the polymers, preventing the exposure of the bitter tasting drug to the 
taste buds.
The methacrylic acid copolymers used included methylmethacrylic ester 
copolymers, such as Eudragit S and Eudragit L and copolymers of ethyl acrylate 
and methycrylic acid as Eudragit L-100-55. The phthalate polymers included 
cellulose acetate phthalate, ethyl vinyl phthalate, polyvinyl acetate phthalate and 
hydroxyl alkyl cellulose phthalates. The solvent system chosen was one in which 
both the active ingredient and the polymers are either soluble or swellable. 
Preferred solvents included water, ketones, alcohols, esters and their mixtures.
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The process of spray drying provided highly porous material thereby requiring a 
secondary granulation to improve the taste masking.
Channeling agents were used to further tailor the drug release from the granules. 
Channeling agents helped in opening up the granules within a specific media. 
These included disintegrants (e.g. croscarmellose sodium, crospovidone and 
sodium starch glycolate), diluents (e.g. lactose, mannitol, sodium chloride, talc, 
polyvinyl pyrrolidone) and gelling agents (e.g. carbopol, and xanthan gum). The CA 
acrylate / phthalate taste masked granules were mixed with flavoring agents such 
as natural or artificial flavors, citric and tartaric acids, sweeteners such as 
saccharin and aspartame, and with other pharmaceutically acceptable excipients. 
They were then formulated as conventional chewable or dispersible tablets, dry 
syrups, suspensions, sachets or any other suitable oral dosage forms.
In another study, Cuna et al. (1997-a, b) developed a microencapsulated form of 
CA using pH-sensitive acrylic polymers. CA was encapsulated in pH-sensitive 
acrylic microspheres in order to be used in the suspension dosage form. Using this 
microencapsulated form it was expected to prevent leaching of the drug from the 
microspheres into the suspension medium and to ensure the release of the drug in 
the first part of the intestine, thus avoiding changes to its bioavailability. For this 
purpose, CA was microencapsulated within several types of acrylic polymers by 
the solvent evaporation and the solvent extraction techniques.
The acrylic polymers selected were Eudragit E (positively charged and soluble at 
pH 5), Eudragit L-55 (negatively charged and soluble at pH > 5.5) and Eudragit RL 
(neutral, insoluble, but readily permeable). The influence of the polymer electrical 
charge on the stability and in vitro release of CA was investigated. Though 
Eudragit E microspheres presented good morphological characteristics and 
dissolution behaviour, the analyses of the stability of CA in the presence of 
Eudragit E by HPLC indicated a negative interaction between both compounds. 
However, formulations made of Eudragit L-55 and RL in the ratios tested (100:0) 
and (90:10) were adequate in terms of the stability of the encapsulated CA.
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The dissolution studies showed a critical pH between 5.2 and 6.0, which allowed 
the complete release of CA in a short period. Furthermore, these polymer 
microspheres were shown to be efficient in masking the taste of CA.
Cefuroxime axetil (CA) was also microencapsulated within various cellulosic 
polymers having a pH-dependent solubility (Cuna et al, 1996). Cellulose acetate 
trimellitate (CAT), Hydroxypropylmethyl cellulose (HPMC) P-5 and P-50 were 
used, with the aim to mask CA taste while assuring its release in the intestinal 
cavity. The drug release studies and the stability assay of the encapsulated 
molecule showed that the HPMCP-55 microspheres represented an useful 
approach in achieving the specific objective.
The dissolution properties of coated CA with stearic acid (SACA) systems with a 
view to investigating the effects of the dissolution medium on both the release rate 
and the physical integrity of the microspheres, were studied by Robson et al (1999, 
2000-a). The release from the spheres was found to be highly dependent on the 
media used. Systems in distilled water (pH 6.8) and pH 5.9 Sorensens modified 
buffer showed a relatively slow release which exhibited linearity with the square 
root of time, implying a diffusion process. The rate of release from systems in pH 
7.0 and 8.0 buffer was considerably faster and did not follow simple diffusion 
kinetics. Examination of the microspheres after immersion in various media 
indicated a change in the integrity of the spheres in those media which showed the 
most rapid release.
This was particularly marked when the systems were dried in the buffer, with 
disintegration observed in the higher pH systems. It was suggested that the 
release of the drug is dependent both on diffusion through the intact microspheres 
and changes in the physical integrity of the spheres as a result of a reaction with 
the surrounding medium (Robson et al, 1999).
In another study, Robson et al. (2000-b) tested the influence of buffer composition 
on the release of CA from the stearic acid microspheres, with particular emphasis 
on establishing the relationship between buffer composition and release at a single 
pH value . Studies of drug dissolution and release from spheres in pH 7.0 citrate 
phosphate buffer (CPB), boric acid buffer (BAB), phosphate buffer mixed (PBM),
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and Sorensens modified phosphate buffer (SMPB) indicated marked differences in 
release profiles from the spheres, with an approximate rank order of SMPB > CPB 
~ BAB > PBM. The role of added sodium was then investigated by examining the 
release profiles in SMPB and PBM to which sodium ions had been added. 
Increases in the sodium content from 0.11 to 0.2 M were found to decrease the 
release rate from the SMPB, while an increase from 0.007 to 1.0 M sodium in PBM 
resulted in a maximum release being seen for the systems containing 0.05 M 
sodium. Studies on surface disintegration, using scanning electron microscopy 
(SEM) and sodium uptake using flame emission spectroscopy, indicated an 
interrelationship between medium composition, disintegration and release.
Microspheres (SACA) were studied using DSC to examine the interaction between 
the spheres and a range of buffer systems, with a view to further enhance the 
understanding of the mechanism of drug release from wax coated particles 
(Robson et al, 2000-c).
DSC studies indicated that upon immersion in SMPB pH 5.9, followed by washing 
and drying, no change in the thermal properties of the spheres was detected up to 
60 min of immersion. A single endotherm was noted at 56°C, which corresponded 
to the melting of stearic acid used in this study, similar results were obtained for 
systems immersed in distilled water (Robson et al, 2000-c).
After immersion in SMPB pH 7.0 and 8.0, however, a second peak was noted at 
approximately 67°C, which increased in magnitude,relative to the lower 
temperature endotherm , with increasing exposure time to the medium. Spheres 
that had not been previously washed prior to drying showed complete conversion 
to the higher temperature endotherm for those two buffers. Systems which had 
been exposed to a range of pH 7.0 buffers CPB, PBM, BAB were then examined. 
Only the CPB systems showed evidence conversion to the higher melting form. 
PBM systems to which further sodium had been added were then examined. A 
maximum conversion was found at 0.05 M sodium (Robson et al, 1999, 2000-b).
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In this chapter the effect of wax coating on CAA physical properties was 
investigated. The wax coat chosen was a mixture of stearic acid and a 
hemisynthetic glyceride, and was used at around 40% w/w. Both thermal behavior 
and in vitro release of wax coated CAA and CADC were tested and compared to 
those of uncoated particles.
5.2 WAX MIXTURES PREPARED
5.2.1 Materials and methods
Table 5.1 summarises wax materials studied in this chapter.
Materials Stearic Acid Gelucire 39/01
Batch No. 605021900 OE2504-2
Retesting Date 04/2002 06/2003
Source Croda Gattefosse
Table 5.1: Waxes studied for coating
The BP and the USP describe SA as a mixture of stearic acid (SA) (C18H36O2) and 
palmitic acid (C16H32O2). The content of SA is not less than 40.0% and the sum of 
the two acids is not less than 90.0%. The USP also contains a monograph for 
purified SA.
SA is widely used in oral and topical pharmaceutical formulations. It is mainly used 
in oral formulations as a tablet and capsule lubricant (Mitrevej et al, 1982). It may 
also be used as a binder, or in combination with shellac as a tablet coating. SA is 
also used in cosmetics and food products. It is generally regarded as a nontoxic 
and nonirritant material, with a melting point of 57°C-60°C (Kibbe et al, 2000).
Gelucire 39/01 (G), a Hemi-synthetic glyceride (glycerol ester of C12-C 18 saturated 
fatty acid esters) is an excipient used for hard gelatin capsules. It is also used as a 
bioavailability regulator for sustained release formulation to protect it against 
oxidation and hydrolysis and in formulation of low density products or toxic or low 
dose active drugs. It has a hydrophilic-lipophillic balance of 1 and a melting point of 
37.5°C-41.5°C (Kibbe et al, 2000). SA was used in this study either purely or as a 
mixture with G , added to lower the high melting point of SA.
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5.2.1.1 Wax mixtures preparation
Mixtures were prepared by weighing the waxes in quantities equivalent to the 
percentage specified for each mixture in Table 5.2. Each mixture was prepared as 
2 gm batches. Materials were transferred to beakers immersed in a water bath 
containing hot water at 60°C.
Mixing was undertaken until waxes were completely melted. Finally, flasks were 
cooled at room temperature with continuous mixing until solidification occurred.
5.2.1.2 Melting point testing:
The melting point of each mixture was tested using a capillary tube filled to 4mm 
with the sample. The parameters of the instrument were set as initial temperature 
of 30°C, heating rate of 2°C/min, and a final temperature of 60°C. When the 
furnace was heated up to the starting temperature, the sample tube was inserted in 
the sample holder.
When the start temperature increased, the furnace temperature also increased at 
the selected heating rate until the sample melted, the melting point was then 
recorded on a digital display. Testing for each sample was repeated three times.
5.2.2 Results and discussions
Table 5.2 shows the results of melting point depression of SA when mixed with G 
in different ratios.
Gleucire 39/01 Stearic acid Melting Point
100% - 37.0°C -  37.8°C
90% 10% 36.3°C -  36.5°C
80% 20% 43.3°C -  42.3°C
70% 30% 46.9°C -  47.1 °C
60% 40% 49.6°C -  48.4°C
50% 50% 51.4°C- 51.2°C
40% 60% 52.3°C -  52.7°C
30% 70% 53.9°C -  53.7°C
20% 80% 54.6°C -  54.6°C
10% 90% 55.2°C -  55.3°C
- 100% 56.7°C -  56.7°C
Table 5.2: Melting points of SA and G mixtures at different ratios, n=3.
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The results in Table 5.2 indicated that the melting point of SA was lowered when 
mixed with varying amounts of G.
Increasing G content to more than 40% caused softening of the wax mixture. Thus 
60:40 ratio was found to be optimum for achieving the melting point depression , 
while retaining wax solid properties.
5.3 MIXTURES OF CAA AND CADC WITH WAXES
Mixtures of CAA and CADC were prepared with SA and G individually and together 
to study their effect on the physical and chemical properties of CA. These mixtures 
were tested as described below.
5.3.1 Materials and methods:
Table 5.3 summarises materials studied as wax mixtures.
Materials 1 CAA SA G CADC
Batch No. CAFAA/003/00 605021900 OE2504-2
Granules 




1 Assay 81.8% 04/2002 06/2003
Water content 0.99% — —
Exp. Date 12/2003 — - -
Source Orchid Croda Gattefosse
Table 5.3: Materials studied as wax mixtures
5.3.1.1 Wax mixtures prepared
The following mixtures were prepared (3 gm of each mixture):
1 : 1 SA with CAA, and, SA with CADC
1 : 1 G with CAA, and, G with CADC
1 : 1 : 1 SA with G with CAA, and, SA with G with CADC
5.3.1.2 Method of preparation
For each mixture, the materials were accurately weighed, and the wax was 
transferred to a glass beaker and melted at (60°C-70°C). The CAA or CADC was 
added in the specified ratio with continuous stirring until a homogenous dispersion 
was obtained. Mixing was continued with cooling until the whole mixture solidified.
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5.3.1.3 Testing of mixtures
Compatibility of CA with each wax mixture was tested using the HPLC and DSC 
methods mentioned under chapter 2, sections 2.9.2.1 and 2.1.2, respectively.
5.3.2 Results and discussions
5.3.2.1 HPLC analyses
All HPLC analyses results of CA in the wax mixtures were 97.0-101.0 mg% CA. 
This indicated good homogeneity (±10%). Chromatographic purity revealed pure 
peaks with no degradation products, indicating that CA was chemically stable in 
the wax mixtures tested.
5.3.2.2 DSC Measurements
DSC testing results of CAA and CADC wax mixtures are presented in Table 5.4.
Material Endothermic peaks Material Endothermicpeaks
CAA 84.0°C -  85.0°C CADC 79.8°C-81.9°C
SA 56.CPC -  58.0°C CADC with SA 80.5°C -  80.7°C 57.4°C -  57.8°C
G 37.CPC -  39.CPC CADC with G 80.6°C -  82.3°C 36.8°C -  37.9°C
CAA with SA 83.3°C -  83.7°C 57.4°C -  58.6°C
CADC with SA 
and G
80.6°C -  82.2°C 
52.9°C -  53.4°C 
36.3°C -  36.7°C
CAA with G 84.1°C -  84.4°C 38.6°C -  39.5°C
CAA with SA and G 83.CPC -  84.CPC 52.2°C -  53.5°C 
37.1°C -  37.2°C
Table 5.4: DSC results of CAA and CADC wax mixtures.
From the DSC results in Table 5.4 it was observed that the melting point of SA was 
depressed when mixed with G, confirming the results obtained from the melting 
point testing of the mixtures, presented under section 5.2.2.
Furthermore, the endothermic peak in each of CAA and CADC thermograms, 
relating to the Tg of CAA overlapping a relaxation peak, was not affected by the 
waxes. Thus, waxes tested were physically and chemically compatible with CA.
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5.4 COATING OF CAA WITH SA
In this section, effect of SA wax coating on the properties and release of C from 
CAA coated particles was studied.
5.4.1 Materials and methods
The following materials (mentioned in Table 5.3) were used to prepare the wax 
coated CAA with SA:
Cefuroxime axetil amorphous (CAA) : 500
Stearic acid (SA) : 400
Isopropyl alcohol (IPA) : 2900 ml extra pure
The solvent I PA was chosen because it dissolves SA, and is considered less
hazardous to the environment than other halogenated hydrocarbons used usually
for organic coatings.
5.4.1.1 Method of coating
The coating solution was prepared by dissolving SA in I PA with the aid of gentle 
heating. CAA was then coated with the coating solution prepared, using the Niro 
Aeromatic Multi Processor (MP1) at exhaust air temperature of 14°C-18°C.
Coating was continued with frequent sampling to test the bitter taste masking 
achieved as a function of time during coating. Approximately all the coating 
solution was consumed to achieve masking of the bitter taste. The coated particles 
were subsequently passed through a 0.20 mm sieve.
5.4.1.2 HPLC assay testing of coated particles
HPLC method mentioned in chapter 2, section 2.9.2.1, was applied to determine 
the content and homogeneity of CA in 5 samples of CAA coated particles with SA. 
The powder was taken in quantities equivalent to the weight needed for sample 
preparation in the HPLC method.
5.4.1.3 Particle size distribution of coated particles
Wax coated CAA particles with SA were tested for particle size distribution using 
the laser particle size analyses method mentioned under chapter 2, section 2.3.2.
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5.4.1.4 DSC of coated particles
Wax coated CAA particles with SA were analysed by DSC, using the method 
described under chapter 2, section 2.1.2, after being gently crushed using a mortar 
and a pestle.
5.4.1.5 In vitro gut absorption testing of coated particles
Wax coated CAA particles with SA were tested for intestinal absorption as 
described under chapter 2, section 2.8.2.2, and samples were analysed as 
described in section 2.9.2.3.
5.4.2 Results and discussions
5.4.2.1 HPLC analyses
The homogeneity results of CA in the SA coated CAA powder were 50.0 -  60.0 
mg% CA. This indicated good homogeneity (±10%). Around 45% wax coating was 
needed to achieve the desirable bitter taste-masking of CAA.
5.4.2.2 Particle size analyses










Figure 5.1: Log-normal particle size distribution of CAA coated with SA
The geometric mean diameter (median diameter) of the SA coated CAA was 
107.0pm.
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The geometric standard deviation of the particle size distribution was calculated as 
was mentioned in chapter 3, equations 3.1 and 3.2. Results were as follows:
d50 107.0 pm . _og = ----------= -------- -— = 1.7
a d15.78 64.8 pm
and
d84.13 182.2 pm „ ,ag = --------- = -------- -— = 1.7
a d50 107.0 pm
The particle size of the SA-coated CAA powder was approximately 5 times higher 
than that before coating (d50 = 20pm). This can be related to the agglomeration of 
CAA powder during wax coating. The standard deviation (5) of particle size 
distribution indicated a log-normal distribution.
5.4.2.3 Dissolution testing
As wax coated CAA particles have very low solubility in 0.01 N HCI (media of 
dissolution test in BP 2000), this test was not conducted on wax coated particles. 
Instead all comparisons were based on in vitro gut intestinal absorption results.
5.4.2.4 DSC measurements
Figure 5.2 shows the DSC thermogram of CA particles coated with SA. The 
thermogram revealed three endothermic peaks, one for melting of SA at 57.0°C, 
the second is characteristic of CAC at 178.0°C, and the third found at 153.3°C, 













0 20 40 60 80 100 120 140 160 180 200
Temp. (°C)
Figure 5.2: DSC thermogram of CAA coated with SA, at heating rate 25°C/min
The DSC thermogram indicated that the wax coating process may have converted 
the pure CAA to CAC polymorph of the melting peak at 178°C, plus another form 
of a lower temperature endothermic peak (153.3°C), which is expected to be 
another polymorph for CAC. This may be attributed to the heat generated from the 
friction of the fluidized particles during coating process which would plasticize CAA 
and enhance crystallisation. It may also be related to the possible dissolution of 
CAA in I PA and subsequent recrystallisation on the particles surface exposed to 
coating solution.
5.4.2.5 In vitro gut absorption testing












105 3.06 ± 0.83
120 3.61 ± 1.05
Table 5.5: In vitro gut C% release from coated CAA with SA, n=3.
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Figure 5.3: In vitro gut release of C from CAA coated with SA, n=3.
The above in vitro gut results indicate a linear zero order release rate of C from 
CAA coated with SA. The lag time noticed for wax coated CAA is related to time 
needed for wax to melt and CAA to dissolve in the absorption media. The release 
rate (K) was significantly reduced (by 10 folds) upon wax coating.This was 
probably as a result of the conversion of the pure amorphous absorbable form of 
the drug to the crystalline form during coating process.
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5.5 COATED CAA WITH SA AND G
5.5.1 Materials and methods
The following materials ( mentioned under sections 5.2.1 and 5.4.1 ) were used to 
prepare wax coated CAA with SA and G:
Cefuroxime axetil amorphous (CAA) : 500 gm
Stearic acid (SA) : 250 gm
Gelucire 39/01 (G) : 150 gm
2-Propanol (IPA), (extra pure) : 2900 ml
5.5.1.1 Method of coating
The coating solution was prepared by dissolving SA and G in IPA with the aid of 
gentle heating. CAA was then coated with the coating solution prepared, using Niro 
Aeromatic Multi Processor (MP1) at exhaust air temp of 14°C-18°C. Coating was 
continued with frequent sampling to test the taste masking achieved with time 
during coating. Approximately all coating solution was consumed to achieve good 
masking of the bitter taste. The coated particles were passed gently through sieve 
0.20 mm.
5.5.1.2 HPLC testing of coated particles
HPLC assay method mentioned in chapter 2, section 2.9.2.1 was utilised for 
analyses of 5 different samples from the coated powder to determine the content 
and homogeneity of CA. Powder quantities analysed were equivalent to the weight 
needed for the sample preparation in the HPLC method.
5.5.1.3 Particle size distribution of coated particles
Wax coated CAA particles with SA and G were tested for particle size distribution 
using the laser particle size analyses method mentioned under chapter 2, section
2.3.2.
5.5.1.4 DSC of coated particles
Wax coated CAA particles with SA and G were analysed by DSC using the method 
described under chapter 2, section 2.1.2, after being gently crushed using a mortar 
and a pestle.
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5.5.1.5 In vitro gut absorption testing of coated particles
Wax coated CAA particles with SA and G were tested for intestinal absorption as 
was described under chapter 2, section 2.8.2.2. Samples of the test were analysed 
as was described under 2.9.2.3.
5.5.2 Results and discussions
5.5.2.1 HPLC analyses
The homogeneity results of CA in coated CAA particles with SA and G, were 52.0- 
59.0 mg% CA. This indicated good homogeneity (±10%). Around 45% wax coating 
was needed to provide the required bitter taste masking of CAA.
5.5.2.2 Particle size analyses
Results of particle size distribution of CAA coated particles with SA and G are 
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Figure 5.4: Log-normal particle size distribution of coated CAA with SA and G
The geometric mean diameter (median diameter) of CAA coated with SA and G 
was 76 pm.
Then the geometric standard deviation of the particle size distribution was 
calculated according to equations 3.1 and 3.2 mentioned in chapter 3. Rresults 
were as follows:
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d50 _ 75.99pm _ 2Q 
d15.78_ 37.49 pm ~a9 =
and
d84.13 140.13 pmog = ----------=  —  = 1.84
a d50 75.99 Mm
It was noticed that smaller particles were obtained after coating CAA with SA and 
G than that with SA alone (d50 = 107 Mm). This can be related to the fact that G 
enhances the wax coat properties and reduces the agglomerate formation during 
coating of CAA powder. The particle size could be fitted to a log-normal 
distribution.
5.5.2.3 DSC measurement
The DSC thermogram of CAA coated with SA and G, presented in Figure 5.5, 
showed four endothermic peaks, two of them for the melting of SA and G at 56.6°C 
36.7°C respectively. The third peak is for melting of the high melting temperature 
CAC polymorph at 177.2°C, while the fourth is thought to be a peak of another 












This indicated that coating of CAA with SA and G, converted the pure CAA to CAC 
polymorphs of melting peaks at 122.0°C and 177.0°C, respectively. This can be
20 40 60 80 100 120 140 160 180 200
Temp. (°C)
thermogram of coated CAA with SA and G, at heating rate 25°C/min
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attributed to the heat generated from the friction of the fluidized particles during 
coating process which would plasticize CAA and enhance crystallisation. It may 
also be related to the possible dissolution of CAA in IPA and subsequent 
recrystallisation on the surface of the particles exposed to coating solution.
The reason here of obtaining a polymorph at a lower temperature (122°C) than 
that obtained with coating with SA alone (153°C), can be related to the presence of 
G. The latter may have modified the recrystallisation conditions of CAA on the 
particles surface during coating, thus leading to such a lower melting temperature 
polymorph.
5.5.2.4 In vitro gut intestinal absorption
Results of In vitro gut C release from coated CAA with SA and G are shown in 
Table 5.5 and Figure 5.6.
I Time (min) Average % C release I (± SD)
15 0.14 ±0.03
30 0.39 ±0.10
45 0.89 ± 0.27
60 1.52 ±0.77
75 2.52 ± 0.80
90 3.40 ±1.07
105 4.57 ± 1.50
120 5.84 ±1.70





* Av. Coated CAA with SA & G 
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Figure 5.6: In vitro gut release of C from CAA coated with SA and G, n=3.
As shown in Figure 5.6, a linear zero order release rate of C from coated CAA was 
shown. The lag time noticed for wax coated particles was related to the time 
needed for the wax to melt and the material to dissolve prior to absorption. It is 
clear that coating of CAA with SA and G showed a 70% increase in CA intestinal 
absorption rate (K) compared to that obtained from coating with SA alone, both 
rates were significantly lower than that from uncoated CAA ( by 6 folds for the 
former, and 10 folds for the latter).
The above results indicated that despite G reduced the melting point of SA ,as was 
shown under section 5.2, it did not significantly enhance the intestinal absorption 
rate of CA from wax coated CAA. Flowever, since it provided a flexible coating 
process, and because of its known effect on preventing oxidation of the wax 
coating, G was included in further coating studies on CA.
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5.6 COATED CADC WITH WAX
It was noticed in previous sections that the absorption rate of CA was significantly 
reduced upon coating.
The section below illustrates the effect of wax coating on the intestinal absorption 
rate of CA from CADC granules.
5.6.1 Materials and methods
CADC in 500 gm quantity, prepared as mentioned in chapter 4, section 4.2.2.5 was 
wax coated with SA and G in the following quantities:
Stearic Acid (SA) : 250 gm
Gelucire 39/01 (G) : 150 gm
2-Propanol : 2900 gm
5.6.1.1 Methods of coating
The same coating procedure described under section 5.5.1.1 was applied to coat 
CADC granules. Coated particles were gently passed through 0.2 mm sieve.
5.6.1.2 HPLC testing of coated particles
HPLC assay method described under chapter 2, section 2.9.2.1 was applied on 5 
samples to determine the content and homogeneity of the active material in CADC 
coated particles with SA and G. Content of CA was tested on powder quantities 
equivalent to weight needed for the sample preparation in the HPLC method.
5.6.1.3 Particle size distribution of coated powder
Wax coated CADC particles with SA and G were tested for particle size distribution 
using the laser particle size analyses method mentioned under chapter 2, section
2.3.2.
5.6.1.4 DSC testing of coated particles
Wax coated CADC particles with SA and G were analysed by DSC using the same 
method described under chapter 2, section 2.1.2, after being gently crushed using 
a mortar and a pestle.
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5.6.1.5 Electron microscopy testing of coated particles
Wax coated CADC particles with SA and G were tested for electron microscopy as 
described under chapter 2, section 2.6.2.
5.6.1.6 In vitro gut absorption testing of coated particles
Wax coated CADC particles with SA and G were tested for intestinal absorption 
and analysed as described under chapter 2, sections 2.8.2.2 and 2.9.2.3, 
respectively.
5.6.2 Results and discussions
5.6.2.1 HPLC analyses
Homogeneity results of CA in coated CADC granules were 0.35mg -  0.38mg% 
CA, reflecting good homogeneity (±10%), and showing that approximately 45% 
wax coating was needed to mask the bitter taste of CA in the CADC granules.
5.6.2.2 Particle size analyses
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Figure 5.7: Log-normal particle size distribution of the wax coated CADC granules.




Then the geometric standard deviation of the particle size distribution was 
calculated according to equations 3.1 and 3.2 mentioned in chapter 3. Results 
were as follows:
d50 33.25 urn _ _og = ---------- = -------- —  = 2.0
d15.78 16.81pm
and
d84.13 63.04 pmag = ---------- = -------- -— = 1.9
d50 33.25 pm
The above results showed finer particles of the wax coated CADC than that of the 
wax coated CAA. This indicated that CADC particles (of bulk density = 0.58 gm/ml) 
underwent collision during coating in the fluid bed, thus they were crushed down to 
give finer particles than their original size (90-100pm). On the other hand, coated 
CADC granules didn’t agglomerate during coating, as happened with CAA powder. 
The particle size could be fitted to a log-normal distribution.
5.6.2.3 DSC measurements
The DSC thermograms of wax coated CADC compared with the wax coated CAA 
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Figure 5.8: DSC thermogram of wax coated CADC, at heating rate 25°C/min.
The thermograms above revealed that there are 4 endothermic peaks for the wax 
coated CADC, two are for melting of G and SA at 40.4°C and 55.8°C respectively. 
The other two peaks are characteristic of CA in both its amorphous form CAA 
having a Tg at 74°C overlapping a relaxation peak, and the crystalline polymorph 
having the melting peak at 170.8°C.
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The DSC measurements indicated that wax coating of CADC led to a partial 
transformation of CAA to the crystalline polymorph of the high melting temperature 
(174.0°C), no other forms were generated. This was different than what was 
obtained from wax coating of CAA, which resulted in complete transformation of 
the amorphous form to other two crystalline polymorphs of the drug having lower 
solubility and permeability.
The presence of excipients in the CADC granules was found to protect the 
amorphous form of CA form complete transformation to other crystalline forms 
upon coating ( reduced the degree of crystallisation). Thus, enhanced to a greater 
degree the stability of the amorphous form.
5.6.2.4 in vitro gut intestinal absorption
Figure 5.9 and Table 5.7 show the results of % C release from the wax coated 
CADC across the intestinal membrane.
I Time (min) Average % C release I (±SD)
15 2.34 ± 0.50
30 4.58 ± 1.20





120 22.86 ± 5.20
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Figure 5.9: In vitro gut release of C from CADC wax coated granules, n=3
The above results indicated a linear zero order release rate of C from wax coated 
CADC. The lag time seen for the wax coated CADC was related to the time 
needed for the wax coat to melt and the CADC granules to disintegrate before 
absorption. The rate of CA intestinal absorption (K) from wax coated CADC was 4 
folds higher than that from wax coated CAA. Thus, excipients included in CADC 
granules reduced the effect of wax coating on the absorption rate of CA.
On the other hand, CA absorption rate from CAA was found to be approximately
1.5 folds higher than that from wax coated CADC. Indicating that the wax coating 
process HAD a negative effect on the release rate of CA, such effect was reduced 
in the presence of the chosen excipients. Thus Ac-Di-Sol, Aerosil 200, and 
Pregelatinized starch 1500 mixed and compressed with CAA before wax coating, 
stabilised ,to a significant degree, the most soluble and permeable amorphous 
form of CAA, by preventing its complete conversion to other less soluble and 
permeable forms upon wax coating.
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5.6.2.5 Electron microscopy of coated particles
The electron microscope images of uncoated CADC, which show rough porous 
surface of the particles are presented in Figure 5.10.
Figure 5.10: Electron microscope images of CADC particles.
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Images of wax coated CADC, shown in Figure 5.11, reflect a relatively smooth and 




Figure 5.11: Electron microscope images of wax coated CADC
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5.7 COATED CAA MIXTURE WITH EXCIPIENTS
In previous sections, it was shown that the presence of any and/or all of the 
excipients Ac-Di-Sol, Starch 1500 and Aerosil 200 mixed and/or compressed with 
CAA stabilised the amorphous form of the drug. Thus, retaining its intestinal rate of 
absorption. To determine whether the effect of these excipients is only obtained 
when in direct contact with CAA in the core or also if surrounding the coated CAA 
particles, wax coated CAA particles were mixed with the same excipients in the 
same ratios found in the CADC granules, and then tested.
5.7.1 Materials and methods
Wax coated CAA (55 gm) prepared as mentioned under section 5.5, was mixed 
with the following excipients (mentioned in Table 4.1, chapter 4), at the amounts 
shown below:
Ac-Di-Sol : 5 gm
Starch 1500 : 9 gm
Aerosil 200 :1 gm
5.7.1.1 Mixture preparation
The mixture was prepared by gentle mixing of the wax coated particles with the 
excipients at the quantities mentioned above.
5.7.1.2 HPLC assay testing
HPLC method described under chapter 2, section 2.9.2.1 was applied to determine 
the content and homogeneity of CA in the mixed wax coated CAA particles with the 
excipients. Five samples were analysed using a powder quantity equivalent to the 
weight needed for sample preparation in the HPLC method.
5.7.1.3 In vitro gut absorption
Wax coated CAA mixture with excipients was tested for intestinal absorption as 
mentioned under chapter 2, section 2.8.2.2. HPLC analyses of the samples was 
done as was mentioned under chapter 2, section 2.9.2.3.
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5.7.2 Results and discussions
5.7.2.1 HPLC analyses
The homogeneity results of coated CAA in the mixture were 41.5gm -  45.0gm% 
CA, indicating good distribution of CAA wax coated particles in the mixture (±10%).
5.7.2.2 In vitro gut intestinal absorption testing
Table 5.8 and Figure 5.12 show the results of the in vitro gut C release from the 
mixture of wax coated CAA with excipients.






90 3.76 ± 0.67
105 4.92 ±0.75
120 6.09 ± 1.07
Table 5.8: In vitro gut C% release from wax coated CAA mixture with excipients, 
n=3.
45
* Av. Coated CAA with Excipients
* Av. Coated CADC 
4 Av. CAA
* Av. Coated CAA
40
35








y = 0.0502x - 0.59 
R2 = 0.9449




0 20 40 60 80 100 120
Time (min)
Figure 5.12: In vitro gut release of C from coated CAA mixture with excipients, n=3.
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The above figure showed a linear zero order release of C form coated CAA mixed 
with the excipients. Its release rate (K) was found similar to that of wax coated 
CAA. This indicated that the excipients did not enhance the absorption rate of CA 
from wax coated CAA, and that they were needed in direct contact with CAA to 
stabilise the drug.
Stabilisation was achieved by prevention of CAA transformation to other poorly 
soluble forms of the drug that were generated during coating process. Once CAA 
had been coated and the formation of less soluble and permeable forms of CA 
occurred, the excipients would have no enhancement effect on the absorption rate 
of the drug.
5.8 CONCLUSIONS
Cefuroxime axetil amorphous (CAA) is not stable under wax coating, which is 
needed to mask its very bitter taste when formulated in the dry suspension dosage 
form.
Stearic acid is the most common wax used for coating of CAA powder and proved 
to be physically and chemically compatible with it.
It was found, however, that the wax coating process of CAA led to the 
transformation of the amorphous form to the less soluble and permeable crystalline 
polymorphs. This led to a significant decrease in CA absorption via the intestine.
It was also shown that the rate of absorption of CA from wax coated CADC 
granules was significantly higher than that from wax coated CAA. This may be 
related to the fact that the excipients (Ac-Di-Sol, Starch 1500, and Aerosil 200), 
available in the granules stabilised, to a larger degree, the amorphous form of the 
drug in the core. The protection of the drug from direct heat and frictional effects 
maintained up to 70% of the original absorption rate of the amorphous form.
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CHAPTER 6
COMPARISON BETWEEN WAX COATED CADC AND 
COMMERCIALLY AVAILABLE WAX COATED POWDER FOR
SUSPENSION
6.1 INTRODUCTION
Cefuroxime axetil dry suspension is widely prescribed by physicians for children 
having bacterial infections. Zinnat® is a commercially available product, which 
contains wax coated CAA to mask the very bitter taste of the active material.
In this chapter, the effect of wax coating on CAA in two preparations was studied, 
these are the wax coated CADC granules and Zinnat® , both formulated in the dry 
suspension form.
6.2 MATERIALS AND METHODS
Coated CADC prepared in the dry suspension form, using the materials shown in 
Table 6.1, and Zinnat® dry suspension batch no. C063339 were tested at 125 mg 
cefuroxime/5ml dose, after 4-6 months of manufacturing.
No. Material Name Batch No. Source Qty/Bottle(gm)
1. Wax coated CADC granules
prepared as mentioned 
under chapter 5, section 
5.6.1.1
— 4.1
2. Sucrose 10872 Andenex-Chemie 40.0
3. Soduim saccharine S46386065493CS Fabric 0.05
4. Xanthan Gum 1175/01 Jungbunzlaver 0.01
5. Titanium Dioxide 0206061606 Ellies & Everard 0.025
6. Tutti Frutti 51624 Dragoco 0.10
7- Lemon Flavour 605238 Dragoco 0.15
Table 6.1: Composition of wax coated CADC dry suspension, batch No. 101003 
(1000 bottles).
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6.2.1 Preparation of coated CADC dry suspension
Wax coated CADC granules were gently passed through sieve 0.2 mm. Using the 
HPLC method mentioned in chapter 2, section 2.9.2.1, assay was done for the 
coated granules to determine the content of the active material. Materials no. 2, 3, 
4 & 5 (Table 6.1) were then mixed with the coated granules for 5 minutes, using 
the tumbler mixer. Finally, materials no. 6 & 7 were added and mixed for 3 minutes. 
Powder was then filled in bottles at the weight 44.5 + 2.0 gm/bottle. For 
reconstitution, 25 ml cold water were added to each bottle to give a final volume of 
50 ml.
6.2.2 Comparison tests between Zinnat® and wax coated CADC
The following comparison tests were done for the two preparations, Zinnat® and 
wax coated CADC dry suspensions.
6.2.2.1 DSC testing
As Zinnat® suspension contains excipients other than wax coated CAA, and in 
order to separate the coated particles from these, contents of three bottles were 
passed through a set of sieves in the range of 0.1-0.7mm, on a vibratory sieve 
shaker. All fine particles of the suspension passed through the sieves except large 
coated particles which were retained on top of the 0.7 mm sieve, as off-white large 
particles.
These particles were then collected, placed on a filter paper connected to a suction 
set and washed thoroughly with water to remove the sugar. Vacuum was applied to 
remove all water traces, and particles were then dried using a vacuum dryer for 10 
minutes.
Coated particles were then gently crushed using a mortar and a pestle, and were 
analysed using the DSC method described in chapter 2, section 2.1.2. Results 
were compared to those of wax coated CADC.
6.2.2.2 In vitro gut absorption testing
In vitro gut absorption was studied for both wax coated CADC and Zinnat® wax 
coated CAA, as mentioned in chapter 2, section 2.8.2.2. Obtained samples were 
analysed as mentioned in chapter 2, section 2.9.2.3.
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6.2.2.3 Pilot bioequivalence study for wax coated CADC against Zinnat®
This study was conducted in accordance with the “Declaration of Helsinki” related 
to conducting bioequivalence studies on humans. The study compared the relative 
bioequivalence of two products (a Test versus a Reference) containing CA.
The Test product, coated CADC in suspension was compared to a Reference 
product Zinnat® suspension (Glaxo, UK), both at 250 mg C dose. The study was 
based on a two phased crossover schemed design, carried out on 3 healthy male 
volunteers whose ages range between18-45 years.The administered dose was a 
single dose of 250mg C, and a one-week wash out interval was allowed between 
the two phases of the study. Sixteen blood samples were withdrawn at 0 (pre­
dose) and at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 4.00, 5.00, 
6.00, 7.00 and 8.00 hours post-dose.
Blood samples were analysed for cefuroxime concentrations using the HPLC 
assay method developed by Wood et al (2001). The bioequivalence of both 
products was assessed by comparing the pharmacokinetic parameters derived 
from the cefuroxime plasma concentration time profiles tmax, Cmax, Ke, 11/2e, AUCo-t 
and AUCo-oo. The Test and Reference products were to be considered 
bioequivalent if the 90% confidence limits of the geometric mean of the log 
transformed ratios of Test product relative to the Reference, for the values AUCo_t, 
AUCo-oo and Cmax, were included within the bioequivalence range of 80-125%.
6.3 RESULTS AND DISCUSSIONS
6.3.1 DSC measurements
Figure 6.1 shows the DSC thermogram of wax coated CAA in Zinnat®, it revealed 2 
endothermic peaks, one for melting of stearic acid at 52.5°C and the other for 
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Figure 6.1: DSC thermogram of wax coated CAA in Zinnat® compared to that of 
wax coated CADC, at heating rate 25°C/min
The above DSC thermograms show that CAA in Zinnat® was totally transformed to 
CAC upon wax coating. While in CADC wax coated particles, only partial 
transformation of CAA to CAC occurred. This is related to stabilisation of CAA in 
the CADC granules core by the excipients present in there.
6.3.2 In vitro gut intestinal absorption results
Table 6.2 and Figure 6.2 show the in vitro gut absorption results of wax coated 
CAA in Zinnat®, presented as %C release across the intestinal membrane.
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^^ -T irn e  (min) 
Trial 15 30 45 60 75 90 105 120
%C release from 
Zinnat® 1.11 2.39 3.76 5.55 7.34 8.78 11.16 12.42
SD 0.30 0.21 0.37 1.25 2.50 2.70 3.70 2.50
Table 6.2: In vitro gut C% release from wax coated CAA in Zinnat®, n=3.
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Figure 6.2: In vitro gut release of C from Zinnat®, n=3.
Figure 6.2 show the linear zero order release rate of C from Zinnat® wax coated 
CAA. The lag time in release is related to time needed for the wax to melt and CA 
to dissolve before absorption starts.
The above results indicated that the rate of intestinal absorption of CA from wax 
coated CADC is approximately double that from the wax coated CAA in Zinnat®. 
This is related to the presence of excipients in the CADC granules which stabilised 
the amorphous form of the drug during wax coating. In Zinnat®, CAA is completely 
transformed to CAC, leading to 60% reduction in the absorption rate of CAA.
244
6.3.3 Pilot bioequivalence study
Mean plasma concentrations and bioavailability data analyses for a single 250mg 
C dose of coated CADC suspension and Zinnat® suspension are presented in 
Tables 6.3, 6.4, 6.5 and 6.6 and in Figures 6.3 and 6.4.
Project Name : Analyses of cefuroxime in Plasma
Study No.: CEFU-ADV-S1000/91 No. of Volunteers:3
Time (h)
0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.50 3.00 4.00 5.00 6.00 7.00 8.00
Vol.# Concentration (|jg/ml)
1(I)A 0.00 0.18 0.55 1.06 1.54 2.17 2.67 2.70 2.48 1.97 1.06 0.56 0.32 0.17 0.10
1(H)B 0.00 0.20 0.79 1.46 1.69 1.97 1.88 1.70 1.64 1.28 0.85 0.54 0.25 0.12 0.00
2(I)A 0.29 1.13 1.72 2.03 1.97 1.82 1.69 1.50 1.39 1.70 1.02 0.64 0.25 0.13 0.00
2 (ll)B 0.23 0.87 1.08 0.97 0.94 0.80 0.75 0.96 1.62 1.58 0.93 0.47 0.24 0.15 0.11
3(I)A 0.29 0.79 1.19 1.25 1.28 1.38 1.69 1.95 2.82 2.23 1.42 0.79 0.33 0.33 0.24
3(II)B 0.34 0.69 0.86 0.81 1.10 1.21 1.61 1.87 1.80 1.49 0.85 0.72 0.38 0.29 0.21
Table 6.3: Mean plasma concentrations of C from Zinnat® and wax coated CADC
dry suspension.
A: Test formulation, wax coated CADC 
B: Reference formulation Zinnat®
I : Phase I 
II: Phase II
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Subject No. CmaxZinnat ® Coated (CADC) (T) (T/R)
1 1.97 2.7 137.06
2 1.62 2.03 125.31
3 1.87 2.82 150.80
n 3 3 3
Mean 1.82 2.52 137.72
SD 0.18 0.43 12.76
Table 6.4: Ratio analyses of untransformed data of cefuroxime for Cmax
Subject No. AUCo^t IZinnat® Coated (CADC) (T) (T/R)
1 6.14 7.96 129.56
2 5.61 7.17 127.81
3 6.72 8.77 130.55
n 3 3 3
Mean 6.16 7.97 129.31
| SD 0.56 0.80 1.39
Table 6.5: Ratio analyses of untransformed data of cefuroxime for A U C o - t
Subject No. AUCo^-
Zinnat® Coated (CADC) (T) (T/R)
1 6.30 8.13 129.04
2 5.85 7.35 125.73
3 7.30 9.45 129.57n 3 3 3
Mean 6.48 8.31 128.11
I SD 0.74 1.06 2.08
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6.3: Semilogarithmic plot of plasma C concentrations after a single dose 
(250mg cefuroxime/5ml). (Pilot bioequivalence results of Zinnat® 
versus CADC dry suspension).
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Figure 6.4: Linear plot of plasma C concentrations after a single dose (250mg 
cefuroxime/5ml). (Pilot bioequivalence results of Zinnat® versus 
CADC dry suspension).
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Data points were connected with each other graphically, they do not represent any 
modeling to an equation.
In the above figures and tables, it was shown that coated CADC is super 
equivalent to coated CAA in Zinnat® with ratios for AUCo^», AUCo^t, and Cmax 
(former to later) of 126%, 128% and 137%, respectively. All values were above the 
regulatory harmonized stated level for bioequivalence of 80% -  125%.
Bioequivalence results confirmed those obtained from the in vitro intestinal 
absorption, of that excipients in CADC granules stabilised the amorphous from of 
the drug, and prevented its complete transformation to other less soluble and 
absorbable forms of the drug. Thus, better bioavailability of CA from wax coated 
CADC was obtained compared to that from Zinnat®.
6.4 CONCLUSIONS
CAA instability under wax coating was relevant in both Zinnat® and wax coated 
CADC. The presence of excipients in CADC granules stabilised the amorphous 
form of the drug and prevented its complete transformation to CAC upon coating. 
Thus, they maintained 70% of the CAA intestinal absorption and provided better 
bioavailability of the drug from wax coated CADC compared to that from Zinnat®.
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CHAPTER 7
SUMMARY, GENERAL CONCLUSIONS AND FUTURE WORK
7.1 SUMMARY
Pharmaceutical materials which exist in different polymorphic forms exhibit 
different chemical and physical properties. Of the most important properties that 
are affected by polymorphism are dissolution, intestinal absorption, and stability 
(Hancock et al, 1997).
Different methods had been previously applied to obtain and stabilise the most 
soluble and absorbable, (usually the amorphous), form of a drug, some of which 
had been discussed in chapter 1. In this study, a simple method was applied to 
stabilise the amorphous form of cefuroxime axetil (CA).
It was chosen as a model drug because CA dosage forms (tablets, 250 and 500 
mg and dry suspension 125 and 250 mg/5ml) are widely prescribed for the 
treatment of upper and lower respiratory tract as well as urinary tract infections. 
This is despite of the very bitter taste of CA, which had been wax coated in dry 
suspension formulations available in the market. In tablets, film coating was done 
to overcome this problem (James et al, 1989).
The official compendia (Eur. Ph, USP and BP) current monographs of CA allows 
for the use of both the crystalline and amorphous materials, without specifying a 
criteria for identification, (e.g. melting point). It has only been mentioned that when 
either form is used to prepare the drug product (tablets), it should meet the 
dissolution requirement of > 60% after 15 min and > 75% after 45 minutes.
In this study DSC, MTDSC, XRPD and DVS were used for testing the different 
polymorphic forms of CA. Results of testing indicated that CA exists in an 
amorphous form (CAA) with a Tg at 74°C, and in a crystalline form (CAC), 
commercialized as a mixture of two polymorphs, having melting peaks at about 
130°C and 180°C respectively. It is expected that the crystalline form is either 
prepared in this way to allow for better dissolution and intestinal permeability of the
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resulting mixture, or that it is the applied purification and the crystallisation 
conditions followed that unintentionally yield such a mixture.
The XRPD testing of CAA revealed broad diffuse peaks, while the CAC 
diffractogram showed sharp diffraction peaks associated with a highly crystalline 
material.
The DVS analyses of CAA indicated a limited water uptake (2%) after exposure to 
high relative humidity conditions (90%RH), close to that of CAC, with no evidence 
of crystallisation in the range 10 -  90%RH. Its sorption and desorption isotherms 
were super-imposed, with a faster water expel upon drying than the water uptake 
during the sorption cycle. Thus, the thermogravemetric analyses of CAA indicated 
a more stable amorphous material than those known in pharmaceutical 
applications.
It was noticed that the Tg of CAA was shifted to lower temperatures with increasing 
water content in the sample (upon exposure to humid conditions). This indicated 
that water absorbed by the amorphous material caused plasticization, and shifting 
of the Tg to lower temperatures. Both thermal and gravimetric (DVS) analyses 
showed a limited water uptake of this form (-2%) with a limited effect presented by 
shifting in the Tg value to lower temperature. This indicated a better stability of the 
amorphous CA compared to other pharmaceutical amorphous systems upon 
exposure to different storage conditions.
When dissolution and in vitro intestinal absorption rates were tested, CAA gave 
higher results compared to CAC. This is despite the fact that the latter was 
introduced in the study at smaller particle size. This indicated that CA form affects 
its absorption rate more significantly than its particle size.
Upon compression CAA underwent partial transformation to CAC. Differential 
scanning calorimetry was found the only technique among others (XRPD and 
DVS) that detected the presence of CAC in compressed CAA material at the15% 
w/w level. Furthermore, it was also found that the DSC technique could detect 
down to 1% w/w concentration of CAC in a mixture with CAA.
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It was not mentioned in the literature the application of any of the XRPD and DVS 
techniques in the detection of a crystalline content in an amorphous material. On 
the contrary, the amorphous content in a crystalline drug was reported to be 
effectively measured using the XRPD at 5-10% w/w (Gerhardt et al, 1994), and the 
DVS at 0.5% w/w concentrations (Buckton et al, 1995-b).
Compression of CAA resulted in partial crystallisation, which led to a significant 
reduction in intestinal absorption (by 30%), and dissolution rates. This was related 
to heat and pressure generated upon compression. They enhanced plasticization 
of the amorphous material, reduced its Tg to that of the experimental conditions, 
and consequently induced crystallisation.
It was found in this study that some excipients can protect the amorphous CA from 
such effect. Hence mixing and compacting CAA with any or all of the chosen 
excipients (Ac-Di-Sol, Starch 1500, and Aerosil 200) at their optimum ratios, 
inhibited its crystallisation.
Good dissolution rates were obtained from the compressed CAA mixtures with 
excipients (> 80% after 15 min, and > 90% after 45 min). On the other hand, the 
CAA original absorption rate was maintained.
Choosing these excipients was based on the idea of using polymers of high 
molecular weights, which may form hydrogen bonding with CA (Ac-Di-Sol, Starch 
1500), and/or an amorphous material which has a high Tg (Aerosil 200). The 
polymeric excipients chosen were found able to stabilise CAA under the 
experimental conditions applied, possibly by linking the CA molecular motions to 
those of the polymers, thus inhibiting its crystallisation. On the other hand, the high 
Tg of Aerosil 200 also formed a barrier against CAA crystallisation.
It should also be mentioned that the physical properties of these excipients (poor 
compressability and high surface area) might have played a role in protecting CAA 
from pressure and heat generated during compression.
Effect of wax coating on CAA was also investigated. Thus, the compressed CAA 
mixture with all the chosen excipients (CADC) was .further, coated with wax and
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tested for changes in physical properties. Results were compared to those of wax 
coated CAA (prepared), and with the commercially available wax coated CAA in 
the market (Zinnat® dry suspension).
Testing of the prepared wax coated CAA particles revealed complete 
transformation to other crystalline polymorphs which showed significant reduction 
in CAA intestinal absorption, for Zinnat® wax coated CAA particles, only the 
crystalline polymorph of the high melting point had been detected, its intestinal 
absorption rate comprised only 35% of that of CAA. Wax coating of CADC particles 
led only to a partial crystallisation of CAA , retaining 70% of the original absorption 
rate of the amorphous drug.
The above mentioned results were also confirmed when a pilot-bioequivalence 
study was conducted for wax coated CADC against Zinnat® in the dry suspension 
form. The study was conducted on 3 volunteers at the dose of 250 mg cefuroxime / 
5 ml. Values of around 130% for Cmax and AUC for CADC were obtained compared 
to Zinnat, indicating higher bioequivalence of the former.This was related to the 
stabilisation effect of the excipients on the amorphous drug in CADC.
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7.2 GENERAL CONCLUSION
Despite the fact that the amorphous form of the drug lack the stability of the 
crystalline, still the former (of better dissolution and higher bioavailability) can be 
used in drug formulations and can be further stabilised. Stabilisation can be 
achieved by different means.
Mixing of CAA with polymeric, high molecular weight excipients and/or amorphous 
materials having high Tg values, was found to achieve CAA stabilisation against 
process conditions. Excipients chosen for this study were able to protect it from 
crystallisation during compression and coating.
Regarding techniques that can be used in detecting the low crystalline content in 
the amorphous drug (CAA), it was found that DSC was more sensitive than XRPD 
and DVS,the well known techniques for detection of low amorphous conent in a 
crystalline material.
7.3 FUTURE WORK
Future work will include isolation and testing of all possible polymorphs of CA, as 
well as, determination of the factors and conditions that yield each form, either 
during the purification of the raw material, or during processing of the finished 
product in its different dosage forms.
More attention will be payed to the separation of the different crystalline 
polymorphs, for the purpose to characterise them and to study their physical 
properties.
On the other hand, screening of other excipients will be done to find other 
stabilisers, which will help in better understanding of other possible stabilisation 
mechanisms.
It will also be taken into consideration, the screening of other active materials for 
the purpose to find candidates that have similar stability to that of CAA, to be used 
in the pharmaceutical preparations.
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